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Abstract 
The balance between angiogenesis and angiostasis is important in growth and 
development processes in the body. However, this balance is disturbed in 
pathological conditions such as atherosclerosis and can cause harmful events like 
increase in size and rupture of the plaque, thrombosis and MI.  Angiogenic and 
angiostatic mediators control this balance. 
Endostatin is one of the prominent angiostatic mediators. It is 22 kDa factor, 
attached to the COOH terminal of collagen XVIII and XV and requires a catalytic 
release for its action. The marked angiostatic effects of endostatin includes 
inhibiting endothelial cell migration, proliferation and apoptosis mainly VEGF 
induced.  Ranges of endostatin concentration in health and diseased populations 
are reported by different research groups.  
Physical activity decreases the risk and development of many angiogenesis 
related health problems including atherosclerosis and numerous cancers. WHO 
and ACSM recommend carrying out more than 30 minutes of moderate intensity 
physical activity on most of the days for all healthy individuals. Physiological 
influences of different physical activities on plasma endostatin concentration are 
controversial and not completely clear. The extent of changes in endostatin and 
its subsequent effects on the concentration of VEGF as a result of exercise are 
equally indistinct and vague. Moreover, influence of different physical 
characteristics and metabolic factors on circulating concentration of endostatin 
is also not clear and poorly speculated. 
The work reported in this thesis, aimed to investigate circulatory endostatin 
concentration in plasma and the effects of different intensities of exercise 
ranging from low to maximum on the distribution of endostatin and VEGF 
concentrations in plasma. Additionally, correlations of anthropometric 
characteristics, metabolic profiles and exercise parameters with endostatin and 
VEGF were investigated.  
The first study aimed to investigate the bioavailability of endostatin in the 
plasma of healthy volunteers and to look for any gender, physical characteristics 
or ethnic based differences. 50 healthy volunteers including 34 males (age = 28.5 
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± 8.5 years) and 16 females (age = 23.1 ± 4.4 years) were recruited to the study. 
Based on their origin, they were divided into three ethnic groups, European (n = 
25), Middle Eastern (n = 10) and South Asian (n = 15). Single blood samples were 
collected through venepuncture. Plasma was separated and subsequently 
analysed for endostatin concentration using ELISA. The mean plasma endostatin 
concentration measured was 105 ng/ml ± 12 ng/ml (ranging 81 to 132 ng/ml). No 
significant differences were observed on the basis of gender or ethnic group. 
The endostatin concentrations were not correlated with different 
anthropometric characteristics. This study provided basal endostatin 
concentration as a reference point for the subsequent studies, which aimed to 
determine the influence of physical activities on endostatin concentrations in 
plasma. 
The second study consists of two phases; the first phase aimed to determine the 
effects of mild, moderate and vigorous exercise on the concentration of 
endostatin in plasma. The duration and work rate for each participant was 
determined through sub-maximal exercise one week before. 22 participants, 16 
males (age = 30.6 ± 7.8 years) and 6 females (age = 26.5 ± 5 years) were 
recruited to the study. Based on their fitness to run on the treadmill, 
participants were divided into walking and running group. One pre exercise and 
two post exercise samples were taken at intervals of 10 and 60 minutes. Low 
intensity exercise decreases the endostatin concentration in plasma, while 
moderate and vigorous intensities increased the endostatin concentrations. The 
effects were never strongly influenced by gender or exercise mode. 
The second phase was designed due to different in influence of low and high 
intensity exercises on endostatin. As endostatin antagonises the VEGF induced 
angiogenesis, it was aimed to investigate the VEGF concentration at these 
intensities. The left over samples were analysed for VEGF. Both the exercise 
intensities increased the VEGF concentration. The increase was more after 
vigorous activity. No correlation between the endostatin and the change in 
endostatin concentration with VEGF or the change in it was observed.   
During this experiment, it was observed that VEGF concentration dropped back 
at 1hour interval despite high endostatin concentration.  
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Therefore, a third study with maximal exercise intensity (VO2max) to volitional 
exhaustion was designed. 8 male healthy volunteers (age = 31 ± 6.1 years) were 
recruited. Body fat percentages, blood glucose and metabolic profiles were also 
included to check for any correlation with endostatin concentration or the 
change in it after physical exercise. Blood samples were taken up to 24 hours 
after exercise. Significant induction in endostatin concentration was observed up 
to 2 hours after exercise. VEGF concentration was also increased by exercise but 
significant only at 30 minutes interval. No significant correlations of endostatin 
or VEGF were observed. 
In conclusion, low intensity exercises did not influence endostatin concentration. 
Moderate to high and maximum intensity exercises, however, significantly 
increase endostatin concentration for up to 2 hours. VEGF concentration is 
influenced by all exercise intensities transiently and less pronounced. Moderate 
to high intensity exercises favours angiostatic phenotype and therefore, help to 
decreases the progression of atherosclerosis.  
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ANOVA Analysis of variance 
BMI Body Mass Index 
CAD Coronary artery diseases 
CI Confidence interval 
CV Coefficient of Variance 
CVD Cardiovascular disease 
EDTA Ethylene Diamine Tetra acetic acid 
ELISA Enzyme Linked Immunosorbent Assay 
FGF Fibroblast growth factor 
H2SO4 Sulphuric Acid 
HIV Human immunodeficiency virus 
HRmax Maximum predicted heart rate 
HSP Heat Shock Protein 
IHD Ischemic heart disease 
IL Interleukin 
KD Kilo Dalton 
kg Kilogram 
ml Millilitre 
mmol millimol 
mRNA Messenger Ribonucleic acid 
ng nanograms 
NO Nitric oxide 
NOS Nitric Oxide synthase 
OD Optical density 
PDA Patent Ductus Arteriosis 
pg picograms 
RHD Rheumatic heart disease 
TMB Tetra methyl benzidine 
VSD Ventricular septal defect 
VEGF Vascular endothelial growth factor 
VO2max Maximum oxygen uptake 
WHO World Health Organisation 
           87 
 
 
 
 
 
 
 
 
1 Introduction and literature review 
 
  
Chapter: 1 
2 
 
1.1 Introduction 
Cardiovascular disease (CVD) especially atherosclerosis, is a major health 
problem globally. Atherosclerosis is the process of building of fibro-fatty lesions 
in the intimal layer of the muscular arteries especially coronary arteries. This 
process of plaque formation takes years and narrows the lumen of the vessels, 
leading to thrombosis and fatal heart attacks (Griffin, 1999). 
CVD accounts for more than 30% deaths across the globe. In Europe it causes 46% 
mortality every year, more in females (51%) than males (42%) (Nichols et al., 
2013). In the UK, CVDs are responsible for 180,000 deaths annually making it the 
leading cause of death (British Heart Foundation, 2012).  
Atherosclerosis has a complex aetiology with many non-modifiable (hereditary) 
and modifiable (life style) factors. However, it is probable that a sedentary life 
style and a lack of physical activity play a significant role in the progression of 
atherosclerosis.  
Scientific and clinical research has focused intensely on this problem over recent 
decades. The link between physical activity and decreased risk of CVD was 
established in early 1950s (Morris et al., 1953). Over time low physical activity 
was established as a risk factor for developing CVD (Williams, 2001). Increased 
physical activity has been extensively investigated as a possible solution for 
primary and secondary prevention of atherosclerosis (Thompson et al., 
2003).The level of risk conferred by physical inactivity is similar to that of other 
major risk factors including high blood pressure, dyslipidaemia and smoking 
(Berlin and Colditz, 1990). 
Physical activity stops the progression of atherosclerosis directly by modifying 
many cellular mechanisms identified as beneficial in preventing the 
development and progression of atherosclerosis. These mechanisms include 
production of heat shock proteins, increase in antioxidant capacity, expression 
of stress proteins and adaptations in mitochondria (Golbidi and Laher, 2011). 
Physical activity also exerts its beneficial effects indirectly by improving glucose 
tolerance, increasing insulin sensitivity and reducing high blood pressure, 
hyperlipidaemia, obesity and platelet aggregation (Gill and Cooper, 2008, 
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Francis, 1998). However, a detailed understanding of physical activity and its 
interactions with these mechanisms is not yet completely clear.  
Studies suggests that angiogenesis is one of the stronger determinants in the 
progression of atherosclerosis (Isner, 1999, O'Brien et al., 1994). It is a marker of 
ongoing diseases and may predict the plaques with risk of expansion and 
thrombosis (Falk, 2006). The process of angiogenesis is controlled by the balance 
between angiogenic and angiostatic mediators. Regulation of angiogenesis is 
very important since poor control can lead to impaired angiogenesis resulting in 
progression of atherosclerosis (O'Brien et al., 1994). However, angiogenesis itself 
is a complex process and many mediators affecting it have been identified 
(Hanahan and Folkman, 1996). VEGF and endostatin have been identified as 
main mediators with angiogenic and angiostatic properties respectively (Kurz, 
2000, Ferrara et al., 2003, Distler et al., 2003, Fu et al., 2009).  
Exercise and physical activity have been found to affect the process of 
angiogenesis by increasing or decreasing the circulatory concentrations of these 
mediators (Suhr et al., 2010, Rehman et al., 2004, Gu et al., 2004). However, 
information on changes in circulatory concentration of angiogenic mediators 
especially endostatin and VEGF by different exercise intensities is limited and 
sometimes confusing.   
Therefore, it is timely to investigate the relationship of exercise and 
angiogenesis with the hope to find facts which might enhance our 
understandings. It was hypothesized that single bouts of exercise might increase 
endostatin concentrations in the circulation of healthy individuals and by 
promoting angiogenic phenotype could protect the body against atherosclerosis.   
It was also hypothesized that the effects of different intensities of exercises 
(mild, moderate, vigorous and maximum) on plasma endostatin and VEGF would 
be different and might be affected by anthropometric and physical 
characteristics, gender and metabolic profiles of the individuals. 
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1.2 Literature review 
This section contains background knowledge of cardiovascular disease especially 
atherosclerosis and angiogenesis. This is followed by an in depth review of VEGF 
and endostatin. It also provides brief information on how physical activities 
influence different cardioprotective mechanisms in the body. Finally, scientific 
rationales for the experimental studies in this thesis are described. 
1.3 An Overview of Cardiovascular Diseases  
1.3.1 Definitions 
Disease of the heart and blood vessels, whether acquired or genetic are referred 
to as cardiovascular disease (Walker et al., 2013). Acquired heart disease usually 
manifests later in life and is classically divided to three broad groups: 
i. Diseases manifested by atherosclerotic processes like coronary artery 
disease (CAD) also called as ischemic heart disease (IHD) or coronary heart 
disease (CHD), stroke and peripheral vascular disease. 
ii. Diseases manifested by chronic inflammatory processes like rheumatic 
heart disease (RHD), cardiomyopathies, myocarditis, endocarditis etc. 
iii. Diseases of the heart caused by hypertension called as hypertensive heart 
disease. 
CAD and stroke are the most important and prevalent types of cardiovascular 
disease and both are caused by the atherosclerotic processes (World Health 
Organization, 2014a). Subsequent paragraphs will focus on the epidemiology, 
pathogenesis and risk factors of CAD and stroke.  
1.3.2 Epidemiology of Cardiovascular Diseases 
Cardiovascular disease remains one of the leading global health problems, 
causing 30% deaths due to all causes (Gaziano, 2008, Deaton et al., 2011, World 
Health Organization, 2014a). This causes three times more deaths than 
infectious diseases including HIV/AIDS, Tuberculosis and Malaria. Thus, in 2012, 
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17.5 million deaths out of 58 million were due to CVD. Coronary heart diseases 
claimed 7.3 million lives and another 6.2 million by stroke, as shown in figure 1-
1.  
 
 
Figure 1-1; Worldwide mortality caused by the leading health problems 
It can be seen that IHD and stroke are the leading causes of mortality worldwide and more than 
infectious diseases.  The Rise in CVD from 2000 to 2011 and decrease in communicable diseases 
can be seen. (Picture taken from WHO website) 
The incidence of the cardiovascular disease is on the rise, equally affecting both 
genders and it currently causes more than 80% deaths in low and middle socio 
economic groups (World Health Organization, 2014a). It is predicted that deaths 
due to CVD will be around 23.3 million by the year 2030 (World Health 
Organization, 2014).   
CVD is a global health problem with no geographic, ethnic or socioeconomic 
barriers (World Health Organization, 2014a). The developing world is more 
affected due to factors such as lack of professional expertise as well as financial 
support (Deaton et al., 2011).  The lower socioeconomic groups in the developed 
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countries have a higher incidence of CVD due to higher prevalence of the risk 
factors (Yusuf et al., 2001). This shifts the diseases burden to the lower socio 
economic group as a result of maturation of the CVD epidemics (World Health 
Organization, 2014a).    
Deaths due to CVDs affect the different regions in the world differently.  Low 
income countries have more mortality and morbidity due to CVD than 
economically stable countries. For example the mortality rate in Russia and 
Egypt is more than 500 per 100,000 inhabitants, while it is between 100 and 200 
in Australia, France and United States.  China, Brazil, South Africa and Saudi 
Arab lies in the middle range of 300 to 450 per 100,000 inhabitants (Fuster and 
Kelly, 2010). 
CVDs also kill people at younger ages in the developing world. For example, in 
USA 9% deaths between 34-61 years age can be attributed to CVD. while in 
countries like South Africa and India this proportion is as high as 41% and 35% 
respectively (Raymond et al., 2006).  
The number of deaths due to CVD varies considerably from country to country 
and over time. There are differences observed between the countries with in the 
same geographical regions and sharing the same cultural values. Three different 
trends in the mortality from CVD since 1950 have been reported (Beaglehole, 
1990, Mirzaei et al., 2009).  
i. A rise and fall pattern: In this pattern the mortality rises to its peak value 
showing an ongoing epidemic of the disease followed by significant fall. 
This pattern is observed in the developed nations including United States, 
Australia and some European countries, where the decline in the mortality 
is more than 50% in the last few decades. 
ii. A steady pattern: This is also called as a flat pattern. In this pattern, a 
relatively low and stable mortality rate is observed. This pattern has been 
mostly observed in Mediterranean countries and Japan.  
iii. A rising pattern: This pattern shows an ongoing epidemic of the CVD by a 
steady increase in the mortality rate. The countries affected by this 
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pattern have shown an alarming increase in the mortality rate and include 
the former Soviet Union, Indian subcontinent and some of the countries in 
Eastern Europe.  
CVD causes more than 4 million deaths in Europe each year. This is 46% of deaths 
due to all causes. CHD and stroke causes more deaths in central and Eastern 
Europe than other parts of Europe (Nichols et al., 2014).  
The CVD is one of the biggest killing diseases in United Kingdom. In England and 
Wales in 2013, CHD caused approximately 64,000 deaths and stroke caused 
approximately 35,000 deaths (Office for National Statistics UK, 2013a). The 
burden of the disease is concentrated in the North of England and Scotland. 
More than 1 in 4 person dies prematurely i.e. before the age of 75 years. The 
incidence of angina is higher in Scotland (British Heart Foundation, 2012). 
Around 7.1% of men and 5.3% of women live with CHD (Information Service 
Division Scotland, 2015). Obesity and high cholesterol levels are also on the rise 
leading in the Scots and this is likely to increase the  incidence of CVD 
(Information Service Division Scotland, 2014). 
This imposes a huge burden on the economy of United Kingdom. The current cost 
is around 30 billion pounds each year. This includes; issuing approximately 266 
million prescriptions and carrying out 90,000 per cutaneous interventions for 
CVD annually (British Heart Foundation, 2010). 
1.3.2.1 CVD in Indian subcontinent and Pakistan; 
The epidemiology of Indian subcontinent especially Pakistan is reported here due 
to 2 reasons; 
i. The incidence and prevalence of CVD in Indian subcontinent is very high 
due to genetic vulnerability of the South Asian population  
ii. The author belongs to Pakistan and will return to Khyber Medical 
University Peshawar, Pakistan, where he is a member of faculty. The 
intentions are that the research and reported information about 
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epidemiological data in this thesis may be helpful for future research in 
Pakistan. 
The clinical picture of CVD in the Indian subcontinent is even worse than Europe. 
The Indian subcontinent including Pakistan, India, Sri Lanka, Nepal and 
Bangladesh accommodates more than 20% of the total world population and may 
be one of the regions in the world with most concentrated CVD burden (Goyal 
and Yusuf, 2006).  Studies done in western countries have also demonstrated a 
high prevalence of the disease in the immigrants from the Indian subcontinent 
(McKeigue et al., 1989, Enas et al., 1992, Balarajan, 1991).  The mortality rate 
in immigrants from Indian subcontinent was highest when studied retrospectively 
and it has showed little improvement in the past few decades. This can be 
explained by the genetic vulnerability to some co-morbid conditions like Insulin 
resistance and the environmental factors leading to disease onset at 
comparatively younger age (Balarajan, 1991). 
In author’s opinion, the data from the Indian subcontinent needs to be revised as 
most of the data is under reported. In 2003, 3- 4% prevalence in rural areas and 
8 to 10% in urban areas were estimated for CVD. Though, these were 3 fold 
higher for the same regions than 40 years ago, but still are much less than actual 
statistics. In 1990 estimated deaths due to CVD in India were around 1.17 million 
with a predictive rise to 2.3 million by year 2010. CVD manifestation starts 
around 10 years earlier in Indians, causing a high premature death rate (below 
the age of 70 years) of 52% compared to the western countries where it is 23% 
(Goyal and Yusuf, 2006).  
Reports available on the burden of CVD in Pakistan are not representative of the 
whole population as there is no national data base with exact figures and 
statistics. The studies done by different investigators are mostly estimates, 
indicating a high prevalence and disease burden of CVD but they are limited to 
self reporting people without the knowledge of their existing health conditions.  
For example, one study reported the CVD prevalence to be 1.9% in wealthy 
population and 0.6% in non wealthy population of Karachi. Main limitation of the 
study was mere reliance on the questionnaire (Hameed et al., 1995).  
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Subsequent studies used better approaches (Jafar et al., 2005, Nishtar et al., 
2004). They reported a of 26.9% prevalence of CVD in males and 30% in females. 
The prevalence was high in females and young adults. The premature prevalence 
reported was 23.6%, which points to a massive disease burden in Pakistan. High 
rates of dyslipidmia, high blood pressure and diabetes in Pakistani population, 
counterbalance their lower rate of smoking and alcohol consumption (Ministry of 
Health Pakistan, 2004).  
1.3.3 Risk factors for cardiovascular diseases 
This section will focus on different risk factors for atherosclerosis in general 
population. Physical inactivity, as risk factor for cardiovascular disease is 
discussed separately in section 1.3.9, of this chapter. 
Risk factors are defined as any behaviour, practice or exposure of an individual 
that leads to the development of a particular health problem (Deaton et al., 
2011). The risk factors for CVD can be ‘non modifiable’ for example age, sex, 
family history or ‘modifiable’ for example cigarette smoking, obesity, high blood 
pressure, abnormal lipid profile, diabetes and lack of physical activity (Susan et 
al., 2009). 
When multiple risk factors are present they combine to increase the risk of 
incidence, mortality and morbidity (Kannel and Gordon, 1968). Though single 
risk factors influence the overall outcome for the CVD, risk factors often tends 
to occur in clusters and accelerate the disease process (Webber et al., 1979). 
Recent research attributes 75 percent of all CVD to smoking, high blood 
pressure, deranged blood glucose levels, high blood cholesterol and sedentary 
life style (Yusuf and Ôunpuu, 2003). A study by Berenson  correlating the extent 
of atherosclerosis at post mortem in 204 young individuals who died of some 
other cause, with the ante mortem history on the risk factors revealed a 
significant aggregating effects of risk factors on atherosclerosis (Berenson et al., 
1998). Subjects with 3 or more risk factors had 35% streak in the intimal layer of 
aorta compared to 19% for those with a single risk factor. The coronary arteries 
showed similar changes. 
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 A study conducted in 52 different countries involving 27098 cases and controls 
revealed that abnormal lipids, high blood pressure, physical inactivity, smoking, 
diabetes, non healthy diet, obesity, alcohol consumption and stress were the 9 
modifiable risk factors in 90 percent of the CVD related events in both males and 
females of all ages (Yusuf et al., 2004). However, poor awareness of the 
modifiable risk factors due to lack of proper education also contribute to the 
increase mortality and morbidity due to CVD in developing world (Rosengren et 
al., 2009). The INTERHEART study  reported that despite the fact that CVD 
causes more deaths than any other disease for both gender, males develop CVD 
generally a decade earlier than females (Anand et al., 2008). The study reported 
that the ratio of males to females suffering from CVD was 3 to 2 before the age 
of 60. 4 out of 5 males with early onset of the disease had an aggregation of the 
risk factors. 
Change in diet with higher consumption of saturated fat, meats and dairy 
product has increases obesity in adults (Friel et al., 2007), as well as in children 
and the incidence of high cases of IHD in adolescence is associated with 
childhood obesity (Baker et al., 2007). 
Smoking is one of the dangerous risk factors leading to CVD with a peculiar 
property of multiplying the risk due to other factors (Deaton et al., 2011). The 
rate of smoking in the developed countries is decreasing compared to developing 
world due to effective enforcement of law, anti smoking campaigns and policies 
(Ezzati et al., 2005). 
However, lack of implementing such policies along with cheap availability of the 
cigarettes in developing world increase the incidence, mortality and morbidity 
due to CVD. 
1.3.3.1 Risk factors in South Asians 
Apart from South Asian ethnicity, as an independent risk factor, regional and 
traditional risk factors contributing to the enormous disease load, do exist 
(Goyal and Yusuf, 2006). Despite apparent low levels of risk factors, south Asians 
have more CVD than European population. An overseas study on South Asians 
showed 5 times higher incidence of diabetes (Bhopal et al., 1999). 
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 High blood pressure was responsible for 1 out of 4 deaths due to CVD in India 
(Gupta, 2004). Similarly, smoking with 56% prevalence rate in men between the 
ages 12 to 60 years and abnormal lipids levels affecting 37.5% of adults are other 
dominant risk factors (Goyal and Yusuf, 2006). 
The data available on the risk factors leading to CVD in Pakistan is 
underreported, outdated and biased due to lack of central data base system. 
Most of the data available are based on cross sectional surveys, population based 
studies with small sample size or estimated numbers of the individuals with 
attributed risk. Contrary to this, studies done on overseas Pakistani population 
are more reliable, systematic and organised.  
High blood pressure and diabetes are considered major risk factors. The national 
health survey conducted 20 years ago, reported 17.9% and 33% prevalence of 
high blood pressure below and above 45 years age (Ministry of Health Pakistan, 
2004). Similar prevalence rates were mentioned in other studies (Jafar et al., 
2003, Shah et al., 2001).  
Obesity in Pakistan is also on the rise and more prevalent in women than men. 
40% of females in urban area above the age of 45 years are overweight or obese.  
Similarly, 12.6% of the population have abnormal cholesterol or lipids levels. 
Dyslipidaemia at young age requiring dietary interventions (62% of school going 
girls and 54% of boys ) were reported  in one of study (Ministry of Health 
Pakistan, 2004).  
In summary, the data from Ministry of Health in Pakistan shows that the risk 
factors for developing CVD are more concentrated in urban areas than rural 
areas. This can be attributed to the fact that urban population consume more 
western diet and are involved in less physical activity. The population in the 
rural area depends mostly on farming, consume more fresh vegetables and fruits 
and perform more physical work. Women in general and especially overweight 
women in urban area are at a high risk of developing CVD. It is probably due to 
their reduced physical activity. The social, cultural and religious discouragement 
also plays a huge role in condensing risk factors in females (Ministry of Health 
Pakistan, 2004). The data from national health survey provided by the Pakistan 
Medical Research Council (PMRC) are tabulated in table 1-1.  
Chapter: 1 
12 
 
 
 Rural area % Urban area% 
Coronary artery 
disease 
Male -- 26.9 
Female -- 30 
Overall -- -- 
Hypertension 
Male 18-25 28-37 
Female 15-28 25-43 
Overall 16.2 21.5 
Diabetes 
Male 10.3 11.1 
Female 4.8 10.6 
TOTAL 6.39-13.5 10.8-16.5 
Obesity 
Male 9 22 
Female 14 37 
Overall -- -- 
Smoking 
Male 39.13 30.51 
Female -- -- 
Overall -- -- 
Abnormal lipids 
Male -- -- 
Female -- -- 
Overall 12.7 12.7 
Table 1-1; Prevalence of CVD and risk factors in Urban and rural area of Pakistan 
It can be seen that even the national level data is not completed for most of the risk factors 
(Modified from Ministry of health Pakistan report). 
 
1.3.4 Pathogenesis of Atherosclerosis  
Atherosclerosis is regarded as the basis of ischemic heart diseases having a 
complex and diverse mechanism based on multiple factors (Berliner et al., 1995, 
Falk, 2006). Atherosclerosis was initially regarded as an age dependent 
degenerative disease, but the advances in science have shown it to be a 
multifocal, immuno-inflammatory disease of medium and large arteries, which is 
initiated by the concentration dependent transport of lipoprotein to the artery 
wall (Young and Parthasarathy, 1994, Falk, 2006). 
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High cholesterol levels are a risk factor for the development of the 
atherosclerosis and are capable of forming atheroma on the susceptible sites 
alone. Other risk factors including smoking, diabetes, high blood pressure and 
inflammation play their role in accelerating the process. However, their role is 
uncertain and could be partially attributed to the rise in the susceptibility of the 
arterial wall or increase in the LDL atherogenicity by different mechanisms, like 
increasing particle size and changing composition. In addition, smooth muscle 
cells, endothelial cells and white blood cells play important roles in 
development of atherosclerosis (Falk, 2006). 
Atherosclerosis begins in the susceptible area of the endothelium, which is intact 
but non-functional and permeable to many plasma molecules. The endothelium 
is lost from this area leaving sub endothelial tissue exposed (Davies et al., 1988), 
which is followed by transport of lipoprotein to the sub endothelial space and 
formation of the fatty streak by oxidation of the lipoprotein (Berliner et al., 
1995, Navab et al., 1995). This modification of the lipoprotein to fatty acid is 
very complex and the precise mechanism is unknown, but Nitric Oxide synthase 
(NOS) produced by macrophages, myloperoxidase and lipoxygenase are thought 
to play important roles in oxidation (Glass and Witztum, 2001). Fatty streak 
molecules induce a chronic inflammatory process and initiate the migration of 
different cells to the sub endothelial space. Due to the inflammatory stimulus, 
the endothelium and platelets enhances the expression of different adhesion 
molecules including vascular cellular adhesion molecule-1 (VCAM-1), inter-
cellular adhesion molecule-1 (ICAM-1), E selectin and P selectin and chemokines 
such as monocyte chemotactic protein 1 (MCP-1). These lead to the migration of 
white blood cells to the atherogenic area (Quillard and Croce, 2015). Circulating 
monocytes and B lymphocytes are the first to respond and their presence in the 
affected area accelerates the ongoing disease process. Recruitment and 
migration of monocytes into the sub-endothelial space is essential for the 
process of atherosclerosis (Rolin and Maghazachi, 2014). Plaque development has 
been reported to be reduced after depletion of monocytes from the circulation.  
A high monocyte count has been identified as one of the independent risk 
factors for development of atherosclerosis (Afiune Neto et al., 2006). The 
process of recruitment is very complex. Initially MCP1 expression was considered 
to play an important role. However, recent work has shown that large number of 
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chemokines and their receptors are involved in this process (Rolin and 
Maghazachi, 2014). The most important include: CCR2, CCR5, CXCR2, CX3CR1, 
CX3CL1 (Fractalkine), CCR1 and CCR2. In addition, to chemotaxis of monocytes 
they also perform additional functions during the disease process. For example, 
adhesion molecule CX3CR1 is expressed on the surface of monocytes. Cross talk 
with CX3CL1 (Fractalkine) on the surface of smooth muscles cells increases the 
expression of other patherogenic and inflammatory mediators including TNF-α, 
MMP-2, IL-6, IL-1β (Butoi et al., 2011). B lymphocytes and plasma cells are 
mostly present in later stage of the disease and mostly in the adventitial layer of 
the vessels. Mast cells are mostly present in the non benign plaque (Kaartinen et 
al., 1998) and neutrophils are usually seen in thrombosed or ruptured plaques 
(Naruko et al., 2002). 
The disease progresses by conversion of monocytes to macrophages which start 
digesting the fatty streak. This leads to the formation of lipid loaded 
macrophages called foam cells. They are considered to be characteristic of 
primitive and recent atherosclerotic activity. The activity of macrophages 
continues till their death which leads to the formation of a soft and destabilized 
lipid core (Glass and Witztum, 2001). Macrophages also contribute to matrix 
degradation by up regulating enzymes like matrix metalloproteinase (MMP) 
(Libby et al., 2002). The immune response due to different mediators discussed 
above, modified LDL and heat shock protein goes side by side throughout all the 
process and modulates the disease (Hansson, 2005). Interaction between foam 
cells and lymphocytes causes the release of inflammatory mediators such as IL-4, 
IL-10 and IL-14 which in turn causes smooth muscle cells to migrate into the area 
(Quillard and Croce, 2015). Smooth muscle cells mediate the fibro-proliferative 
response for healing the artery. Both the inflammatory and healing process 
continue in parallel and in most cases, leaving a massive effect on the vessel 
wall. The lumen is reduced in the process leading to compromised blood flow 
and may precede an ischemic event (Patel, 2014). At the same time, the 
formation of a collagen rich matrix produced by the smooth muscle, is beneficial 
as it can stabilise the plaque and reduce the devastating consequences of 
rupture and thrombosis (Schwartz et al., 2000). 
Cell death due to apoptosis and necrosis in the area of the plaque can occur, 
during the process of atherosclerotic plaque formation (Falk, 2006). This can be 
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followed by calcification of the necrotic area which may increase with age 
(Hoffmann et al., 2003). As this process of deposition of lipid and cholesterol 
continues along with proliferation and migration of smooth muscle cells, the 
plaque grows in size and becomes unstable. MMPs secreted by macrophages 
degrade the fibrous plaque and many other mechanisms including angiogenesis, 
plaque haemorrhage and infiltration of inflammatory cells, makes the plaque 
vulnerable to rupture (Quillard and Croce, 2015). 
In advanced atherosclerotic plaque there is a greater chance of plaque rupture. 
The review by Falk, reported that globally 76% of the mortality due to heart 
attack is because of rupture and/or thrombosis of the plaque (Falk et al., 2004). 
Erosion of the plaque and other ill defined events were responsible for the 
remaining of 24% of the mortality. Plaque rupture was more common in males 
(∼80%) than in females (∼60%). Coronary artery thrombosis was most frequently 
due to rupture of a plaque.  
1.3.4.1 Angiogenesis in malignant plaque and rupture of the plaque 
Angiogenesis also called neovascularisation (see section 1.3.5 for details), is 
frequently present in the advance stages of atherosclerosis  and is probably one 
of the markers distinguishing a malignant plaque from a benign one (O'Brien et 
al., 1994). Under normal physiological conditions angiogenesis is rare in arteries. 
It is thought that endothelial dysfunction initiates the process of angiogenesis 
following plaque formation (Moreno et al., 2006). Atherosclerosis stimulates 
angiogenesis by switching on the angiogenic switch through changing the 
concentrations of angiogenic and angiostatic mediators (Matsunaga et al., 2005). 
In the initial stages as the plaque size increases, intimal neovascularisation as 
well as hyperplasia of the vasa vasorum in the adventitial layer occurs to provide 
nutrition to the plaque cells and medial arterial walls. In the later stages, 
however, the ectopic neovascularisation is initiated by vessels in vasa vasorum 
(Patel, 2014). The intimal neovascularisation is derived mostly from adventitial 
vessels in most cases (96.5%) as compared to arterial lumen (3.5%). Typically, 
angiogenesis originates in the adventitial layer and erodes into the base of the 
plaque. Increased blood pressure in the atherosclerotic area causes the 
adventitial vessels to collapse and impairs the local blood flow which in turns 
produces local hypoxia and stimulates angiogenesis (Fleiner et al., 2004). 
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Adventitial angiogenesis continues as the disease progresses. It is thought to be 
an adaptive mechanism to provide nutrients to the medial wall and prevent local 
ischemia. However, despite its protective role, it contributes to the increase in 
plaque size and leads to adverse cardiovascular events. Vessel density in the 
vasa vasorum in advanced stages of atherosclerosis has been reported to be 
higher than early stage (Fleiner et al., 2004). In the later stages of the disease 
the sub-intimal space and media decreases and become sandwiched between 
intima and adventitial, leading to sprouting of the neo-vessels to plaque in the 
intima (Herrmann and Lerman, 2007). 
Vessels formed as a result of the angiogenesis lead to local influx of the 
inflammatory cells, red blood cells and plasma protein, which may play an 
important role in the rapid progression of atherosclerosis (Virmani et al., 2005). 
These neo-vessels are leaky, more delicate and prone to micro and gross 
haemorrhage into the plaque area (Armstrong et al., 2011). The leaky neo-
vessels cause more influx of inflammatory cells and RBCs into the plaque. Lyses 
of the RBCs adds to increase lipid load and plaque size and hence increase the 
plaque vulnerability to rupture (Moreno et al., 2004).  
In summary, angiogenesis plays an important role in the early stage of 
atherosclerosis by providing nutrition to the medial wall of the diseased artery. 
In the later stages, angiogenesis provides a secondary route for transfer of many 
inflammatory mediators and lipid deposition into the plaque. This in turn adds to 
the vulnerability of the plaque to rupture. However, angiogenesis is not the only 
process increasing the malignancy of atherosclerotic plaque. Many other 
mechanisms are thought to play important roles as shown by morphological 
characteristics of malignant plaques i.e. thin fibrous cap, angiogenesis, large 
lipid core, necrosis, intra plaque haemorrhage and excessive inflammatory cells 
infiltration (Nighoghossian et al., 2005, Patel, 2014).  
1.3.5 Angiogenesis 
Angiogenesis is defined as the formation of new vessels from the capillary beds 
already present (O'Brien et al., 1994). The word is derived from ancient Greek.  
“Angio” means vessel and “genesis” means birth, collectively meaning the 
production of new vessels (Korivi et al., 2010). However, vasculogenesis is also a 
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process of formation of vessels from the primitive vascular plexus and can be 
differentiated from angiogenesis. The latter arises from the pre-existing vessels. 
Vasculogenesis starts during embryonic life and give rises to heart and first 
vascular web. Subsequent remodelling and expansion of this primary network to 
secondary network is brought about by angiogenesis (Distler et al., 2003, Korivi 
et al., 2010). 
The term angiogenesis was formerly used to describe the formation of vessels 
after terminal capillaries. The most recent studies use angiogenesis to describe 
the conversion and development of simple vascular networks into a more 
complex ones (Carmeliet, 2000). Angiogenesis occurs under normal physiological 
conditions in processes like wound healing, body development, damaged tissue 
repair, female reproductive cycle and pregnancy. However, progressive 
angiogenesis can be dangerous, for example in the presence of primary plaque, 
it can expand the size of plaque causing significant complications like vascular 
thrombosis and rupture of the plaque etc (O'Brien et al., 1994, Isner, 1999, 
Kahlon et al., 1992). Moreover, impaired regulation of angiogenesis can also  
lead to other pathological conditions like tumour progression and metastasis etc 
((Boehm et al., 1997) (Distler et al., 2003), delayed wound healing (Charifi et 
al., 2004), age related macular degeneration and diabetic retinopathy (Korivi et 
al., 2010). 
Angiogenesis is regulated through a balance of endogenous angiogenic 
(activators) and angiostatic (inhibitors) factors (Hanahan and Folkman, 1996) 
with a precise mutual interactions (Distler et al., 2003). Any shift in favour of 
positive regulators will lead to angiogenesis and a shift towards negative 
regulators will lead to angiostasis. Under normal physiological conditions, the 
angiostatic factors outweigh the angiogenic factors, not allowing the 
angiogenesis to occur. It is only under pathological circumstances like wound 
healing the angiogenic factors overcome the angiostatic factors leading to 
angiogenesis (Distler et al., 2003, Hall et al., 2006).  
To date about 30 angiogenic and angiostatic factors are known. Angiostatic 
mediators include Endostatin, Angiostatin, Thrombospondin, Pigment epithelium 
derived factor (PEDF) etc (Distler et al., 2003).  
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Angiogenic factors are divided to 3 different categories based on their effects at 
different levels and target cells. These categories include;  
i. Factors affecting degradation of basement membrane and consist mostly 
of proteolytic enzymes like plasminogen activator (PA) and matrix 
metalloproteinases (MMPs) (Liekens et al., 2001).  
ii. Factors affecting endothelial cell proliferation and migration and these 
include; VEGF, Angiopoietin, Fibroblast growth factor (FGF) and other 
cytokines, chemokines and enzymes. This group also includes non directly 
related mediators such as tumor necrosis factor-alpha (TNF-α) and 
transforming growth factor-beta (TGF-β) (Klagsbrun and Moses, 1999). 
iii. Factors which help in migration, cell to cell and cell to basement 
membrane interactions called adhesion molecules. These include;  
different Immunoglobulins, selectins, integrins and cadherins (Bischoff, 
1997). 
The process of angiogenesis can be activated readily through various mechanisms 
and factors; such as metabolic stress, physical stress, inflammation. Metabolic 
stresses include hypoxia, decreased pH and low calcium levels (Carmeliet and 
Jain, 2000, Korivi et al., 2010). 
1.3.5.1 Mechanism of angiogenesis 
Angiogenesis starts with dilatation of the vessels mediated by Nitric Oxide (NO), 
released by the vascular endothelial growth factor VEGF (see section 1.3.7) 
through its action on NOS. VEGF also increases the permeability of endothelial 
cells with formation of vacuoles from central to peripheral part. The transport 
of plasma protein and plasminogen to the surrounding space rises and serves as 
base for the migration of endothelial cells (Kohn et al., 1992, Dvorak et al., 
1995). Before this migration, removal of the mural cells, reshaping of the stroma 
and degradation of the basement membrane is mediated by angiopoietin along 
with different mediators including plasminogen, proteases, chymase and matrix 
metalloproteinase (Moses, 1997).  
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This is followed by VEGF, FGF and angiopoietin dependent migration of 
endothelial cells through the degraded basement membrane and proliferation in 
the reshaped perivascular space. They form a tube like structure by arranging 
themselves in a monolayer (Distler et al., 2003). Transport of mesenchymal cells 
and their proliferation and conversion into pericytes and smooth muscle cells at 
the anti-luminal surface occurs. These cells stabilises the vascular tube (Kurz, 
2000).  
1.3.5.2 Different angiogenic and angiostatic mediators and their role in 
control of angiogenesis 
As mentioned in section 1.3.5, angiogenesis is controlled and regulated by many 
endogenous angiogenic and angiostatic mediators. This section will briefly 
discuss some of the most important angiogenic and angiostatic mediators and 
their role in angiogenesis. 
Angiogenic mediators 
Vascular endothelial growth factor (VEGF) 
VEGF is probably the most important angiogenic factor and it initiates the 
process of angiogenesis. It has been shown that disruption of a single allele of 
the VEGF gene in mice causes severe vascular abnormalities and intra uterine 
death (Ferrara et al., 1998). The specific actions of VEGF include: endothelial 
cell proliferations and migration, increasing permeability of the endothelial 
cells, induction of the MMP and plasminogen and increasing endothelial cell 
survival by decreasing apoptosis (Distler et al., 2003). This is further discussed in 
section 1.3.7. 
Fibroblast growth factor (FGF) 
There are 22 different types of fibroblast growth factors identified so far in 
human body. They are heparin sulphate binding proteins. FGF were amongst the 
first molecules shown to initiate angiogenesis (Ornitz and Itoh, 2001). They act 
on endothelial cells and are involved in proliferation of endothelial cells. They 
work in close contact with VEGF as they increase the expression of VEGF and 
plasminogen activator (Distler et al., 2003). They have four different types of 
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receptors (FGFR1, FGFR2, FGFR3, and FGFR4) which are expressed by different 
cells and tissues (Ornitz and Itoh, 2001). FGF are expressed by almost all tissues 
in the body. They are involved in a variety of functions including embryonic 
development, organogenesis, tissue maintenance, repair and regeneration. They 
are also involved in phosphate, bile acid, carbohydrate and lipid metabolism 
(Ornitz and Itoh, 2015). 
Angiopoietin 
These are paracrine growth factors which act on endothelial cells. There are 2 
types of these factors angiopoietin 1 and 2. Angiopoietin 1 is involved in the 
vessel stabilization (Ikeoka et al., 2014) while angiopoietin 2 in the presence of 
VEGF causes migration and proliferation of endothelial cells while in the absence 
of VEGF; it causes apoptosis and destabilizes the blood vessel (Distler et al., 
2003).  
Platelet derived growth factor (PDGF) 
This growth factor is involved in mitosis of cells of mesenchymal origin including 
smooth muscle cells and glial cells. There are 4 different types of PDGF (PDGF A 
– D) and 2 different types of receptors (Distler et al., 2003). They are involved in 
smooth muscle cells and pericytes proliferation during angiogenesis (Carmeliet 
and Jain, 2000, Shah et al., 2014). 
Transforming growth factor-β (TGF-β) 
TGF-β receptors are expressed by pericytes and endothelial cells. TGF-β has 
been reported to have both pro-angiogenic and anti-angiogenic properties. An in 
vitro study has reported angiogenic effects (increased proliferation and 
migration of endothelial cells) of TGF-β while in higher dose the effects are 
opposite (increased proliferation and migration of endothelial cells) (Pepper, 
1997). 
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Tumor necrosis factor-α (TNF-α) 
(TNF-α) is an inflammatory mediator which has similar effects on angiogenesis as 
TGF-α. It also promotes mitosis of endothelial cells and formation of vessel tubes 
in low doses while in high doses it inhibits the FGF induced proliferation of 
endothelial cells (Distler et al., 2003). 
Chemokines 
Chemokines such as CXCR2 and CXCR4 are involved in angiogenesis. They act as 
chemotactic proteins for the migration of endothelial cells (Kanzler et al., 
2013). 
Integrins 
Integrins work as adhesion receptors for many angiogenic and angiostatic factors 
and play important role in the control of angiogenesis. They promote and control 
endothelial cells adhesion, migration and survival (Foubert and Varner, 2012). 
Cadherin 
They are trans-membrane molecules and are involved mainly in cellular 
signalling mechanisms. VE- Cadherin is specifically involved in angiogenesis and 
works closely with β- catenin and maintains the cell to cell adhesion (Bentley et 
al., 2014). 
Other angiogenic factors 
Beside the molecules discussed above many other molecules has been shown to 
have angiogenic effects. These include MMPs, plasminogen, erythropoietin, NO, 
platelet endothelial cell adhesion molecule, insulin like growth factor and 
epidermal growth factor. Their roles are in the later stages of angiogenesis and 
most of them are initiated in response to VEGF action (Distler et al., 2003). 
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Angiostatic factors 
Many endogenous angiostatic factors have been discovered. The most important 
include: 
Endostatin  
It is discussed in detail in section 1.3.6.  
Angiostatin  
Angiostatin is derived from plasminogen. It was first purified from urine of mice 
(O'Reilly et al., 1994). It requires the action of MMPs to produce it from 
plasminogen. It inhibits proliferation and migration of endothelial cells and tube 
formation (Eriksson et al., 2003). It has also been reported to inhibit smooth 
muscle cells migration and proliferation (Walter and Sane, 1999). 
Thrombospondin  
These are glycosylated extracellular proteins with angiostatic effects on 
endothelial cells. TSP-1 and TSP-2 are mainly involved in decreasing endothelial 
cells migration and survival by enhancing apoptosis (Carmeliet, 2000). 
Other angiostatic factors 
Beside the factors discussed above many other angiostatic factors have also been 
reported. These include pigment epithelium derived growth factor, TGF-β, 
MMPs, TNF – α, restin, tumstatin. Interestingly, some of these mediators, such as 
TGF- β, TNF – α, MMPs posses both angiogenic and angiogenic properties (Distler 
et al., 2003). 
The VEGF family plays the most important role in angiogenesis, whereas the 
most important angiostatic inhibitors include Angiostatin, Endostatin and 
Thrombospondin (Korivi et al., 2010, Dameron et al., 1994, O'Reilly et al., 1997). 
However, endostatin has been identified as the main potent inhibitor of 
angiogenesis and is one of the major topics of research in recent times. 
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1.3.6 Endostatin  
Endostatin is one of the potent angiostatic mediators (O'Reilly et al., 1997, 
Abdollahi et al., 2004, Yamaguchi et al., 1999). Endostatin halts angiogenesis by 
specifically inhibiting the proliferation of endothelial cells (O'Reilly et al., 1997). 
It was identified for the first time in conditioned media of 
haemangioendothelioma cells of mice (O'Reilly et al., 1997).  
1.3.6.1 Structure of the Endostatin 
Endostatin is a 20 kDa, C-terminal fragment of collagen XVIII and collagen XV 
(Sasaki et al., 2000, O'Reilly et al., 1997). There are 28 types of collagens 
identified in the mammals (Ricard-Blum, 2011). They are involved in the 
formation of the extracellular fibrillar network. Collagen XVIII and Collagen XV 
are found in the basement membrane (Sasaki et al., 2000). Collagen XVIII is also 
found in the intestine, choroid plexus, skin, liver and kidneys (Halfter et al., 
1998). 
They are classified as part of the multiplexins family with a central collagen 
triple helix sequence and terminal C domain called Non Collagenous or NC1, to 
which endostatin is attached (Marneros and Olsen, 2001). 
Figure 1-2 shows the difference between collagen XV and XVIII. The N terminal 
of collagen XVIII shows three different variants as a result of alternative splicing  
(Muragaki et al., 1995). Both collagen XV and XVIII are proteoglycans which 
differs from other members due to prominent modification by chondroitin 
sulphate in collagen XV (Li et al., 2000) and by heparin sulphate in collagen XVIII 
(Halfter et al., 1998). They are thought to play a significant role in the 
organization of basement membrane and other extracellular structure, as well as 
a source of endostatin release (Sasaki et al., 2002).  
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Figure 1-2; Structure of collagen XV and XVIII 
Collagen XV and collagen XVIII domain structure showing that Collagen XVIII has three different 
splice variants. The endostatin is attached to the NC1 terminal. Figure reproduced with permission 
from (Sasaki et al., 2002). 
The structure and function of endostatin have been studied by many researchers 
(Hohenester et al., 1998, Sasaki et al., 2002). Both endostatin XV and XVIII have 
been isolated from many species including murine cells (O'Reilly et al., 1997), 
bacteria (Ramchandran et al., 1999) yeast (Dhanabal et al., 1999a) and 
mammalian cells (Yamaguchi et al., 1999). 
The form of the endostatin obtained from bacteria was found to be highly 
insoluble with improper folding due to disulfide linked oligomers (Boehm et al., 
1998). However, endostatin in monomeric forms were obtained from yeast and 
mammalian cells with proper folding and high solubility (Sasaki et al., 2002).  
NC1 domain of collagen XVIII consists of 312 residues in human, which comprises 
of N terminal region, a middle hinge part and a C terminal part, to which 
endostatin is attached. The middle part or the hinge contains proteolytic sites 
sensitive to many endogenous proteases, as shown in figure 1-3. These proteases 
initiate the release of endostatin from basement membrane to soluble endocrine 
form (Sasaki et al., 1998). 
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The hinge is flexible and is longer in collagen XVIII with more proteolytic sites 
than in collagen XV. That is why collagen XVIII possesses high susceptibility for 
the proteolytic cleavage and most available form (Sasaki et al., 1998, Felbor et 
al., 2000).  
 
Figure 1-3; NC1 part of collagen XVIII 
Schematic structure of the NC1 part of collagen XVIII is shown. TP is the region of the N terminal 
which shows the area of attachment with collagen XVIII, while ES shows the C terminal area to 
which endostatin is attached. Arrows shows the proteolytic sites and the number represents the 
approximate sequence positions within NC1. Reproduced with permission from the author given in 
appendix “G” (Sasaki et al., 1998). Note that NC1 for collagen XV is identical to this with a smaller 
hinge and less proteolytic sites. 
When the structure of endostatin was determined using high resolution X-Rays 
crystallography, it is globular, about 3 nm in diameter and has 16 beta strands, 2 
alpha helices and 2 disulfide bridges, as shown in figure 1-4 A & B (Hohenester et 
al., 1998, Sasaki et al., 2002).   
The same studies also reported the presence of a patch containing 11 arginine 
residues and a site for zinc binding in collagen XVIII. Arginine residues give 
endostatin XVIII a much higher affinity for binding with heparin than endostatin 
XV, which lacks both. Zinc, however, is thought to provide structural strength to 
the shape of endostatin. Removal of the zinc from recombinant mouse 
endostatin did not affect the inhibitory activity of endostatin (Sasaki et al., 
1999). 
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Figure 1-4; Atomic structures of Endostatin for (A) collagen XVIII and (B) collagen XV 
Collagen XVIII showing 16 beta strands indicated as A-P, 2 alpha helix indicated as 1 & 2, 
disulphide bridges are in Yellow and Zn attachment sight in Pink. Note that there is no zinc 
attachment sight in collagen XV. Figure reproduced with permission from Review Article by 
(Sasaki et al., 2002). 
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1.3.6.2 Release of endostatin and molecular mechanisms for endostatin 
actions  
As discussed earlier, release of endostatin requires a proteolytic cleavage. Many 
endogenous enzymes groups such as protinases including matrix 
metalloproteinases (MMP 3, 7,9, 12,14, 20) (Ferreras et al., 2000), elastase (Wen 
et al., 1999) and cathapsin L (Felbor et al., 2000) have been shown to increase 
the endostatin release.  
Endostatin has been shown to inhibit angiogenesis through many mechanisms. 
Some of them are listed below and shown in figure 1-5. 
Endostatin binds to the α5β1 on the surface of the endothelial cells. After 
binding with the help of cavolin-1, a cascade of molecular events starts leading 
to activation of actin stress fibres. These in turn decrease the migration of 
endothelial cells (Wickström et al., 2003). 
Endostatin has also been reported to bind directly to VEGF receptors and to 
block the VEGF induced phosphorylation of KDR/FLK-1. This stops the signalling 
mechanism of VEGF (Kim et al., 2002). The inhibition of Wnt/β-catenin signalling 
pathway at the level of β-catenin has also been suggested as one of the possible 
mechanisms of endostatin (Hanai et al., 2002). 
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Figure 1-5; Mechanisms for release and different actions of endostatin 
The possible different mechanisms of release and actions of endostatin on VEGF and other 
receptors are shown. Reproduced with permission from the author given in appendix “G” (Seppinen 
and Pihlajaniemi, 2011) 
 
1.3.6.3 Effects of endostatin 
The physiological role and the different cellular responses by endostatin are 
diverse and research is still underway to explore its precise role. Some of the 
established facts are listed below; 
1. A comprehensive and novel in vitro study revealed, endostatin for the 
first time as an inhibitor of endothelial cell proliferation in low 
concentration (O'Reilly et al., 1997).  
2. Endostatin has been shown to disrupt various cellular events in 
angiogenesis including endothelial cell migration induced by VEGF 
(Yamaguchi et al., 1999) and FGF (Eriksson et al., 2003). It also induces 
apoptosis (Dhanabal et al., 1999b) and affects cellular adhesions (Dixelius 
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et al., 2002). Endostatin also inhibits the conversion of pro MMP2 to 
MMp2, which reduces the endothelial cellular invasion (Kim et al., 2000). 
3. Endostatin also inhibits the release of circulatory endothelial progenitor 
cells into the blood stream in mice treated with VEGF (Schuch et al., 
2003). 
4. Endostatin also changes the genetic regulation of angiogenesis. The effect 
is bifocal; including up-regulation of angiostatic  genes and mediators and 
down-regulating the angiogenic genes (Abdollahi et al., 2004). 
5. Endostatin also inhibits proliferation and migration of lymphatic 
endothelial cells. Mice with skin cancers and high expression of endostatin 
were found with decreased lymph vessels density and metastasis through 
it (Brideau et al., 2007). 
6. Endostatin has been used to stop angiogenesis in laser induced ruptured 
Bruch’s membrane of the choroid (Mori et al., 2001). Similarly, formation 
of new vessels in retina and retinal detachment was slowed, when mice 
were given long release intraocular endostatin. No toxicity was reported 
for long term expression and the overall results were reduction in vascular 
permeability, macular oedema and degenerative changes (Takahashi et 
al., 2003). 
7. Endostatin has also shown good effects in reducing the markers and onset 
of inflammatory diseases such as inflammatory arthritis (Yin et al., 2002), 
cystitis (Beecken et al., 2004) and asthma  in mouse models (Suzaki et al., 
2005). 
8. The progression of nephropathy in streptozocin induced type 1 diabetic 
mouse was delayed by endostatin, which suppressed glomerular 
hypertrophy and albuminuria. The hyperglycaemia was however, not 
affected by high endostatin concentrations (Ichinose et al., 2005). 
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1.3.6.4 Endostatin and tumour suppression 
Angiogenesis around many tumour cells has been widely and extensively studied 
(Seppinen and Pihlajaniemi, 2011). As reviewed by Folkamn, endostatin has been 
reported to inhibit 65 different types of cancers including; ovarian, prostate, 
pancreatic, small cell lung tumors and leukaemia. It also affects many tumors 
genetically, leading to down regulation of the angiogenesis (Folkman, 2006). The 
review also reported endostatin to be active against cancers both of human and 
animal origin, with no toxicity reported, in trials as longer as 3 and half years. 
Evidence about endostatin, as endogenous inhibitor of tumour  in genetically 
knocked out mice exists (Sund et al., 2005). Clinical evidence of this effect in 
humans can be correlated to the fact that individuals with trisomy 21 (Down’s 
syndrome) have low incidence of solid tumours. They possess an extra copy of 
collagen XVIII gene and have high concentrations of circulatory endostatin 
(Zorick et al., 2001). Increasing the concentration of endostatin in plasma by 1.6 
fold (almost equal to that of individuals with Down’s syndrome), resulted in 3 
fold slower growth of tumour in mice than wild type (Li and Olsen, 2004). 
Endostatin has been used in  phase 1 (Eder et al., 2002), phase 2 (Whitworth, 
2006) and phase 3 (Sun et al., 2005) clinical trials with less than expected 
results. However, the mechanism of release of endostatin, type, route of 
administration and dosage is still debatable and research has not unified on 
single treatment strategy (Abdollahi et al., 2005).   
Recent research aims to find alternative ways to extract recombinant endostatin 
with high potency, effective dosage and administration mode (Fu et al., 2009, 
Whitworth, 2006). These efforts may see the beneficial effects in near future. 
1.3.6.5 Endostatin and cardiac protection 
Being a potent angiogenic inhibitor, endostatin plays its role in the 
cardioprotective mechanism of the body (Golbidi and Laher, 2011). Increase in 
angiogenic activity signifies healing of the ischemic area (Isner and Losordo, 
1999). However, persistent angiogenesis in cholesterol fed mice, increased the 
plaque expansion significantly up to 14 folds (Celletti et al., 2001). The 
experiment was repeated in rabbits to address question of species difference, 
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with similar results. The progressive angiogenesis also increases plaque 
vulnerability with significant morbid outcomes such as plaque rupture and 
vascular thrombosis (Kahlon et al., 1991). 
These findings signifies the presence of an efficient control mechanism and free 
availability of endostatin in circulation has been suggested to control progressive 
angiogenesis in diseased conditions (Miosge et al., 1999). Endostatin provides 
cardiac protection mainly by halting the angiogenic process and stimulating 
apoptosis (Taddei et al., 1999, Shichiri and Hirata, 2001). Decreases in size of 
atherosclerotic plaque in mice has been reported after treating with 
recombinant endostatin at 20 mg.kg-1.day-1 for 16 weeks (Moulton et al., 1999).  
As discussed earlier in section 1.3.4, formation of the foam cells by macrophages 
after retaining the LDL, is one of the initial steps in atherosclerosis (Williams and 
Tabas, 1998). The blood vessels with the atherosclerotic plaque have been found 
with less endostatin. Based on these observations, Zeng and his colleagues 
demonstrated in vitro, that in the presence of recombinant human endostatin, 
the retaining of LDL decreases significantly (Zeng et al., 2005). 
Angiogenesis is a favourable sign for recovery after myocardial infarction (MI). 
However, using anti endostatin antibody treatment in rats after MI, resulted in 
significantly higher mortalities and morbidities than control group (Isobe et al., 
2010), which also shows its importance in the overall control of the process. 
In conclusion, on the one hand endostatin is involved in the cardio protective 
mechanism of the body against progression of atherosclerosis. The different anti 
atherosclerotic actions of endostatin include inhibition of neovascularisation, 
suppressing the endothelial cell proliferation, reducing the macrophages in the 
plaque area, interfering with the low density lipoprotein retention mechanism 
and antagonising the vascular endothelial growth factor (VEGF) signalling. On 
the other hand, it is required for remodelling of the left ventricle after acute 
myocardial infarction (Isobe et al., 2010, Maemura, 2010).    
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1.3.6.6 Tissue forms and processing of endostatin 
Immuno-staining of the basement membrane of blood vessels has shown 
expression of both types of collagen. Based on this, endothelial and smooth 
muscle cells were assumed to be involved in production of collagen XV and XVIII 
(Marneros and Olsen, 2001). Similarly, human vasculature medium was shown 
with more expression of endostatin than other tissues such as brain and 
myocardial tissues (Sasaki et al., 1998). Out of the two isoforms, endostatin 
derived from collagen XVIII is more frequently available form (Sasaki et al., 
2000).  
Collagen XVIII has been studied in liver cells, especially hepatocytes. They 
revealed a strong expression of collagen XVIII and are thought to be a source of 
endostatin into circulation (Schuppan et al., 1998). 
1.3.6.7 Plasma endostatin concentration in healthy and clinical populations 
The concentration of endostatin in plasma of healthy volunteers is discussed in 
depth in chapter 3 sections 3.2. 
Briefly, endostatin is freely available in circulation. It was first detected by using 
radioimmunoassay methods (Ständker et al., 1997).  The concentrations of 
endostatin measured in plasma and serum were in the range of 0.1-300 ng/ml. 
Lower concentrations were found in urine using the same methods (Sasaki et al., 
1998).  
The basal concentration of circulating endostatin may be generated as a result 
of physiological collagen turnover (O'Reilly et al., 1997). It may play a vital role 
in “Angiogenic Switch”, a homeostatic mechanism controlling angiogenesis 
(Boehm et al., 1997) (Distler et al., 2003).  
Literature has frequently reported higher endostatin concentrations in 
circulation of patients with neoplastic conditions such as stage IV Clear Cell 
Renal carcinoma (Feldman et al., 2000), Colorectal carcinoma (Feldman et al., 
2001a) and non neoplastic conditions with peculiar regulations of angiogenesis, 
such as systemic sclerosis (Hebbar et al., 2000) and diabetes (Sponder et al., 
2011). The specific mechanisms for these differences are not completely clear. 
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However, as mentioned in section 1.3.6 endostatin was purified from 
conditioned media of the cancer cells for the first time and it is possible that 
cancer cells produce both VEGF and endostatin simultaneously (O'Reilly et al., 
1997, Liu et al., 2011, Senger et al., 1983).  
1.3.7 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is an angiogenic factor and a key 
regulator of vasculogenesis and angiogenesis (Ferrara et al., 2003, Neufeld et 
al., 1999). It is a homodimeric glycoprotein having high binding affinity with 
heparin and heparin sulphate in the extracellular matrix (Ferrara and Henzel, 
1989). It is in brain, kidney, heart, spleen, pituitary follicular cells and many 
other cells (Veikkola and Alitalo, 1999). Its production can be induced in 
different types of cells including skeletal muscle cells, myocardial cells, vascular 
and lymphatic endothelial cells, stem cells, monocytes and cancer cells when 
they are exposed to hypoxic conditions (Holmes et al., 2007, Ferrara et al., 
2003, Carmeliet, 2004). It has a molecular weight of 45 kDa. 
The VEGF family consists of 6 isoforms, VEGF (also referred as VEGFA), PlGF 
(Placental growth factor), VEGFB, VEGFC, VEGFD and VEGFE (Veikkola and 
Alitalo, 1999). These isoforms differ from each other in molecular weights and 
functional abilities, such as attachment capability to cell receptors and 
proteoglycans.  
VEGF was discovered in 1983 by Senger et al.  He characterised it as a growth 
factor with a high affinity for heparin causing mitosis of the endothelial cells, 
during the study of vascular patterns in pituitary cells (Senger et al., 1983). 
Purification and cloning of VEGF was done by Ferrara and colleagues (Ferrara 
and Henzel, 1989).  
It is of great importance both during physiological and pathological angiogenesis 
(Ferrara et al., 2003). VEGF specifically causes division of endothelial cells, one 
of the basic pre-requisites for angiogenesis (Neufeld et al., 1999).  
VEGF A is the prototype of all these factors and is simply referred as VEGF due 
to its important and rate limiting role in the process of angiogenesis (Ferrara et 
Chapter: 1 
34 
 
al., 2003). Therefore, this study aims to conduct the research on this VEGF A 
isoform. 
1.3.7.1 Variants of VEGF 
Based on the amino acid sequence and alternative splicing of the VEGF mRNA, 4 
different variants of VEGF are reported. They are VEGF121, VEGF165, VEGF189, and 
VEGF206 (Leung et al., 1989, Tischer et al., 1989). Less frequently available  
variants VEGF145  and VEGF183 were discovered later on (Neufeld et al., 1999). 
The ability of these isoforms to bind with heparin and heparin sulphate differs 
from each other (Park et al., 1993). The VEGF165 has optimum binding capability 
with heparin and heparin sulphate and is closely similar to the native VEGF in 
properties (Houck et al., 1992). Due to easy cleavage of the VEGF165 at the C 
terminus in the extra cellular matrix, this isoform possess optimal biological 
properties and bioavailability, which makes it the predominant VEGF (Keyt et 
al., 1996).  
1.3.7.2 Regulating factors for VEGF 
The regulation of VEGF is carried out by many internal and external stimuli. 
These stimuli/factors can also be called indirect stimuli/factors for the process 
of angiogenesis and vasculogenesis. 
 Hypoxia 
Cell hypoxia is the most potent stimulator of VEGF expression and the 
mechanism is identical to the process, by which hypoxia induces expression of 
erythropoietin (Goldberg and Schneider, 1994). Hypoxia mediates the 
transcription of  VEGF mRNA by binding hypoxia inducible factor 1 (HIF-1) to the 
HIF-1 site on VEGF promoter gene, leading ultimately to over expression of the 
VEGF (Levy et al., 1995).  
Cytokines and other growth factors 
A plethora of stimuli are involved indirectly in regulating the expression of VEGF 
mRNA in different cells. These stimuli include cytokines such as Interleukin1-
beta (IL-1β) (Li et al., 1995), Interleukin6 (IL-6) (Cohen et al., 1996), growth 
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factors such as, fibroblast growth factor 4 (FGF-4) (Deroanne et al., 1997) and 
transforming growth factor beta (TGF-β) (Pertovaara et al., 1994). 
1.3.7.3 VEGF Receptors 
There are two main subtypes of VEGF receptor. VEGF receptor 1 (VEGFR-1) and 
VEGF receptor 2 (VEGFR-2), which are members of the receptor tyrosine kinases 
(RTKs) family (Ferrara et al., 2003). VEGFR-1 and VEGFR-2 are expressed mostly 
by endothelial cells (Neufeld et al., 1999) and some other cells such as 
monocytes (Barleon et al., 1996) and stem cells in bone marrow (Katoh et al., 
1995). Though the activity of VEGF is limited to VEGFR-1 and VEGFR-2, but these 
receptors are capable of transducing the signals from all other members of VEGF 
family (Takahashi and Shibuya, 1997). Just like VEGF activation, hypoxia can 
regulate the expression of both receptors directly (Gerber et al., 1997) and 
indirectly (Wilting et al., 1996). 
Activation of these receptors initiates different types of responses. For example 
activation of VEGFR-1 leads to migration of the endothelial cells (Barleon et al., 
1996). Activation of VEGFR-2 receptors leads to the proliferation of the 
endothelial cells (Ferrara et al., 2003). These differences in signalling cascade 
caused by the activation of these receptors are not completely clear. Briefly, 
activation of VEGF receptors cause breakdown of the basement membrane 
through production of proteases like phospolipase C-γ in the first phase. In the 
later phase, these receptors up regulate the expression of integrins required for 
angiogenesis and ultimately take part in the proliferation and migration of 
endothelial cells (Ferrara et al., 2003). VEGF165 also interact with other 
receptors such as neuropilin-1 (NP-1), located on endothelial cells surface (Soker 
et al., 1998). 
1.3.7.4 Functions of VEGF 
VEGF plays central role in the process of angiogenesis and vasculogenesis and is 
involved in many physiological and pathological process, in developmental and 
adult life.  
During development of the embryo, VEGF induced by hypoxia causes 
angiogenesis accompanied by organ development. The best example is the 
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development of retina and its vascular system. Some of the studies reported that 
reduced VEGF supply can lead to non development of organs like corpus luteum 
in rat models (Ferrara et al., 1998).  
Early neonatal development needs optimal activity of VEGF. It was showed that 
partial inhibition of VEGF leads to early neonatal death and stunted nourishment 
in mouse models (Gerber et al., 1999). 
Optimum concentration and activity of VEGF is required for the development of 
cardiovascular system. VEGF Knockout mice show premature deaths due 
incomplete cardiovascular system development (Carmeliet et al., 1996).  
VEGF production by tumour cells is essential for their growth (Hanahan and 
Folkman, 1996, Folkman, 1990). Inhibiting the VEGF signalling mechanism in 
tumor cells has shown impaired and reduced growth of cancer (Kim et al., 2000). 
Moreover, chemotherapies which includes anti VEGF receptor drugs gives a 
better prognosis (Klement et al., 2000) and reduction of tumor metastasis 
(Skobe et al., 1997). These findings suggest the development of anti VEGF drugs 
as a treatment option for many cancers.  
VEGF plays an important role in ovarian angiogenesis during follicular stage. The 
inhibition of VEGF during this stage has shown delayed follicular development 
(Ferrara et al., 2003). 
VEGF also promotes production of surfactants in alveoli and tends to stop 
apoptosis by over expressing anti apoptotic proteins and hence increase 
endothelial cells survival (Gerber et al., 1998). 
1.3.8 Techniques for measurement Endostatin and VEGF 
Different techniques such as ELISA, Western blotting, Mass spectrometry etc, 
have been used to measure circulatory endostatin and VEGF concentrations. This 
is reviewed in chapter 3, table 3-1. ELISA has been used frequently due to its 
peculiar abilities of measuring single proteins in a sample and one of the most 
validated tools for biomedical research across the globe on cytokines and other 
protein derived factors (Leng et al., 2008).  
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1.3.8.1 Enzyme Linked Immunosorbent Assay (ELISA) technique 
Over the last few decades the improvement in the field of research is enormous 
and older techniques are widely replaced by much better and sophisticated 
ones. 
One such technique is ELISA, introduced in 1971 by Engvall, which take over the 
older isotopes labelling technique. The latter technique had a greater chance of 
contamination (Butler et al., 1978). ELISA is the best validated techniques used 
in clinical and research laboratories (Leng et al., 2008). 
1.3.8.2 Principle of ELISA 
The principle of ELISA is based on the antigen antibody interaction where 
samples with unknown quantity of the antigens interact with pre-coated 
antibodies on to the well of ELISA plate. After immobilization of the antigen, 
detection antibody is added to the wells, which form antigen antibody complex. 
An enzyme is attached to this complex. The ELISA plate is washed between the 
steps with wash buffer to remove unbound antibodies. In the final step a 
substrate solution is added to the well which produces signals on reaction with 
enzymes, in form of developing a colour. A stop solution, usually sulphuric acid 
(H2SO4) is added in the final stage to shut off the activity of enzymes. The colour 
intensity can be quantified by reading with a multichannel spectrophotometer 
(Crowther, 2008).  
There are three different types of ELISA. 
Direct ELISA 
In this type of ELISA, antigen is incubated to the plastic wells, followed by a 
direct application of antibody with enzymes. 
Indirect ELISA 
In this type of ELISA, antigen is incubated into the plastic wells, followed by a 
primary antibody. After incubation, a secondary antibody with enzymes is 
introduced against primary antibody. The secondary antibody is usually referred 
as anti species conjugate. 
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Sandwich ELISA 
This is one of the more specialized forms of ELISA, used for antigens in low 
quantity or unrefined forms. In this type of ELISA the antigen does not attach 
directly to the wells. The principle of this type of ELISA is based on two 
monoclonal antibodies. The first antibody is added directly to the wells (Pre 
coated) to which the antigen is incubated. The second antibody is added after 
the incubation of the antigen to the first antibody, as illustrated in the figure 1-
6. The second antibody is usually conjugated with enzymes like peroxidase. The 
sandwich ELISA can be direct or indirect. More complex forms of Sandwich ELISA 
also include competition or inhibition ELISA, which work on the same principles 
with pre-titration labelled antibodies and antigen (Crowther, 2008). 
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Figure 1-6; Sandwich ELISA technique 
Two antibodies have been used. First one is pre coated and the second one is used in the 
conjugated step with enzyme. This type could also be referred as direct Sandwich ELISA 
technique. Reprinted with permission from (Crowther, 2008). 
 
1.3.9 Physical Activity  
As the research in this thesis focuses on effects of physical activity on 
angiogenesis mediators, the importance of physical activities in decreasing CVD 
related events along with different effects on endogenous cardioprotective 
mechanisms, are outlined in the following sections. 
Physical activity is defined as the production of movement of the human body as 
a result of contraction and relaxation of the skeletal muscles, consuming more 
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energy than the body at rest (Pate et al., 1995, World Health Organization, 
2014b). 
However, physical activity should not be confused with exercise. Exercise is a 
form of physical activity which is more robust, well ordered, controlled and 
recurring movements of the body muscles with the aim to improve or maintain 
physical fitness (Thompson et al., 2003). According to the American College of 
Sports Medicine, exercise is defined as “Any and all activities involving 
generation of force by the activated muscle(s) that result in disruption of 
homeostatic state”. 
Exercise is categorised into endurance exercise, resistance exercise and sprint 
exercise based on the mode, duration and intensity of the physical activity 
(ACSM, 2013).  
Endurance exercise is performed against relatively low resistance for relatively 
long periods. It involves many repetitions of muscle contraction. Resistance 
exercise is performed against higher resistance for shorter periods of time. 
Sprint exercise refers to short periods of exercise against low resistance. The 
activity usually is maximal and intense (Ghosh et al., 2010). Endurance or 
resistance exercise can be combined with sprint exercise like running with extra 
weight (Ghosh et al., 2010). 
1.3.9.1 Intensity of exercise 
Intensity refers to the rate at which the energy is consumed during physical 
activity (Pate et al., 1995). The intensity of exercise can be expressed in 
absolute or relative terms. Absolute intensity indicates the rate of energy 
consumption during exercise. It is denoted directly in watts, or METs or 
metabolic equivalents. It can also be described indirectly in terms of oxygen 
consumption. One METs is equal to basal metabolic rate which is ≈3.5ml of 
oxygen/kg/min. Relative intensities refer to the individual’s capacity of 
performing exercise. This is usually expressed as percentage of the predicted 
maximal heart rate (HRmax)  or predicted maximal oxygen consumption (VO2max) 
(Fletcher et al., 2001, ACSM, 2013). Different Sub-maximal intensities of 
exercise based on ranges of HRmax and VO2max are given in table 1-2. Near 
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maximal to maximal exercise refers to maximum tolerable effort of individuals 
and they are determined by various criteria discussed in chapter 6. 
 
Exercise intensity HRmax% VO2 max% 
Light 57 to < 64 37 to < 45 
Moderate 64 to < 76 46 to < 64 
Vigorous 76 to < 96 64 to < 91 
 
Table 1-2; Different types of exercise intensities based on percentages of predicted 
maximum heart rate (HRmax) and predicted maximum oxygen consumption (VO2max). Table 
adapted from ACSM  
  
1.3.9.2 Physical activity and risk of cardiovascular disease 
In addition to the risk factors listed in section 1.3.3, lack of physical activity is 
one of the basic modifiable risk factor for CVD. According to the World Health 
Organisation, lack of physical activity causes 6% of deaths due to all causes 
worldwide, making it the 4th leading cause of mortality and is responsible for 
approximately 30% of the ischemic heart diseases and 27% of type II diabetes 
(World Health Organization, 2014b). Regular physical activity substantially 
reduces other risk factors for cardiovascular diseases like obesity (Wing and Hill, 
2001), diabetes (Gill and Cooper, 2008), high blood pressure and elevated 
triglycerides and lipoproteins (Waxman, 2005). Moreover, physical activity can 
help to control bodyweight by balancing the energy consumption to intake 
(DeLany et al., 2014). 
The importance of physical activity in decreasing the mortality and morbidity 
due to cardiovascular disease is widely accepted (Sofi et al., 2008). A recent 
large scale study has shown that regular physical activity can modify the genetic 
predisposition of individuals by 40% to health problems like obesity which is one 
of the major risk factor for CVD (Li et al., 2010). In addition, post MI survival 
rate is greater in individuals involved in physical activity then those with a more 
sedentary life style (Berlin and Colditz, 1990). A meta- analysis of 33 studies 
involving 883,372 participants showed that there was a significant reduction of 
33% in mortality due to all causes amongst the participants, who were actively 
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involved in physical activities. The meta-analysis also revealed a 35% risk 
reduction in cardiovascular mortality showing the inverse relationship of physical 
activity to cardiovascular mortality and morbidity (Nocon et al., 2008). 
Over the last few decades decrease in the low incidence of CVD in active 
population has been reported extensively, in reviews and meta analysis of 
prospective and retrospective research studies (Lee et al., 1997, Williams, 
2001). These finding are consistent with other studies and provides sufficient 
data to identify physical inactivity, as a cause of cardiovascular disease (Powell 
et al., 1987). Physical activity increases the life span by postponing mortality as 
the risk of CVD decrease significantly with each percentile increase in it (Lee et 
al., 1997). This risk reduction ratio is even more pronounced in fit and physically 
active participants (Williams, 2001). 
Modern lifestyles have led to increased numbers of inactive people. This in turn 
increases the obesity due to disturbances of energy balance (DeLany et al., 
2014). Consequently, a cascade of other risk factors like insulin resistance, 
obesity and high blood pressure is initiated with onset of many diseases (Yusuf 
and Ôunpuu, 2003).Thus increasing physical activity remains one of the strongest 
areas for primary prevention of the CVD. Beside these, physical activity is also 
beneficial socially in providing and improving physical and mental health 
(Penedo and Dahn, 2005). The application of increased physical activity as 
preventive measure requires a more multi-dimensional and culturally accepted 
approach (World Health Organization, 2014b). 
1.3.9.3 Physical activity for prevention of CVD 
The World Health Organization recommends that populations should adopt a 
healthy diet and perform the recommended minimum physical activity in order 
to decrease the risk of CVD. The global recommendations are summarised in 
table 1-3; 
 
 
Chapter: 1 
43 
 
 
Age Recommendations 
5-17 years 1 hour of moderate physical activity per week is a must. For further 
benefits physical activity which strengthens muscles and bone should be 
incorporated. 
 
18-64 years Minimum 2 and half hours of moderate or 1 and half hour of strenuous 
activity per week is a must. To gain further benefits the duration can be 
extended and aerobic exercise can be incorporated. 
65 years and old Minimum 2 and half hours of moderate physical activity with aerobic 
exercise is a must. They can increase the duration for better outcomes and 
muscles strength. However, exercise for this age group is limited to the 
ability and degree of mobility of the individual. It is recommended to 
perform physical activity on 3 days of the week at least. 
Table 1-3; Minimal recommendations of physical activities for different age groups by WHO 
 
The American College of Sports Medicine (ACSM) and the Centre for Disease 
Control (CDC) recommends that individuals should do moderate physical activity 
on most days of the week for about 30 minutes per day (Pate et al., 1995). This 
suggestion is supported by the American Heart Association (Thompson et al., 
2003) and the Ministry of Health in Pakistan (Ministry of Health Pakistan, 2004). 
1.3.9.4 Physical Activity and Cardioprotective Mechanisms 
It is quite clear that exercise and physical activity enhances cardiac protection 
but the detailed cellular mechanism is not clear. Particular attention has been 
given to the influence of physical activity on super oxide dismutase (SOD) and 
inducible heat shock protein (Yamashita et al., 1999). However, the recent 
development of new techniques (In-situ hybridization, immunohistochemistry, 
proteomics etc) have identified other cardioprotective mechanisms within 
coronary muscles (Golbidi and Laher, 2011).  
Heat Shock Proteins (HSPs) 
Heat shock response or the production of heat shock protein, also referred as 
“cellular stress response”, is the usual response of cells to a number of 
exogenous stimuli including ischemia, oxidative stress, increased intracellular 
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calcium concentrations, hypoxia, acidosis and protein degradation (Marber et 
al., 1995, Golbidi and Laher, 2011). Cardiac HSPs is over expressed after physical 
activity. An extensive study revealed, over expression of myocardial HSPs 30 to 
60 minutes after an exercise bout in rat myocardium (Powers et al., 2008). The 
mechanism of over expression of the myocardial HSP after exercise is unclear. 
However, other associated changes such as the reductions of glucose and  
glycogen  concentrations, formation of reactive oxygen species, reduction of 
intracellular pH and increased intracellular calcium concentration all take place 
in parallel which might cause HSP over expression (Powers et al., 2008).  
There are different types of HSP including HSP10, HSP40, HSP60, HSP 90 and HSP 
70. All are considered to have cardioprotective qualities (Latchman, 2001). HSP 
70 has been studied in detail and HSP72 a member of the HSP70 family has been 
shown to increase myocardial antioxidant activity. During reperfusion after an 
ischemic episode this protects cells from death by stabilizing the mitochondrial 
complex (Steel et al., 2004), and enable cells to recover quickly (Benjamin and 
McMillan, 1998, Golbidi and Laher, 2011). 
In contrast, other studies reported that during ischemic reperfusion, the over 
expression of HSPs does not stimulate the cardiac protection (Hamilton et al., 
2001).They maintained that  superoxide dismutase was responsible for the 
cardioprotective mechanism in response to exercise (Quindry et al., 2007). It is 
possible that there could be convergence of several different mechanisms onto 
one single mechanism, leading to the initiation of responses necessary for the 
body defence (Golbidi and Laher, 2011).  
Myocardial antioxidant capacity 
Another cellular mechanism against free radicals is the antioxidant system of the 
cells with enzymes such as glutathione, peroxidise, catalase and superoxide 
dismutase (SOD). It is complemented by other components like vitamin E and 
vitamin C which bind with the reactive oxidants and convert them to less 
reactive species (Golbidi and Laher, 2011). Both these enzymatic and non 
enzymatic systems work simultaneously to protect cells (Golbidi and Laher, 
2009). For example, superoxide dismutase neutralizes superoxide to form 
peroxide which is reduced by glutathione peroxidase (Cox et al., 2010). 
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The effect of exercise on the antioxidant capacity of the myocardium has 
remained an important area for research and it has been widely investigated. 
Where, some researchers reported an increase in myocardial glutathione 
peroxidise after exercise (Gunduz et al., 2004), others disagree (Hamilton et al., 
2003). Similar contradictory results about increase and decrease in catalase 
expression after exercise has also been documented (Demirel et al., 2001, 
Lennon et al., 2004). 
However, the best evidence about the increase in antioxidant capacity after 
short term endurance exercise concerns manganese superoxide dismutase 
(MnSOD), which provides protection against heart attacks (Yamashita et al., 
1999). 
Cyclooxygenase II (COX-2) and inducible nitric oxide synthase (iNOS) 
Cyclooxygenase II and inducible nitric oxide synthase play an important role in 
the later phase of ischemic preconditioning. They provide protection to 
myocardium against reperfusion (I/R) injuries after ischemia (Bolli, 2000). Sub 
maximal ischemic stress can activate many complicated stress related 
mechanisms and exercise can produce and activate these pathways in the same 
manner as ischemic stress (Bolli, 2000). 
Nitric oxide (NO) plays a major role in the late phase of ischemic preconditioning 
(Stein et al., 2004). The existing nitric oxide are used and the iNOS is up-
regulated to increase the production of more NO (Stein et al., 2004).This 
triggers many mechanisms involved in cardiac protection such as reductions in 
cardiac oxygen consumption (Shen et al., 1995) and inhibition of the calcium 
transport by the cells (Mery et al., 1993). In addition, NO also produces other 
effects like reversible inhibition of programmed cell death and mitochondrial 
respiration. These mechanisms deliver prolonged protection of heart muscles 
(Loke et al., 1999).  
Exercise plays a central role in regulation of nitric oxide production and even a 
short sessions of physical activity provides a better and prolonged protection to 
the heart muscles in dogs (Babai et al., 2002). 
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Cardiac mitochondria   
Cardiac mitochondria play an important role during the ischemic insult (Golbidi 
and Laher, 2011). Regular exercise brings significant changes in the myocardial 
mitochondria and leads to the adaptations that are more of cardioprotective 
phenotype. For example, endurance exercise reduces the production of reactive 
oxygen species in cardiac mitochondria and this in turn results in high tolerance 
to calcium (Marcil et al., 2006). Moreover exercise also enhances the production 
of antioxidants which in turn increase the anti-apoptotic property of 
mitochondria (Kavazis et al., 2008). Exercise also enhances the level of enzymes 
involved in energy expenditure during exercise,  like acyl-CoA, which enhance 
the β-oxidation of fatty acids and in turns improves the bioenergetics (Kavazis, 
2009). 
Autophagy 
Autophagy is the process of replacement of all old eukaryotic cells and their 
organelles with new cells (Debnath et al., 2005).The process is essential to keep 
the balance between the new generating cells and old cells. The target cells are 
engulfed by the phagosome and transferred to lysosome where they are 
degraded by the lysosomal enzymes (Brady et al., 2007). Autophagy is very 
important during the turnover of amino acids and organelles where it causes 
protein degradation (Tsukada and Ohsumi, 1993). Protein degradation increases 
during exercise and so is the apoptotic activity of the cardiac cells. Exercise 
exerts its cardioprotective effects by up-regulating autophagy during the actual 
endurance physical activity (Dohm et al., 1987),as well as down regulating 
necrosis and apoptosis (French et al., 2008). Autophagy protects cells from 
apoptosis during ischemic injury, as the later causes inflammatory responses 
(Golbidi and Laher, 2011). 
Coronary circulation, arteriogenesis and angiogenesis  
Physical activity enhances the coronary collateral circulation by arteriogenesis 
and angiogenesis (Leung et al., 2008). By widening diameter of coronary arteries 
and arterioles, regular physical activity leads to formation of vascular systems 
with improved blood supply, compensating for the loss occurring through 
occlusion of others arteries (Brown, 2003). 11 to 15 weeks of endurance exercise 
in patients with coronary artery diseases and angina increased thresholds for 
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angina, which suggest improved blood supply to heart muscles (Sim and Neill, 
1974). 
Exercise facilitates angiogenesis either by increasing division of already existing 
endothelial cells or through the mobilization of the progenitor endothelial and 
macrophage cells from the bone marrow (Rehman et al., 2004). There are also 
suggestions of a rise in the mobility of the progenitor cells after exercise in 
healthy individuals (Laufs et al., 2005) and cardiac patients (Steiner et al., 
2005).  
Physical activity affects angiogenesis through over expression of the main 
angiogenic mediator, vascular endothelial growth factor (VEGF) (Isner and 
Losordo, 1999) . However, impaired regulation of angiogenesis can lead to 
angiogenesis dependent diseases like atherosclerosis (Golbidi and Laher, 2011). 
In that case, the angiostatic mediators tend to stop the process of angiogenesis. 
Therefore a fine balance between the pro angiogenic and pro angiostatic factors 
always exist and exercise also plays a key role by in maintain this balance by 
affecting angiostatic regulators like endostatin, leading to inhibition of plaque 
expansion (Gu et al., 2004).  
1.3.10 Conclusion and aims 
It is evident from the preceding sections, that cardiovascular disease remains as 
one of the major health problems across the globe. Research has also 
established many mechanisms in the body which tries to protect the body from 
the development of atherosclerosis. These mechanisms include local coronary 
adaptations as well distant muscular, nervous and blood related events. 
Angiogenesis plays a vital role in the development of atherosclerotic plaque. 
Angiogenesis is regulated by many endogenous angiogenic and angiostatic 
mediators. Vascular endothelial growth factor (VEGF) and endostatin are the 
most important mediators in the process of angiogenesis with opposing actions.  
Evidence also suggests that exercise and regular physical activities are beneficial 
in the primary and secondary prevention of cardiovascular and many other 
metabolic diseases. 
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Exercise affects the angiogenic process overall but the precise effects of 
different intensities of structured exercise on these mediators; especially 
endostatin is not completely understood. Moreover, the protocols of exercises 
and the timings for sample collection to measure these mediators are sometime 
not appropriate.  In addition, most of the studies professional athletes with 
better coronary adaptations have been used as volunteers. Population with 
sedentary behaviour are at higher risk of developing atherosclerosis and the 
effects of exercise in such individuals may be different. 
The hypotheses to be tested are;  
i. Different intensities of exercise would acutely affect endostatin and VEGF 
concentrations differently with inverse relationship.  
ii. It is possible that the effects of the same intensity of exercise might be 
influenced by anthropometric and physical characteristics of the 
individuals as well as gender and exercise mode.  
Therefore, the aim of this thesis is to find out the effects of different intensities 
(mild to maximum) of exercise on plasma endostatin and vascular endothelial 
growth factor concentrations. This project includes 3 studies with separate aims 
highlighted as follow: 
The first study was a pilot project with the following aims; 
i. Establish a basal plasma endostatin concentration within a population of 
healthy individuals 
ii. Investigate whether endostatin concentrations differs between genders 
iii. Investigate whether concentrations differs across anthropometric factors  
iv. Evaluate the ELISA technique for measuring the endostatin concentration 
The first part of second study aimed to investigate the impacts of 3 different 
intensities of exercise (mild, moderate and vigorous) with different durations 
and equal amount of energy expenditure on the plasma endostatin 
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concentration. The second part aims to determine the effects of low and high 
intensities of exercise on plasma VEGF concentration. 
The third study was aimed to investigate the impact of single bout of high 
intensity exercise to the level of volitional exhaustion, on both plasma 
endostatin and VEGF concentrations for up to 24 hours after exercise. 
  
           87 
 
 
 
 
 
 
 
2 Material and methods 
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All the experimental work related to participants and plasma samples were 
carried out in laboratories of the West Medical Building, University of Glasgow, 
between May 2012 and September 2014. 
2.1 Contribution of author and other staff members to 
research discussed in this thesis 
The research in this thesis was designed by the author with advice from his 
supervisor Dr RH Baxendale.  
The author was solely responsible for recruitment of volunteers, anthropometric 
measurements, air displacement plethysmography, blood pressure 
measurements, phlebotomy, plasma separation and ELISA analyses. Mrs. 
Josephine Cooney (Department of Biochemistry, Western infirmary Glasgow), 
provided advice when required about the quality control, reliability and the 
pipetting techniques.   
The exercise tests were carried out with the help of two lab technicians: Mr 
John Wilson and Miss Lynsey Johnston. Mr John Wilson helped me in the 
exercises protocol described in chapter 4 & 5 (sub-maximal exercise), while Miss 
Lynsey Johnston helped in the maximal exercise discussed in chapter 6. 
Plasma analyses for lipid profile were carried out in the Biochemistry 
Department of Western Infirmary, Glasgow by Mrs. Josephine Cooney and Miss 
Khloud Ghafouri.  
All calculations including measurements of different components of exercises, 
IPAQ questionnaire analyses, and statistical analyses were carried out by the 
author.  
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2.2 Ethical review process and approvals 
Ethical approvals were granted by the College of Medical Veterinary and Life 
Sciences Ethics Committee for Non-Clinical Research.  The committee approved 
3 different applications for phases of the study reported in this thesis .All the 
ethical approvals are attached in appendix “A”. It is worth noting that approval 
for the first study took a longer time. The application to the committee was 
made in December 2011 and the final approval came in May 2012, after some 
minor changes. This delayed the start of the experimental work. 
Volunteers in all 3 experiments were given a chance to discuss the complete 
experimental procedures and were provided with the Participant Information 
Sheets before their recruitment into the study. After their agreement, they were 
asked to sign two consent forms, one each for researcher and participant.  
Information sheets and sample of consent form are shown in appendices “B” and 
“C”. 
The participants were informed that participation is entirely voluntary and they 
can stop the experiment at any point of time, if they do not want to participate. 
2.3 Participants 
Young healthy volunteers were recruited for all the 3 experiments.  They were 
mostly students from the University of Glasgow and contacted through posters 
displayed around the main campus and in the School of Life Sciences. In some 
cases, personal contacts to fellow students and friends were also made. 
After showing interest to take part in the study, each volunteer was contacted 
and the experimental procedure was explained. The information sheet was given 
to them and any question asked, was answered.  
Once they agree to participate, they were asked to complete confidential health 
screening questionnaires to confirm their good health. Participants with 
potential health problems, on medication or smokers were not recruited to the 
study. Few such cases were encountered and they are mentioned in material and 
methods section of each study, with respective causes for non recruitment. 
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Three different experiments involving volunteers were performed at different 
times. A short 4th experiment was also carried out on the leftover plasma 
samples obtained from volunteers in experiment 2. A separate approval from 
ethical committee was obtained for that. 
The first experiment had 50 volunteers including 16 females and 34 males. Their 
anthropometric and physical characteristics are given in chapter 3.  
The second experiment included 22 volunteers, 6 females and 16 males. Their 
mean age and anthropometric measurements are given in chapter 4. Each 
volunteer visited the laboratory 4 times, one week apart. The first session 
included familiarisation with equipments and a sub maximal V
.
O2 test to elicit 
intensities and durations for the exercises in main trial. The main trial included; 
exercise at 3 different intensities for different durations followed by taking 
blood samples at different time intervals up to 1 hour.   
In the final study 8 male volunteers were recruited. The participants attended 
the laboratory on 2 consecutive days. The first day was exercise day followed by 
serial blood samples up to 6 hours after exercise. On the second day the 
participants attended the lab for a final 24 hours blood sample. Methods and 
techniques specific to the studies are discussed in the relevant chapter.  
2.4 Inclusion and exclusion criteria 
The inclusion criteria for recruitment into the first study were as follow; 
Healthy male/female volunteers aged 18 to 60 years, 
Not on any medication, 
Non smokers, 
Have not performed any physical vigorous activity/ exercise in the last 24 
hours 
 
The exclusion criteria were; 
Participants with history of known cardiovascular disease or abnormalities, 
If the participant was anaemic on general physical examination, 
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Current illness, 
Lactation, 
Pregnancy, 
Taking part in another research study 
 
The inclusion criteria for second and third study were the same except the age 
of participants were between 18 and 40 years. The volunteers were asked to 
refrain from physical activity for 24 hours before the main trial on all occasions. 
 
2.5 General plan of the experiments 
The design of first study was simple. All the participants attended the lab on 
only one occasion. During this visit the nature of the research was explained to 
them. After their agreement, they were asked to fill consent forms and two 
questionnaires to assess their general health and physical activity behaviour. 
These questionnaires are attached in Appendix “D2” & “D3”.  After measuring 
their weight, height, heart rate and blood pressure, a single sample of 10 ml 
blood was taken. 
In the second experiment the participants, after showing interest were asked to 
attend the lab for familiarization session during which, the use of the 
equipments and nature of the experiment were explained. After the participant 
agreed to take part and signing the consent forms, their health status was 
assessed using health screening questionnaires. The participants wore sports 
clothes. Their height, weight, blood pressure and pulse rate were measured. The 
participants in study 2 were asked to perform a sub maximal exercise test. Data 
from this test was used to predict the intensities and durations of the exercises 
in the main trial. The time and dates for the further 3 visits were arranged and 
they were asked to refrain from physical activity for 24 hours before each main 
trial. The order of the exercise on subsequent visits was randomly arranged. On 
each visit, participants performed exercise at certain intensity for certain 
duration, elicited from the sub maximal exercise test on the first visit.  
On the main trial day, their height, weight, blood pressure and pulse were 
measured again. A cannula was passed in an ante-cubital vein.  Blood samples 
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were taken immediately before and at 10 and 60 minutes after completion of 
exercise. The cannula was then removed. 
The volunteers in 3rd experiment attend the lab on 2 consecutive days. After 
showing interest the nature of the experiment was explained to the participants. 
Written informed consent was taken and questionnaires assessing the health 
status of the volunteers were completed. Their height, weight, waist & hip 
circumference, blood pressure, heart rate and body fat percentages were 
measured. Cannula was put in and basal blood samples were taken. Participant 
exercised on treadmill till exhaustion. Serial blood samples were taken at 10, 
30, 60, 120 and 240 minutes after exercise. The cannula was removed. The 
participant attended the lab on next day for a final 24 hours blood sample.  The 
details of the cannulation are given in section 2.10. No infection or adverse 
effects were encountered during any cannulation. 
2.6 Baseline measurements 
2.6.1 Weight 
The weight of each volunteer was recorded using a digital balance (Seca 213, 
Germany). The weight was recorded to 0.1kg. Volunteers stood barefoot with 
minimal possible clothing during the weighing. The scale was checked for zero 
error each day and adjusted accordingly. Volunteers were weighed, with both 
feet on the scale in flat position and arms on the respective lateral sides of the 
body. 
2.6.2 Height 
A fixed stadiometer (Seca, Germany) was used to measure heights of the 
volunteers. The volunteers stood barefoot with the back positioned against the 
scale.  They assumed the lateral anatomical position with chin up, and arms 
relaxed on the respective lateral sides. They were instructed to take a deep 
breath and movable head board was pressed on to the top of the head, with 
pressure enough to compress the hair. The height was measured to the nearest 
0.1cm. 
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2.6.3 Body mass index 
Body mass index (BMI) was calculated using the weight in Kilograms (kg) divided 
by square of the height in meters. 
BMI = Weight (kg)/ (Height (m))2 
2.6.4 Measurements of Blood Pressure 
Blood pressures were measured using the electronic blood pressure monitor 
(Boso Medicus, Jungingen, Germany). Blood pressure was checked after the 
individual rested for 5 minutes. Most of the time, right arm was used for 
checking the blood pressure and in case of any ambiguity contra-lateral arm was 
used to confirm the readings are correct. 139/89 mm Hg was considered as the 
upper limit of the normal range (NICE Clinical Guidelines, 2011). Volunteers with 
blood pressure levels more than permitted were excluded from the study with 
the instructions to have an appointment with General Practitioner. During the 
whole recruitment, two such cases were encountered. 
2.6.5 Waist and hip circumference 
An inelastic and flexible measuring tape was used to measure the waist and hip 
circumference (Seca, Germany). The waist circumference was measured at the 
level of navel, midway between the costal margin and the superior iliac crest in 
a horizontal plane. The hip circumference was taken around the hips at the 
maximum circumferential points in a horizontal plane. These measurements 
were carried out by the same sex investigator and providing full privacy to the 
subjects. The values presented are mean of 3 values. 
2.6.6 Body composition 
A Bod Pod (Bod Pod®, Version 1.69, CA, USA) shown in figure 2-1, was used to 
estimate body fat percentages in the final study. The machine was calibrated 
daily using cylinder of known volume as recommended by the manufacturer. The 
details of the volunteers with height, age and sex were entered using desktop 
computer attached to the Bod pod. 
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The volunteer wore minimal clothing whilst they sat in the Bod pod quiet and 
relaxed with their hands in the lap.  Two or three measurements were made.  
Based on the calibration, the Bod pod uses the air pressure to estimate body 
density and fat percentage. Each measurement takes about 90 seconds and a 
mean of two or three measurements is displayed on the screen at the end.  A 
complete analyses of body composition including; body mass, fat mass, fat 
percentage, lean mass, density and volume of the body is displayed. The device 
is shown in Fig 2-1. 
The principle of Bod Pod (Manufacture information) is based on determining the 
body density from body volume, predicted through air pressure using Boyle’s law 
(COSMED LMI, 2011); 
P1V1= P2V2= Constant 
 
The pressure increases with the decrease in volume and vice versa. Based on 
this, Bod Pod software calculates the pressure changes with volume changes 
during the calibration. The software uses this method to calculate the volume of 
the chamber without the participant and then with the participant. From this 
the volume of the participant is measured as follows; 
 
Volume of the participant = volume of the empty chamber – volume of the 
chamber with participant 
 
Density of the body of the participant is then calculated by using density and 
weight of the participant as follow;  
 
  Density (d) (kg/l) = Weight (kg) / Volume (l) 
 
The participant breathes normally during this process and the volume of the 
body is corrected by the Bod pod using the relaxed tidal breathing volume. 
From the density of the body, lean body fat weight is measured using the Siri 
equation; 
 
Percent Fat = [495/density] - 450 
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Knowing the percent fat lean body mass percentage can be determined as 
follow; 
 
   Percent lean weight = 100 – percent fat 
 
 
 
 
Figure 2-1; Bod pod measurements 
Picture shows one of the participants in Bod Pod chamber for measuring body fat percentage. 
2.7 Exercise 
Different intensities of exercise were used in different studies described in the 
subsequent chapters of this thesis. All of the exercises were carried out on the 
same calibrated automated treadmill (Woodway Ergo ES2, Germany). The 
volunteers were familiarised with the treadmill speeds and controls before test. 
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In study 2, the aims for the participants were to exercise at 60%, 70% and 80% of 
their predicted maximum heart rates. For this reason, all the participants 
undertook a sub-maximal exercise test to estimate the speed necessary to elicit 
these intensities. The test consisted of 4 stages to determine the relationship 
between oxygen consumption and increasing speed. The primary idea was to use 
the same exercise protocol for all participants during sub-maximal test.  This 
protocol asked the volunteers to start running at 6 km/hr in the initial stage for 
5 minutes. Thereafter, speed was increased by 1 km/hr, every 5 minutes. In 
total 4 stages were measured for each participant. The expired air was collected 
in Douglas bags during the last minute of each stage. 
However, some of the volunteers were not able to run at this speed. For all such 
volunteers, the speed was adjusted according to their comfort. In order to get 
higher heart rates during the sub-maximal tests, the inclination angle of the 
treadmill was increased every 5 minutes. Same speed for each volunteer was 
employed in the main trials. 
2.7.1 Sub-maximal oxygen consumption test 
During the sub-maximal test volunteers walked or run on a treadmill (Woodway 
Ergo ES2, Germany), according to their comfort, using standard Douglas bag 
technique for collection of expired gases.  
The volunteers wore head sets to support the apparatus for collecting expired 
air gases. Volunteers breathed through a mouth piece (Medgraphics, Minnesota, 
US) attached to two-way respiratory valve (Hans Rudolph, Two-Way Non-
Rebreathing valve, Kansas, US), while wearing a nose clip to stop nasal 
breathing. The mouth piece was connected to light weight tube of 150cm length 
and 30mm width, which terminates on a two way valve at the junction with the 
Douglas bags (Medgraphics, Minnesota US). The expired air gases were collected 
during the last minute of each stage. During this period, the heart rate was 
monitored continuously and recorded every 15 seconds. The average heart rate 
during collection time was used in the final calculations. 
The temperature of the room was kept at 21oC for all sub-maximal tests. At the 
start of the test, all volunteers stood on the treadmill at rest for 5 minutes. 
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After this, the first stage of the test was started based on selecting a 
comfortable speed (4 to 5 km/hr for walking group and 6 km/hr for running 
group) for each participant. If it was a walking protocol, the gradient of the 
treadmill was increased in each subsequent stage by 3%. In case of a running 
protocol, speed was increased by 1 km/hr. The test was stopped at the end of 
the stage, if the heart rate reached 85% of maximum predicted. Usually the test 
comprised 4 stages excluding the rest stage, as shown schematically figure 2-2. 
Predicted maximum heart rate was calculated using the formula; 
 Maximum heart rate (HR max) beats.min-1 =220 - age in years 
 
Figure 2-2; Multi stage sub-maximal exercise test 
Schematic diagram of 4 stage sub-maximal exercise test performed by the participants in chapter 
4. It is presented with gradient % which was used for walking group. The test was the same for 
running group except they started at higher speed (6 km/hr) which was increased by 1 km/hr 
instead of gradient%. The light blue blocks represent the expired air and heart rate measurement 
periods. 
 
2.7.2 Measurement of Oxygen and Carbon dioxide in the 
expired air gases during sub maximal test 
A Servomex 1440 Dual Gas Analyser (Servomex Limited, Sussex, England) was 
used to measure the concentration of oxygen (O2) and carbon dioxide (CO2), as 
fractions of the collected gases. It was calibrated with standard gases of known 
concentration each day before test. The flow rate of gases through the machine 
Chapter: 2 
61 
 
were determined and added to the remaining volume in the Douglas bags at the 
end. The flow rate used was 0.5litre/minute. 
The remaining volumes of gases in the Douglas bags were measured using 
Harvard Dry Gas Meter (Harvard Apparatus Limited, Kent England). The 
temperature of the expired air was measured by a digital thermometer 
connected to the outlet of dry gas meter. The barometric pressure was recorded 
using the Fortin barometer (FD, Watford UK). 
2.7.3 Calculation of oxygen uptake (V
.
O2), carbon dioxide 
production (V
.
CO2)  
The expired air gases were collected at ambient temperature and pressure. A 
correction factor was used to convert the recorded volumes to standard 
temperature and pressure. This process is based on the universal gas equation. 
Ambient pressure and temperature refers to the pressure and temperature 
during test conditions, while standard pressure refers to 760mm of Hg and 
standard temperature refers to 273K (0◦C). The expired air contains water 
vapours that exert pressure which was corrected using the following equations: 
V
.
ESTPD = (V
.
EATPS x (BP – SWVP)/760) x 273/ (273 + t) 
Where STPD refers to standard temperature and pressure, ATPS refers to 
ambient temperature and pressure with water vapours, BP is barometric 
pressure and t refers to temperature of the gas in degrees Celsius. 
SWVP refers to the saturated water vapour pressure at ambient temp and was 
calculated as follow: 
SWVP = (1.1001 x t) – 4.19 
SWVP is measured in mm of Hg and t is temperature in degrees Celsius. 
 
Chapter: 2 
62 
 
Oxygen uptake and carbon dioxide production were calculated as follows:   
       Oxygen uptake = Volume of O2 inspired - Volume of O2 expired 
V
.
O2=V
.
I x FIO2%/100 - V
.
E x FE O2%/100 
 
Carbon dioxide production = Volume of CO2 expired - Volume of CO2 Inspired 
V
.
CO2 = V
.
E x FE CO2%/100 - V
.
I x FICO2%/100 
Where V
.
O2 refers to the oxygen uptake and is expressed (l/min). To get the V
.
O2 
in ml/kg/min, we multiplied the volume in litres by 1000 and divided it by the 
weight in kg. 
V
.
CO2 refers to the carbon dioxide production and is expressed (l/min). To get 
the V
.
CO2 in ml/kg/min, the volume in litres was multiplied by 1000 and divided 
by weight in kg. V
.
I refer to the inspired air volume per minute and V
.
E refers to 
the measured expired volume per minute.  FIO2% is the percentage of oxygen in 
atmospheric air taken as 20.93% and FEO2% is the percentage of oxygen measured 
in the expired air. FECO2% is the percentage of carbon dioxide in the expired air 
and FICO2% is the percentage of carbon dioxide in the atmospheric air which is 
0.03%. 
Inspired air gas (V
.
I) is an unknown value and Haldane transformation was used to 
determine the inspired air volume (Consolazio et al., 1963). The Haldane 
transformation equation is as follow: 
         V
.
I= V
.
E x FEN2%/FIN2% 
Where FEN2% is the percentage of nitrogen in the expired air and FIN2% is the 
percentage of nitrogen in the atmospheric air. 
Once the volumes of inspired gases are known; oxygen uptake, carbon dioxide 
production, respiratory exchange ratio and minute ventilation values were 
determined.  
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2.7.4 Calculation of energy expenditure 
The second study required the participants to use 200 kcal of energy during each 
session of the exercises based on different intensities. Therefore, the energy 
expenditure per minute at that specific intensity was calculated to find out 
durations required for one session of exercise. For this reason, respiratory 
exchange ratio was calculated during each stage of the sub maximal exercise 
from V
.
O2 and V
.
CO2. 
Respiratory exchange ratio (RER) = V
.
CO2 /V
.
O2  
Where V
.
CO2 is the volume of carbon dioxide produced and V
.
O2 is the volume of 
oxygen consumed. 
The rate of carbohydrate oxidation and rate of fat oxidation were calculated, 
using the indirect calorimetric method described by (Frayn, 1983). 
Rate of carbohydrate oxidation (CHO) = (1.4 x V
.
CO2-V
.
O2)/0.3 
Rat of fat oxidation = (V
.
O2 - V
.
CO2)/0.57 
 
The rates of oxidation of fat and carbohydrate are expressed in gram/minute. 
The rate of energy expenditure was then calculated using the following formula: 
Energy expenditure EE (kJ/min) = (Rate of carbohydrate oxidation x15.6) + (Rate 
of fat oxidation x 39) 
This rate of energy expenditure is in kilojoules (kJ) per minute. Values of 15.6 
and 39 refer to the density of energy in kJ per 1gm of carbohydrate and fat 
molecules respectively. To convert the energy expenditure to kcal/min the 
values were divided by conversion factor as follow; 
     EE kcal/min = EE kJ.min-1 x 0.239 
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2.7.5 Measurement of predicted maximal Oxygen 
Consumption (V
.
O2 max), intensities and durations for 
main trials 
In the second study, participants had to perform exercises at 60%, 70% and 80% 
of their predicted maximum heart rate. For this reason predicted maximal 
oxygen consumption was calculated (V
.
O2 max), by plotting average heart rate at 
each stage against the oxygen consumption (V
.
O2). The slope of the graph was 
extrapolated to the predicted maximum heart rate, as shown in figure 2-3. The 
unknown values were calculated with the formula given in the figure, where x 
refers to the value at specific time point. 
 
Figure 2-3; Prediction of maximal oxygen consumption (V
.
O2max) from sub-maximal oxygen 
uptake (V
.
O2) 
The graph represents data of one subject, showing oxygen consumption in ml/kg/min and heart 
rate in beats per minute during different stages of sub-maximal test. Five samples (including rest 
sample) were taken during the test. After plotting the data a linear trend line was added with 
extrapolating it to the maximum predicted heart rate of 190 beats per minute. Participant was 30 
years old. The line is fitting the data properly, as shown by R
2
=0.9954. 
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 Once the V
.
O2 max value is established, it is straightforward to calculate the V
.
O2 
at 60%, 70% & 80% of the heart rate, which are shown by the green, blue and red 
lines. The estimated V
.
O2max in this case was 52 ml/kg/min and the values were 
17 ml/kg/min, 26 ml/kg/min and 38 ml/kg/min respectively, for exercise at 
60%, 70% and 80% of the predicted maximum heart rate. 
Graphs for each individual were plotted for determining work rate (speed or 
gradient) and energy expenditure per minute at each respective intensity. 
Finally, 200 kilocalories were divided by the amount of energy expenditure per 
minute at respective specific speed to find out the duration of exercise for each 
subject. 
2.8 Heart rate 
Heart rate of the volunteers was monitored during all trials mentioned in this 
thesis through short range telemetry system (Polar FT1, Finland).  
2.9 Maximal exercise 
For the study discussed in chapter 6, the volunteers performed maximal exercise 
test on a treadmill (Wood way, Germany). The test was carried out according to 
protocol designed by Taylor (Taylor et al., 1955), with slight modifications. The 
initial warm up stage of the test started at speed of 5.6 km/hr and a gradient of 
10% which was equal to 230W. After this, speed was kept constant at 8 km/hr, 
for all volunteers with an initial gradient of 0. The gradient was then increased 
at a rate of 2.5% every three minute, till volitional exhaustion. After the first 
test was conducted, it was found out that the work load of 230W in the warm up 
stage is more than the work load of 211W in stage 1. So in the subsequent tests, 
the speed of the warm up was decreased to 4.6 km/hr with 10% gradient. This 
was equal to a work load of 193W. 
Volunteers wore a head set to support the mouth piece attached to the one way 
valve, as described in section 2.6.1, for analysing the expired air. The expired 
air passed through a breath by breath analyser (Medgraphics, Braunfels, 
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Germany), which was calibrated with the known concentrations of O2 and CO2 
before every single test, as shown in figure 2-4.   
To ensure volunteers are not hyperventilating, they were asked to stand calm on 
the treadmill for at least three minutes until RER of < 0.85. Heart rates were 
recorded throughout the test and perceived rates of exertion were recorded at 
the end of each stage, using Borg Scale (Borg, 1973). 
The machine analyses every single breath in real time and displays the results on 
the screen attached to it.  These include; oxygen uptake (V
.
O2), Carbon dioxide 
production (V
.
CO2), respiratory exchange ratio (RER) and respiratory rate. 
Each stage was 3 minutes long. The calculations are based on data collected 
between 1 minute 45 seconds and 2 minutes 45 seconds of this period. The data 
from the last minute of the last stage was taken as the maximal effort and 
oxygen uptake was considered as (V
.
O2max).  
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A 
 
B 
 
Figure 2-4; (A) Maximal oxygen consumption test and (B) breath by breath analyser 
Panel (A) shows picture of one participant during maximal exercise test, breathing through one way 
value while wearing nasal clip. Panel (B) shows the breath by breath analyser with participant data. 
Picture presented with written permission of the participant and laboratory assistant.  
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2.10 Post exercise lactate concentration 
In chapter 5, one of the required criteria of the maximal exercise effort was to 
determine blood lactate concentrations at 1 min, 3 min and 5 minutes intervals 
post exercise. The thumbs of the volunteers were pricked with disposable lancet 
and small amount of blood was collected in short capillary tube (Analox, London, 
UK). The tubes are heparinised to stop blood clotting. This was then transferred 
through a small pipette directly to the blood lactate analyser (Analox, London, 
UK), which read the sample within 30 seconds and display result. 
2.11 Blood sampling 
In all the three sets of experiments serial blood samples were collected by 
insertion of a 20G cannula (Versatus-W, Leuven, Belgium) in the ante-cubital 
vein. Standard aseptic procedures were used. The cannula was connected to 3 
way valve connector (BD ConnectaTM, Sweden) after removal of needle. The 
connection was kept in place by applying transparent I.V line dressing (EASI-V, 
Unimedical,UK), as shown in figure 2-5. Blood samples were taken by 
attachment of the holder to the three way connector and collecting the blood in 
6ml EDTA (ethylene di-amine tetra acetic acid) tubes (BD Vacutainer, Plymouth, 
UK). These tubes were selected to meet requirements of the ELISA kits. After 
taking blood samples, the cannula was flushed with non-heparinised normal 
saline solution (0.9% NaCl) to prevent blocking of the cannula.  
Where single blood samples were required, they were taken aseptically with 21G 
butterfly (Nipro Corporation, Zaventem, Belgium) from anti-cubital vein. All 
blood samples were immediately kept on ice before centrifugation. 
Plasma from the blood was separated using centrifuge machine (Universal 320R, 
Tuttlingen, Germany) at 1000 revolutions per minute for 15 minutes at 4◦C. 3 
aliquots of plasma were separated in 0.5ml of Eppendorf tubes and kept in 
freezer at -80oC prior to analyses. The storage times were kept minimal. In most 
of the analyses, the storage time was less than 2 months except the second part 
of study 2, where analyses of the VEGF were done after 6 months. These storage 
times are acceptable. An extensive study on storage timings and VEGF 
concentration has shown that the VEGF protein concentration is affected by 
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repeated freeze thaw cycles and extended storage time before centrifugation. 
Once the centrifugation is done in time (2 to 4 hrs), the protein concentration 
can be accurately determined up to 2 years (Azimi-Nezhad et al., 2012). The 
samples used in our studies were always centrifuged within 30 minutes of 
collection and thawed only once. 
 
 
Figure 2-5; Cannula in ante cubital-vein 
Picture showing the cannula in the anti-cubital vein of a participant attached to a 3 way connector 
filled with normal saline to keep the tube patent. 
2.12 ELISA 
The plasma samples were analysed for endostatin, VEGF and insulin through 
ELISA techniques. All the ELISA performed in these studies used quantitative 
sandwich ELISA technique, which works on the principal of two antigenic 
determinants directed against two monoclonal antibodies. The first monoclonal 
antibody is fixed to the walls of micro titration well on the ELISA plate to which 
the antigen in the samples attaches. The second one is in conjugate solution 
attached to peroxidase enzyme. Unbound antibodies are washed away in the 
washing process and substrate solution is added to the wells. The substrate 
solution contains Tetramethyl benzidine (TMB) and hydrogen peroxide which 
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produces a colour on reacting with the enzyme labelled antibodies. After 
incubation, the density of the colour corresponds to the concentration of antigen 
in the sample. At the end, stop solution (1M H2SO4) is added and the end point 
colour density is read with a spectrophotometer. 
2.12.1 Endostatin ELISA 
The concentration of endostatin was determined in all the blood samples using 
Quantikin® ELISA human endostatin kits (R&D systems for Europe, Abingdon, 
UK). 
2.12.1.1 Sample preparation and dilutions 
All the solutions in the kit were brought to room temperature as per description 
of the kit. The plasma samples liquefy when kept at room temperature for 20 to 
30 minutes. All solutions were prepared and diluted as per instructions included 
with the kit. A copy of the full instructions was downloaded from the 
manufacture website (R & D system, 2015a) and is attached in appendix “F1”. 
Standards were prepared in a series of dilutions. 
Plasma samples required 50 fold dilutions, for which 20µl of plasma were added 
to 980µl of calibrator diluting solution, provided with the kit. Care was taken to 
follow the exact steps and technical hints provided by the kit manufacturer. 
Face masks were worn all the time to avoid cross contamination with saliva, as 
saliva also expresses endostatin. 
2.12.1.2 Test procedure 
Exact procedures were followed as mentioned in the guide book provided with 
the kit. Controls provided separately by the same manufacturer were also tested 
(Quantikin® ELISA kit controls QC81). All the samples, controls and standards 
were analysed in duplicate. 
Assay diluent was added to all the wells before 50µl of samples, controls and 
standards were added. The plate was kept for 2 hours incubation on a plate 
shaker at 450 rpm before washing it 3 times with a buffer solution in an 
automated plate washer (Dynex MRW AM60, USA). In the next step 200µl of 
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human endostatin conjugate solution was added to each cell, followed by 2 
hours incubation. After repeating the washing step, 200µl of substrate solution 
was added to the plate followed by 30 minutes incubation in dark. 
Finally, stop solution containing 1M sulphuric acid was added to the plate and 
end point reading was taken at 450 nm and 570 nm by spectrophotometer 
(Spectra Max M2, CA, USA). 
The concentrations of the standards were plotted against the absorbance by 
using the software (Softmax pro 5.4). A specimen curve is shown in the figure 2-
6. Based on the linearity of the curve, concentrations of the samples were 
calculated by the software, from their respective absorbance. 
2.12.1.3 Precision of the ELISA 
The consistency and reliability of the actual samples were checked through the 
results of the controls. Inter and intra assays controls were carried out in all 
trials. The coefficients of variance (CV%) recorded were less than 5% for inter 
and intra assays precision. 
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Figure 2-6; Computer generated standards curve 
An example of computer generated standard logarithmic curve used by the Soft Max Pro 5.4 
software for reading the Plasma endostatin concentration.  Linearity is shown by R
2
 = 0.999 
 
2.12.2 VEGF 
VEGF in plasma samples were also determined through Quantikin® ELISA human 
VEGF kits (R&D systems for Europe, Abingdon UK). 
The principle of the Kit is sandwich ELISA which is the same as described for 
endostatin. The tests were performed according to the standard protocols of the 
kit and the samples were run in duplicate. The precision of assays were checked 
during each trial through repeated measures of controls (Quantikin® 
immunoassay control group 1) provided with the kit. A complete detail of the 
procedure downloaded from the manufacture website (R & D system, 2015b) is 
given in appendix “F2”. 
 Endostatin  standards conc (ng/ml) 
0.1 1 10 
0.01 
0.1 
1 
10 
StandardCurv
e 
Log-Log Fit: Log(y) = A + B * Log(x): A B R^2 
Std (Standards: Conc vs 
MeanValue) 
-
0.832 
1.26 0.999 
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2.12.3 Insulin 
Concentrations of insulin in plasma were determined using commercially 
available ELISA kit (Mercodia, Uppsala, Sweden). It is a solid phase two site 
enzyme immunoassay kit working on direct sandwich technique principle. High 
and low control of the same company were used for inter assay precision. The 
CV for the test was less than 3%. Complete details are downloaded from the 
commercial website of the manufacture (Mercodia diagnostics, 2015) and given 
in appendix “F3”. 
2.13 Lipid profile  
2.13.1 Spectrophotometric assays 
The analyses were carried out by Mrs. Josephine Cooney and Kholoud Ghaffori 
(Department of Biochemistry, Western infirmary Glasgow) using clinical 
chemistry analyser (ILABTM 600, Instrumentation Laboratory, USA).  
Commercially available enzymatic kits were used for the analyses of plasma 
glucose (Glucose hexokinase, Randox laboratories, UK), total and high density 
lipoprotein cholesterol (HDL) (CHOL and HDL-C, Roche diagnostic, UK), 
triglyceride (TG) (Randox Laboratories, Crumlin, UK) and non- esterified fatty 
acid (NEFA)  (Wako chemicals, USA). 
Friedewald equation was used for the determination of low density lipoprotein 
(LDL), as follow (Friedewald et al., 1972); 
LDL mmol.l-1 = Total cholesterol – HDL cholesterol – (TG /2.2) 
For small density lipoprotein SDLDL, enzymatic kit (Denka Seiken, Tokyo, Japan) 
was used. 
2.14 Statistical analyses 
Statistical analyses were performed using statistical software SPSS (IBM SPSS 
statistics for Windows, Version 17, Armonk, NY) and Minitab for windows 
(Version 16, MINITAB Inc., State college, PA). Normality of the data was checked 
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using Kolmogorov- Smirinov and Shapiro-Wilk tests of normalities. Log 
transformations of the data were done where appropriate. Descriptive statistics 
were carried out and expressed as mean ± SD (standard deviation). Time trends 
were measured using one-way ANOVA with repeated measures. Independent 
sample t-test was used to differentiate between males and females or walking 
and running group. Relationships between basal endostatin concentrations, VEGF 
and the change in these mediators with basal anthropometric measure, 
metabolic profiles and exercise parameters were determined through Pearson 
correlations. Linear regressions were used for determining dependency of 
endostatin on different variables. P values of < 0.05 were accepted significant.
           87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Measurement of endostatin concentration in 
plasma of human volunteers 
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3.1 Introduction 
As discussed in detail, in chapter 1 section 1.3.5, angiogenesis is essential to 
many normal development processes in the human body. These include 
embryonic development, organogenesis, the healing process and tissue 
regeneration. On the other hand, it also contributes to the progression and 
maturity of many cardiovascular and cancerous diseases including atherosclerosis 
(O'Brien et al., 1994).   
There is a fine balance between the angiogenic and angiostatic mediators in the 
overall process of angiogenesis and shift in favour of any particular phenotype 
determines the outcome of angiogenesis (Boehm et al., 1997). The angiogenic 
mediators like VEGF and FGF etc favour angiogenesis, by binding to the 
endothelial surface cell receptors and initiating a cascade of intracellular 
signalling pathways. However, endogenous angiostatic mediators, including 
angiostatin and endostatin tend to stop the angiogenic process by mechanisms 
involving antagonising the actions of angiogenic mediators (Eriksson et al., 
2003). 
Endostatin, discovered by O’Reilly et al in 1997, has come to the front as one of 
the main angiostatic mediators (O'Reilly et al., 1997). Endostatin plays an 
essential role in control of the angiogenesis. By inhibiting angiogenesis, 
endostatin prevents progression of atherosclerosis (Zeng et al., 2005), primary 
growth of tumors and metastasis (O'Reilly et al., 1997). 
Endostatin is a small globular protein attached through a hinge to the C terminus  
of collagen XV and XVIII in the basement membrane of endothelial cells (Sasaki 
et al., 2002). It is also found in many other body tissues including heart, skeletal 
muscles, liver, placenta, ovaries, prostate and kidneys (Deininger et al., 2003). 
Release of the endostatin requires a proteolytic cleavage (Sasaki et al., 2002). 
The release of endostatin and its up-regulation in an in vitro setup were 
enhanced after the endothelial cell lines were subjected to cellular stress, 
hypoxia and interferon-γ challenge. Moreover, nitric oxide synthase inhibitors 
reduced the release of endostatin (Deininger et al., 2003). 
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3.2 Plasma endostatin concentration in healthy 
population 
The available literature contains several studies reporting the concentration of 
endostatin in the plasma. These are summarised in table 3-1. The data in this 
table shows that the sample populations are often small and drawn from 
patients with a range of pathologies. In addition, a variety of analytical 
techniques have been used. Thus the current literature does not provide the 
average plasma concentration in normal population. 
Some studies have reported the plasma endostatin concentration as low as 1.0 
ng/ml while others have reported this level to be in the range of 300ng/ml 
(Refer to table 3.1). These huge differences in means and ranges are not 
completely clear.  
 
It is clear from the table, that for the determination of endostatin concentration 
in plasma, different methods like mass spectrometry, radioimmunoassay, 
western blots and ELISA have been used frequently. The difference in the 
reference range could possibly be due to use of different techniques. However, 
even the same techniques used in different studies have reported significant 
differences in the basal plasma endostatin concentrations (Zorick et al., 2001, 
Suhr et al., 2007).  
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Reference Mean [ES] Plasma Mean [ES} Serum Mean Age years Assay Method Comments 
(Ständker et al., 1997) 10-10M   Mass 
spectrometry 
Human plasma hemofiltrate was used for isolation of 
endostatin using mass spectrometry 
(Hebbar et al., 2000)  Healthy volunteers = 
9.9 ± 9.7 ng/ml  
Sclerosis patients 63.2 
± 20.2 ng/ml 
48.5 ± 12.7 
54.1 ± 14.6 
Enzyme immune 
essay 
50 patients with different levels of established 
sclerosis were evaluated for plasma endostatin 
concentration. 
(Feldman et al., 2000)  Controls =14.1 ng/ml 
(1.0-19.3 ng/ml) 
Renal cancer patient = 
24.6 (15.1- 54ng/ml) 
Patients=48 
Controls= age 
matched 
Competitive 
enzyme 
immunoassay 
Serum samples of at pre- nephrectomy stage of 15 
renal cancer patients were analysed against fresh 
samples from 18 healthy controls 
(Zorick et al., 2001)  Downs patients (38.6 ± 
20.1 ng/ml) 
Healthy controls (20.3 
± 11.5 ng/ml) 
 ELISA Endostatin concentrations of Down syndrome 
patients were almost double to that of normal 
healthy volunteers. 
(Feldman et al., 2001a) colorectal cancer 
patients (71.6 ± 28.6 
ng/ml) 
Healthy controls 
(43.2 ± 15.1 ng/ml) 
 60 years 
 
 
56 years 
Competitive 
enzyme 
immunoassay 
High endostatin concentrations were found in plasma 
of 30 colorectal cancer patients. Elevated levels 
were associated with disease progression. 
(Feldman et al., 2001b)  controls = 25.8 ng/ml 
Sarcoma patients = 43 
ng/ml  
Patients=44 yrs, 
Age matched for 
controls  
Competitive 
enzyme 
immunoassay 
Serum samples from 25 soft tissue cancer patients in 
pre surgery states were analysed for endostatin and 
compared to controls. 
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(Gu et al., 2004) 20.3 ± 3.2 ng/ml  volunteers = 33 
± 13 
ELISA 7 healthy volunteers performed high intensity 
exercise. Their baseline concentrations were 
checked before exercise. 
(Teh et al., 2004) controls (34.97 ± 3.76 
ng/ml 
Patients (30.62 ± 
4.54 ng/ml) 
  ELISA Post operative breast cancer patients had a higher 
endostatin concentrations in plasma compared to 
controls. 
(Suhr et al., 2007) 87.3 ± 5.7 ng/ml  27.8 ± 5.4 ELISA 
Western Blot 
In this study 12 male cyclist perform exercise with 
and without hypoxia and vibration, and their effect 
on angiogenesis. 
(Sponder et al., 2011) Smoker elderly 
(103.3 ± 16 ng/ml) 
Non smoker elderly 
(116.3 ± 15 ng/ml) 
Young Non smoker 
(93.4 ± 15 ng/ml) 
Diabetic (108.5 ± 17 
ng/ml) 
 47.12 (39-62) 
 
51.55(36-70) 
 
23.16 (18-34) 
 
57.86 (42-70) 
ELISA Impact of exercise was checked on the plasma 
endostatin concentration in 17 elderly smokers, 20 
non elderly smokers, 19 young healthy non smokers 
and 14 type 2 diabetics. Endostatin concentration 
was measured before and after exercise. 
(Sponder et al., 2013) Female athletes (129 
± 21 ng/ml) 
Female controls (89 ± 
15 ng/ml) 
Male athletes (148 ± 
28 ng/ml) 
Male controls (93 ± 
15 ng/ml) 
 26 ± 5 
 
23 ± 4 
 
24± 4 
 
23 ± 4 
 
 
ELISA Impact of bicycle exercise in athletes and sedentary 
males and females was checked. Baseline endostatin 
concentration was observed to be high in athletes 
than sedentary volunteers. Exercise increased the 
endostatin concentration in both groups. 
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(Makey et al., 2013)  111 ± 5 ng/ml 24 ± 0.8 ELISA Low intensity exercise was performed in females 
belonging to African American (n = 35, mean age 
26.1 ± 1.21) and Caucasian (n = 37 mean age 22.1 ± 
0.84) ethnicities. No effect of exercise on plasma 
endostatin concentration was observed. 
Table 3-1; Evidence table of previous studies with different endostatin concentrations 
A chronological arrangement of the different studies reporting the endostatin concentrations in healthy and diseased population is shown. Endostatin concentrations 
are outlined as mean ± SD with ranges, where possible. Age of the participants and techniques used for analyses of endostatin are also given in separate columns. 
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3.3 Rationale of the study 
The ultimate aim of this project was to investigate if exercise has an effect on 
concentration of endostatin in plasma. The available literature provides a broad 
range of concentrations reported in relatively small samples of healthy controls. 
Thus, it was essential to use one standard technique to measure endostatin 
concentrations, as reference point following studies. Moreover, as healthy and 
sedentary individuals are the major proportion of western population, this study 
seeks to determine the basal endostatin concentration in plasma of healthy 
volunteers. 
The hypothesis for this study was;  
I. The concentration of endostatin in plasma will be different in males and 
females. 
II. Increasing age, weight and BMI, and poor physical fitness will affect 
endostatin concentrations in plasma. 
3.4 Aims of the study 
The aims of the study are as follow; 
a. To measure the basal concentration of endostatin in plasma of healthy 
adult population. This will be used, as a reference concentration for 
further studies. 
b. To determine if the basal concentration of endostatin in plasma differs 
between genders. 
c. To determine the difference in basal endostatin concentration with age, 
height, weight, and physical activity behaviour of the individuals.  
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3.5 Material and methods 
The experimental protocol was approved by the University of Glasgow, College 
of Medical, Veterinary and Life Sciences Ethics committee. The ethical approval 
is attached in appendix “A1”. All recruitments and experimental procedures 
were carried out in the different labs of school of Life Sciences. 
3.5.1 Volunteers recruitment 
The volunteers were recruited through poster presentation in the public places 
of the University of Glasgow and advertising through social media. In some 
cases, volunteers were also approached through personal contacts.  Mostly, 
students of Glasgow University were recruited to the study. 
Volunteers were enrolled to the study, after initial screening by asking questions 
about the inclusion and exclusion criteria. One male participant was dropped out 
of the study due to high blood pressure reading on three consecutive occasions. 
Three females were not included. One of them was suffering with Pernicious 
anaemia. Another was taking a course of oral antibiotics. The third one was 
enrolled in a regular swimming practice sessions. The participants belonged to 3 
main geographical regions, Europe, Asia and Middle East. 
The purpose and potential risks of the experiment were explained to each 
subject and any specific questions asked, were answered. After their agreement 
to participate, the time and day of sample collection was agreed. Participants 
were advised not to participate in any physical activity on the day before the 
blood sample. In total, 50 healthy adult volunteers were recruited to the study.  
The characteristics of the volunteers are summarised in table 3-2. This 
subdivides the data by gender to allow comparison. Another table 3-3 shows 
these data by geographical origin of the volunteers. 
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Total Female Male P-Value 
Sample size (n) 50 16 34  
Age (Years) 26.7 ± 7.80 23.1 ± 4.4 28.5 ± 8.5 0.021 
Height (m) 1.71 ± 0.07 1.66 ± 0.1 1.74 ± 0.05 <0.001 
Weight (kg) 73.6 ± 10.4 67.8 ± 8.01 76.3 ± 10.4 0.006 
BMI (kg/m2) 24.89 ± 2.77 24.65 ± 2.33 25.0 ± 2.98 0.676 
Heart Rate (bpm) 75 ± 5 77 ± 6 73 ± 5 0.090 
SBP (mm Hg) 123 ± 9 118 ± 12 125 ± 7 0.059 
DBP (mm Hg) 74 ± 8 73 ± 8 74 ± 8 0.378 
MET.min.week-1 2471 ± 1627 2572 ± 1536 2424 ± 1689 0.768 
PA (High)% 38 50 32.4 0.370 
PA (Moderate)% 52 37.5 58.8 
PA (Low)% 10 12.5 8.8 
Table 3-2; Characteristics of the participants 
Characteristics of the all individuals are presented as pooled data and divided by gender. The right 
hand column shows the results of independent sample t-test. P-value <0.05 shows significant 
difference between male and female volunteers. Male participants were significantly older, taller 
and heavier than females. The lower panels of the table show the outcome of Chi Square test. It 
can be seen that most of the volunteers reported a moderate physical activity. BMI; Body Mass 
index, SBP; Systolic blood pressure DBP; Diastolic blood pressure (values are presented as 
mean± SD), MET are the metabolic equivalent minutes of basal metabolic rate 
 
3.5.2 Protocol of the study 
After giving informed consent, the volunteers filled out the International 
Physical Activity Questionnaire (IPAQ short form), as shown in appendix “D1”. 
This was used to assess their physical activity.  Height, weight, heart rate and 
blood pressure of the volunteers were recorded, as discussed in section 2.5.  
A tourniquet was applied to the arm of the volunteers to make the anti-cubital 
veins visible. Blood was taken with 21G butterfly (Nipro Corporation, Zaventum, 
Belgium) using standard aseptic technique. The blood was collected in 6 ml EDTA 
tubes (BD vacutainer, Plymouth, UK). Pressure was applied at the site of 
venepuncture for 30 seconds to 1 minute, to stop bleeding followed by applying 
sterile adhesive plaster. 
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3.5.3 Sample storage 
The blood samples were put on ice immediately after collection and centrifuged 
within 30 minutes of collection.  A Universal centrifuge (Universal 320R, 
Germany) spun the samples at 4◦C and 1000 RPM for 15 minutes. Each sample of 
plasma was divided into 3 aliquots and transferred into 0.5 ml Eppendorf tubes. 
After exact labelling the plasma samples were stored at -80◦C in an ultra low 
temperature freezer (New Brunswick Scientific, U725-86, US), for up to one 
month before analyses. 
3.5.4 Physical activity measurements from IPAQ 
questionnaires 
The weekly physical activities of the participants were determined from IPAQ 
questionnaires and were categorised in low, moderate and high activity groups. 
The activity in MET.min.week-1 was also calculated numerically, according to the 
data processing rules given in the guide book (IPAQ, 2005). These are given in 
table 3.2 and discussed in section 3.7. The rules for measuring these activities in 
categorical and numerical form are given in appendix “E”. 
3.5.5 Sample analysis 
All the samples, standards and controls were thawed and brought to room 
temperature before analyses. The samples were analysed for plasma endostatin 
concentration, using QuantikinR  ELISA kit bought from R&D systems. Details are 
given in section 2.11.1. The samples were run in duplicates after dilution 
following the instructions of the manufacturer. A series of standards and 
controls were provided with each kit and these were used to generate 
calibration plots. Figure 2-6, shows a typical standard curve for the analysis. The 
minimum concentration of endostatin in standards was 0.313 ng/ml. The 
minimum concentration of endostatin in analysed sample was 81 ng/ml, which 
exceeds the minimum detectable standard. Similarly the maximum 
concentration detected was 132 ng/ml, which was also within the range of 
detection of the kit.  
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3.5.6 Statistical analyses of the data 
Statistical analyses were carried out using SPSS 17 statistical software. The 
normality of the data was tested using Kolmogorov- Smirinov and Shapiro-Wilk 
tests. Where it was important, not normally distributed data was subjected to 
log transformation. Histograms and Q-Q plots showing the normalities of some 
variables are given in figure 3-1 & 3-2. 
Summary statistics were calculated. Independent sample T-tests were used to 
investigate difference between means for males and females. ANOVA was 
applied to check the difference between means of participants from different 
ethnic groups.  Box plots were produced to demonstrate the difference between 
the mean endostatin concentrations for different data sets.   
Pearson correlations tests were used to investigate the correlations of 
endostatin with anthropometric and physical characteristics of the volunteers.  
Scatter plots with fitted lines were produced to show, the relationship between 
plasma endostatin concentration and different anthropometric variables. Simple 
linear regressions were carried out for uni-variate and multivariate analysis to 
investigate association of endostatin concentrations with other variables.  
Categorical data of physical activity was analysed using Chi-square tests. P value 
less than 0.05 was accepted as significant.  
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3.6 Results 
3.6.1 Distribution of the data 
Results were obtained for all 50 volunteers. Kolmogorov- Smirinov and Shapiro-
Wilk tests were used to investigate the normality of the data sets. The data 
were normally distributed. The analyses were easier with normal distribution of 
the data. This might be expected for the height and age but even variables like 
MET minutes showed a normal distribution which would have been harder to 
predict, as shown in figure 3.1.  
 
A) 
 
B) 
 
  
Figure 3-1; Normality test for (A) BMI and (B) MET- minutes per week of the volunteers 
showing normal distributions. 
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3.6.2 Difference in characteristics of males and females 
The data shown in table 3-2 were subjected to independent sample T-tests. 
These revealed that males were significantly older (P = 0.021), taller (P <0.001) 
and heavier (P = 0.006) than females. No statistical differences were observed 
for other variables. 
The data collated from IPAQ questionnaires were analysed according to the 
provided guidelines for data processing (IPAQ, 2005), attached in appendix “E”. 
The data was analysed for different types of physical activity both in categorical 
(high, moderate and low physical activity) and continuous forms (MET-min per 
week).  
Chi square test showed no significant difference in physical activity levels 
between male and female volunteers (P = 0.370). Most of the participants had a 
moderate level of physical activity, as shown in table 3-2. 
3.6.3 Endostatin concentration in plasma for all volunteers 
The concentration of Endostatin in plasma was normally distributed, as shown by 
the histogram and Q-Q plot in Figure 3.2. The mean value for plasma endostatin 
in all samples was 105 ± 12 ng/ml (Mean ± SD). The range of concentration 
observed in this data set was from 81 to132 ng/ml.  
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   A) 
 
   B) 
 
Figure 3-2; Normality for endostatin concentrations of all participants 
Panel (A) shows a histogram of the endostatin concentrations in plasma with a normal distribution 
curve fitted to the data. Panel (B) shows the same data re-plotted as Q-Q plot. The data was 
normally distributed as shown by Kolmogorov- Smirinov and Shapiro-Wilk tests (P = 0.2 & 0.6) and 
can be easily appreciated with naked eye.  
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3.6.4 Comparison of endostatin concentration in plasma 
between males and females 
Endostatin concentration for males and females were found normally distributed 
(P = 0.20 & 0.5), as shown by Q-Q plots in figure 3-3. The individual data points 
for males and females are plotted in figure 3.4A. Box plots of data for males and 
females are shown in figure 3.4B. 
The mean endostatin concentration for male was 107 ± 13 ng/ml, while for 
females; it was 102 ± 12 ng/ml. When mean concentrations for both groups were 
compared, no significant difference was observed (P = 0.21). 
A) 
 
B) 
 
Figure 3-3; Q-Q plots for normality of endostatin concentrations in females (left) and males 
(right)  
Normality for endostatin concentrations in females and males are shown by Q-Q plot. The data was 
normally distributed. The observed values are lying closely to the expected normal values and can 
be seen by the distribution of the data close to the expected fit line. 
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A) 
 
B) 
 
Figure 3-4; A) Endostatin concentrations in males and females (B) Box plot showing group 
data for males and females  
Endostatin concentrations in plasma for males and females are shown. Panel (A) shows the data 
for males and females with mean endostatin concentration (dotted line) for the pooled data, while 
Panel (B) shows Box plots with median value and range for the both groups. No significant 
difference between the mean endostatin concentration of both groups was observed (P = 0.21). 
Chapter: 3 
91 
 
3.6.5 Endostatin concentration in different geographical 
groups 
The participants came from three main geographical regions: Europe, The Middle 
East and South Asia. This distribution reflects the proportion of international 
students in the university campus. The difference in their physical 
characteristics are summarised in table 3-3. As most of the volunteers were 
university students, they share many similar characteristics.   
There was no significant difference between the ages of male participants. 
European females were significantly younger than Middle Eastern females (P = 
0.009). There were no females in South Asian group. European males and 
females were comparatively more active than volunteers in other groups. Middle 
Eastern females reported the lowest physical activity. In addition, they had 
higher pulse rates and low systolic blood pressures, as shown in table 3-3.  
Individual concentrations of Endostatin for participants in each regional group 
are plotted, in figure 3-5A. The data were normally distributed. The 
concentrations of endostatin from Middle Eastern participants lie within a 
narrower range (95 -119 ng/ml), and this could be a consequence of low 
numbers of participants in this group. 
A one-way ANOVA was used to investigate differences in endostatin 
concentrations between the groups. The mean endostatin concentrations for all 
the groups are shown, in table 3-3. Box plot shows median values with range of 
data for males and females, in figure 3-5B. No significant difference in 
endostatin concentration was found.  
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  Europeans Asians Middle Eastern P-  Annova 
Sample size (n) M 14 15 5  
F 11 - 5  
Total 25 15 10 
 
 
Age (years) M 25 ± 10.5 32 ± 6.06 27.2 ± 6.02 0.081 
F 21.2 ± 1.6 - 27.6 ± 4.5 0.009 
Total 23.3 ± 8.1 32 ± 6.06 27.4 ± 5.04 0.004 
 
Height (m) M 1.75 ± 0.04 1.74 ± 0.05 1.74 ± 0.04 0.60 
F 1.67 ± 0.1 - 1.62 ± 0.1 0.24 
Total 1.72 ± 0.1 1.73 ± 0.05 1.68 ± 0.08 0.08 
 
Weight (kg) M 76.3 ± 11.6 76.2 ± 10.8 76.9 ± 2.9 0.99 
F 68.9 ± 8.3 - 65.6 ± 7.8 0.46 
Total 73 ± 10.7 76 ± 10.8 71.2 ± 9 0.15 
 
HR M 74 ± 6 74 ± 5 71 ± 3 0.54 
F 76 ± 6 - 78 ± 5 0.60 
Total 75 ± 6 74 ± 5 74 ± 5 0.97 
 
SBP M 127 ± 5 122 ± 9 127 ± 2 0.11 
F 120 ± 12 - 116 ± 11 0.54 
Total 124 ± 10 122 ± 9 121 ± 9 0.16 
 
DBP M 77 ± 9 72 ± 7 78 ± 5 0.18 
F 73 ± 8 - 73 ± 10 0.96 
Total 75 ± 9 72 ± 7 75 ± 8 0.48 
 
Met.min.week-1 M 2803 ± 1704 2065 ± 1695 2441 ± 1747 0.50 
F 2850 ± 1031 - 1958 ± 2346 0.30 
Total 2824 ± 1420 2065 ± 1695 2200 ± 1967 0.48 
Endostatin 
(ng/ml) 
M 107 ± 15 106 ± 13 108 ± 7 0.90 
F 101 ± 14 - 103 ± 7 0.70 
Total 105 ± 14 106 ± 13 106 ± 7 0.80 
Table 3-3; Anthropometric and physical characteristics of volunteers from different regional 
groups 
Differences in characteristics of the individuals from different regional groups are shown. As 
expected, no significant difference in variables with the exception of age can be seen. The lower 
portion contains the mean endostatin concentrations in different groups. No significant difference 
was observed, as shown by P values. 
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A) 
 
B) 
 
Figure 3-5; Endostatin concentrations for different ethnic groups (A) individual values & (B) 
Group data 
Panel (A) represent the dot plot with individual values for different ethnic groups. Panel (B) 
represents the median and range for males and females in each group. Dotted line represents the 
mean concentration for all data. European participants show bigger range than others. Blue colour 
represent female and Green colour represent male groups. 
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3.6.6 Correlation of endostatin with different anthropometric 
and physical variables 
The third aim of research in this chapter was to investigate any correlation of 
endostatin concentration with different anthropometric and physical 
characteristics of the participants. This was done using Pearson correlation 
tests. As the data was normally distributed using Pearson correlations will 
provide strength of linearity between the endostatin and other variables.  
Table 3-4 shows the correlation values (r) and significance (P) for all variables as 
pooled data set, while table 3-5 represent the same data for different regional 
groups. No correlations of statistical significance were found between most 
variables and plasma endostatin concentration, as shown in table 3-4. However, 
the correlation between basal heart rate and plasma endostatin concentration 
was trending significance (P = 0.053) for the data set of all individuals. Further 
analyses of the data by gender revealed, that males had a negative correlation 
between heart rate and plasma endostatin concentration, as shown in figure 3-
8A.  
Secondary analyses (splitting data by ethnic group and gender) revealed that 
Middle Eastern females also showed a negative correlation between resting heart 
rates and plasma endostatin concentration (P= 0.005, r = -0.973) i.e. participant 
with low basal heart rate tend to have high endostatin concentration. On the 
other hand, in South Asian volunteers, there was a positively correlation for age 
(P = 0.049, r = 0.51) and diastolic blood pressure (P = 0.037, r = 0.54). These 
findings are tentative. This was not a primary aim of the study. The sample size 
is very small. A larger study would be required before drawing a confident 
conclusion.  
However, the regression analyses were inconclusive in providing any association 
between different anthropometric variables and plasma endostatin 
concentrations, as shown in table 3-6. Uni-variate as well as multi-variate 
analyses were carried out. In Uni-variate analysis heart rate and physical activity 
was approaching significance (highlighted area) which is lost by inclusion of 
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other variables, as shown in multi-variate analyses. The overall value for R2 in 
multi-variate analyses was 0.182.
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 n  Age
 Height Weight BMI SBP DBP HR MET.min.week-1 
Male 34 r 
P 
.114 
.520 
-.093 
.600 
-.152 
.390 
-.152 
.392 
-.029 
.872 
.279 
.110 
-.351* 
.042 
-.265 
.130 
Female 16 r 
P 
-.081 
.766 
-.106 
.696 
.047 
.863 
.165 
.541 
.301 
.257 
-.107 
.692 
-.023 
.932 
-.048 
.860 
Total 50 r 
P 
127 
0.379 
.026 
.857 
-.023 
.873 
-.059 
.686 
.156 
.279 
.173 
.230 
-.275 
.053 
-.208 
.148 
Table 3-4; Pearson correlation of endostatin with anthropometric and physical variables for all individuals 
A trend in correlation between basal heart rate and endostatin concentration can be observed. Male individual had a significant negative correlation between heart rate 
and endostatin concentration. r; Pearson coefficient value, P; Significance of the correlation, SBP; Systolic blood pressure, DBP; Diastolic blood pressure 
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Ethnicity  n  Age
 Height Weight BMI SBP DBP HR MET.min.week-1 
European Male 14 r 
P 
-.116 
.694 
-.192 
.512 
-.328 
.253 
-.321 
.263 
-.080 
.786 
.040 
.892 
-.395 
.162 
-.254 
.381 
Female 11 r 
P 
-.409 
.211 
-.036 
.916 
.167 
.623 
.238 
.481 
.298 
.373 
-.234 
.488 
.114 
.739 
.020 
.954 
Total 25 r 
P 
-.085 
.686 
.032 
.881 
-.073 
.727 
-.110 
.600 
.206 
.323 
-.023 
.913 
-.198 
.342 
-.166 
.429 
 
South Asian Male 15 r 
P 
.516 
.049 
-.108 
.701 
-.053 
.851 
-.033 
.908 
-.037 
.897 
.542 
.037 
-.302 
.274 
-.395 
.145 
 
Middle 
Eastern 
 
Male 5 r 
P 
.552 
.335 
.496 
.396 
.815 
.093 
.813 
.094 
-.037 
.953 
.673 
.213 
-.203 
.744 
.170 
.784 
Female 5 r 
P 
-.001 
.999 
-.352 
.561 
-.474 
.420 
-.304 
.619 
.510 
.380 
.426 
.474 
-.973 
.005 
-.514 
.129 
Total 10 r 
P 
.253 
.480 
.265 
.460 
.340 
.337 
.182 
.615 
.451 
.191 
.551 
.099 
-.685 
.029 
-.145 
.816 
Table 3-5; Pearson correlations of endostatin with anthropometric and physical variables for individuals in different regional groups 
No correlations were found for height, weight, SBP, DBP, BMI and MET minutes with endostatin concentration. Strong negative correlation was observed in Middle 
Eastern females for heart rate. South Asian males were positively correlated for age and DBP. r; Pearson correlation coefficient value P; Significance of the correlation, 
SBP; Systolic blood pressure, DBP; Diastolic blood pressure
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Endostatin Uni-variate Multi-variate    
 Beta (CI) P Beta (CI) P 
Age 0.13 (-18.1 - 46.7) 0.38 -0.05 (-50 - 39.0) 0.81 
Height 0.03 (-46 - .355.4) 0.86 -0.55 (-6920 - 499.4) 0.75 
Weight -0.02 (-0.4 - 0.3) 0.87 0.78 (-6 - 7.8) 0.78 
Sex 0.18 (-2.8 - -12.5) 0.21 0.10 (-9 - 14.1) 0.65 
BMI -0.06 (-1.6 - 1.1) 0.69 -0.65 (-24 - 17.7) 0.77 
SBP 0.16 (-0.2 - 0.6) 0.28 0.17 (0 - 0.8) 0.38 
DBP 0.17 (-0.2 - 0.7) 0.23 0.04 (-1 - 0.6) 0.81 
HR -0.27 (-1.3 - 0.009) 0.05 -0.29 (-1 - 0.1) 0.10 
MET_min.week-1 -0.21(-.004 - .005) 0.15 0.06 (-.004 - 0.005) 0.84 
PA Level -0.23 (-10.2 - 0.9) 0.10 -0.27 (-16 - 5.5) 0.32 
Table 3-6; Regression analysis for endostatin with anthropometric and physical variables 
Uni-variate and multi- variate regression analyses for all variables were carried out, as shown by 
Beta coefficient (Beta) with confidence intervals (CI) and significance (P). It can be seen that 
variables which were trending significance in uni-variate analyses (Highlighted area) lost its 
significance in multivariate model. The overall dependency of endostatin on the different 
anthropometric characters were only 18% in multivariate analyses (R
2
=0.182).   
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Female  Male 
 
A) 
 
B) 
 
C) 
 
D) 
 
Figure 3-6; Fitted line plots for height and weight with regression lines females and males  
Fitted line plots showing the regression lines (solid lines) and 95% CI (dotted lines) lines for height 
and weight with endostatin. The wide CI and low R
2
 values clearly show no significant association 
of endostatin with weight and height in both female (A & C) and male volunteers (B & D). 
 
 
 
Weight (kg) Weight (kg) 
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A) 
 
B) 
 
                                             
                                       C) 
 
Figure 3-7; Fitted line plots for age with regression lines for (A) males, (B) females from 
pooled data and (C) Asian males  
Fitted line plots showing the regression lines (solid lines) and 95% CI (dotted lines) lines for age 
with endostatin. Section C has comparatively shorter CI for South Asian males. The R
2
 value 
shows weak link between the age and endostatin. 
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A)  
 
 
B) 
 
 
                                       C) 
 
Figure 3-8; Fitted line plots for HR (heart rate) with regression lines for (A) males, (B) 
females from pooled data and (C) Middle Eastern females 
Fitted line plots showing the regression lines (solid lines) and 95% CI (dotted lines) lines for heart 
rate with endostatin. Middle Eastern females have very short confidence interval and high R
2
 value, 
which shows a strong relationship of basal heart rate and endostatin, as shown in panel C (n=5). 
 
(bpm) (bpm) 
(bpm) 
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3.7 Discussion 
Since the discovery of endostatin, in the last few years a large number of studies 
have pointed towards its anti-angiogenic effects and potential to protect 
individuals from progression of atherosclerosis and cancers. However, to fully 
understand its physiological role, it is essential to know the range of its 
concentration in plasma. To the best of author’s knowledge, there is no study to 
demonstrate the baseline endostatin concentration in healthy volunteers with 
the aim to find a mean concentration with reference range. That’s why this 
study measured the concentration of endostatin in plasma samples from healthy 
volunteers. The study achieved the aims outlined in section 3.4. Mean endostatin 
concentration for all individuals was measured and difference in mean for males 
and females was compared. In addition, the association of different 
anthropometric and physical variables with endostatin concentration were also 
checked.  
The analyses undertaken in this study showed that mean plasma endostatin 
concentration was 105 ng/ml with a range of 81 to 132ng/ ml. These results are 
consistent with the results published by (Sponder et al., 2011), who reported a 
mean concentration of 93.4 ± 15.3 ng/ml and (Suhr et al., 2007), who found a 
mean concentration of 87.3 ± 4.5 ng/ml. The studies carried out by Sponder 
included 13 male healthy volunteers while the latter study had a sample size of 
88. Another study published recently, reported mean endostatin concentration 
of 111 ± 5 ng/ml, in 72 healthy females (Makey et al., 2013). 
However, these results are significantly different from the mean plasma 
endostatin concentration of  20.3 ng/ml reported by (Gu et al., 2004), 14.1 
ng/ml by (Feldman et al., 2000) and 43.2 ng/ml by (Teh et al., 2004), for 
healthy volunteers of different ages in their studies.  These differences in 
concentrations could be attributed to the different techniques (ELISA, Western 
blot, Mass spectrometry etc) used for analyses. It should be noted from the 
studies listed in table 3-1, that more recent studies have reported comparatively 
high endostatin concentrations, which is pointing towards more sophistication 
and maturity of techniques with time. 
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However, the sensitivity of the ELISA kits from different manufactures might be 
a factor. Different studies using the same ELISA kits (Accucyte, Cytimmune 
Sciences Inc., MD, USA) have reported a low endostatin concentration (Gu et al., 
2004, Zorick et al., 2001), which could possibly be the reason for reporting low 
endostatin concentration. Moreover, the media used for analyses (plasma, 
serum, haemofiltrate) may have different sensitivity and specificity for the same 
techniques. Nonetheless, these differences are not completely clear because 
concentrations reported by the same author in different studies using the same 
techniques and media, show significant difference for healthy volunteers (e.g. 
see Feldman et al., 2000 and 2001a in Table 3.1). One might speculate about the 
causes of these differences. Serum concentrations of endostatin have been 
reported to be affected by circadian rhythms (Glenjen et al., 2002), age 
(Bruserud et al., 2005, Brixius et al., 2008) and physical activity (Gu et al., 2004, 
Bruserud et al., 2005). It was not possible to address these factors in this 
project. 
The results in our study seems more reliable due to the larger sample size, good 
quality control indicators and the results lying within the range provided by the 
kit supplier. It is worth noting, that even this larger sample does not find 
volunteers with endostatin concentrations as low as those reported elsewhere 
(Feldman et al., 2001a, Gu et al., 2004). It is also unlikely that geographical 
variations could explain these differences. Figure 3-5B, compares European, 
Middle Eastern and South Asian populations, with only minor differences 
observed. 
The second aim of the study was to investigate the difference in concentration 
of endostatin between males and females. The mean plasma endostatin 
concentration appears higher in male than female volunteers. This is shown in 
figure 3-4B. However, the difference is not statistically significant (P = 0.21). 
These results are in agreement with the result from other studies, where the 
male shows more mean concentration than female (Feldman et al., 2001b, 
Zorick et al., 2001). Though these studies have not mentioned any direct 
comparison between the two groups, the difference looks non significant. In 
addition, another study which compared the concentration on gender basis also 
reported a slightly higher but non-significant concentration in males (Sponder et 
al., 2014).  
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The hypothesis tested in this study was that females might have lower 
concentrations of plasma endostatin. The basis of this expectation lies in the 
lower concentration of many biological molecules such as haemoglobin in 
females (Walters et al., 1973). Gu speculated that endostatin in circulation 
might be due to physiological collagen turnover (Gu, 2004).Based on this 
supposition, it can be assumed that more muscle mass in males may cause higher 
physiological collagen turnover which consequently might increase circulatory 
endostatin.  
Plasma endostatin concentrations in volunteers of different ages were also 
investigated. The volunteers had a broad range (19-60 years) of age. However, 
age of 96% of the participants were 40 years and below. The oldest participant in 
the study was 60 years old male and his plasma concentration was 109 ng/ml, 
which is very near to the mean concentration. No significance correlation of 
plasma endostatin with age was found when the data from all volunteers was 
investigated, as shown in table 3-5 and figure 3-7C. The data from the South 
Asian volunteers showed a positive correlation with age (P = 0.049). Strong 
conclusion from this correlation cannot be drawn because; firstly the P value is 
border line to significance, secondly sample size is small (n = 15) and thirdly by 
including the male participants from Middle Eastern and European group, 
significance is lost (P = 0.52), as shown in table 3-4.  
However, significantly higher endostatin concentration in older participants than 
young adults has been reported previously (Sponder et al., 2011, Bruserud et al., 
2005). With advancing age the chances for angiogenic dependent diseases 
increases. It is possible that the circulatory endostatin concentration rises as an 
adaptive protective mechanism. 
It was important to know that variations in physical and anthropometric 
characterises might affect the endostatin concentration in plasma. But the 
plasma endostatin concentration seemed uncorrelated with most of physical and 
anthropometric parameters such as height, weight, BMI and blood pressure, as 
shown in table 3-4 and figure 3-6. The author is unaware of any previous 
published data reporting these observations. However, when the data was split 
on ethnic and gender basis, the results suggest that endostatin concentration in 
plasma was correlated with some characteristics. For e.g. a positive correlation 
Chapter: 3 
105 
 
with DBP was observed in South Asian participants. These observations must be 
treated with caution; firstly, due to small number of participants in the 
respective groups and secondly, the volunteers included in the study were 
healthy with normal ranges of blood pressure.  
Similarly, resting heart rate was found to be negatively correlated with plasma 
endostatin concentrations, as shown in table 3-4, 3-5 and figure 3-8. Middle 
Eastern females showed a strong negative correlation. This is notable but 
inconclusive finding, as this group has only 5 female participants. Heart rates are 
usually unstable and can be easily influenced by many stimuli including time of 
the day (Massin et al., 2000) and fear response due to release of adrenaline 
(Fellows et al., 1985). 
Physical activity has been widely accepted to decrease the risk of cardiovascular 
related mortality and morbidity (Nocon et al., 2008). The physical activities 
were assessed using the short form of International Physical Activity 
Questionnaire. They were categorised in low, moderate and high activity groups. 
The activity in MET.min.week-1 was also calculated numerically, according to the 
data processing rules given in the guide book (IPAQ, 2005).  METs refer to 
multiples of resting metabolic rate during an activity. MET-minutes are the MET 
score of an activity during a specific time period. The analysis revealed no 
significant relationship between plasma endostatin concentration and reported 
physical activity (P = 0.816). This is shown in tables 3-4 and 3-5.  
Higher concentrations of plasma endostatin were reported by Sponder in male 
and female athletes than in matched controls (Sponder et al., 2013). This 
difference in results could be due to several factors. Perhaps habitual physical 
activity has different effects from shorter periods of intense athletic training. It 
was assumed before the study, that regular physical activity might have an 
effect on the basal endostatin concentration. As participants were mostly 
students of the University of Glasgow, their involvement in physical activities 
was expected to be more than population in general. To minimise this effect, all 
volunteers were asked to abstain from physical exercise for 24 hours before the 
trial. 
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However, under or over reporting of physical activities, unclear definitions of 
different intensities of activities, and the presence of the option “I don’t know” 
in the questionnaire, could be the possible reasons for the data of physical 
activity being unreliable. More sophisticated approaches such as using 
accelerometers and GPS devices, to monitor the physical activity behaviour of 
the participants prior to blood sampling, could have provided more accurate 
information. Due to large sample size, cost of the GPS devices was one of the 
barriers in implementations.  
The distribution of plasma endostatin concentration seems normal in volunteers 
from different ethnicities, as shown figure 3-5A & B. To our knowledge this is a 
new finding.  
The strengths of the study include; a wide sample size and inclusion of both 
male and female participants from different ethnic groups with wide range of 
age and other parameters including height, weight, BMI and heart rate. 
There were some limitations to the study such as more males (n = 34) than 
females (n = 16). This was not intentional and volunteers were recruited 
randomly. Moreover, 3 female participants were not recruited to the study due 
to different reasons, given in section 3.5.1. The results imply no difference on 
basis of gender and the imbalance between the number male and female 
participants may not have a profound influence on the results. However, the 
strength given to the results in setting the trends with a more evenly gender 
distribution, could not be rejected completely. 
Plasma samples were run in duplicate on ELISA kits to calculate mean values for 
each subject as compared to the classical triplicate pattern used in many 
studies. There are two reasons for this: firstly the ELISA manufacturer 
instruction says the plasma samples to be run in duplicate and secondly time and 
financial restraints. Triplicate results might have produced more accurate mean 
result but the good quality control indicators (inter and intra assays CV% <10 & 
5% respectively) show that handling technique of the plasma samples, controls 
and standards, including  pipetting and different steps in the analyses, were 
carried out accurately. The differences in mean endostatin concentrations were 
small and triplicates would have minimal effects on the overall results. 
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The experiment was not planned to investigate the difference in concentration 
in different regional groups. The regional groups were included only, when the 
initial statistics revealed no difference between the male and female 
participants and their demographic relationship with plasma endostatin 
concentration. This is also the reasons of the uneven distribution of participants 
in different ethnic groups. The results could be more reliable, had there been 
more participants in each group and study planned on more ethnic bases in the 
initial stage.  
3.8 Conclusion 
In conclusion all the aims of the study were achieved.   
I. The mean endostatin concentration in healthy adult population was 
measured. This will allow a suitable sample size to be estimated for 
further research, which aims to determine the effects of exercise on the 
plasma endostatin concentration.  
II. The endostatin concentration was found to be slightly lower in female 
than male participants and the difference was insignificant. Moreover, the 
basal plasma concentrations were found to be independent of age and 
other demographic characteristics.  
III. Moreover, the distribution of basal endostatin among individuals from 
different regions was normal and comparable. 
Based on this study’s results, further research in to the effects of exercise on 
plasma endostatin concentration could be carried out without any specific 
gender or anthropometric requirements. 
           138 
 
 
 
 
 
 
 
 
 
4 The effects of different intensities of exercise on 
plasma endostatin concentrations 
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4.1 Overview 
 The research in chapters 4 & 5 represents same study in two parts. The results 
are reported separately for clarity. The first part consists of the effects of short 
periods of different exercise intensities on the concentration of endostatin in 
plasma. The initial plan of the study was to investigate endostatin, but during 
the experiments secondary analyses were conducted to examine the effects of 
some exercise intensities on VEGF. The sections are written in the order, the 
research was carried out.  
4.2 Introduction 
The importance of physical activity for decreasing the risk of many chronic 
diseases including cardiovascular disease and diabetes is established worldwide 
and discussed already in section 1.3.9. Enhanced physical activity decreases the 
risk of these diseases through different mechanisms including local 
cardiovascular adaptations such as production of heat shock proteins and 
increasing anti oxidant capacity (Golbidi and Laher, 2011). It also modifies other 
risk factors like obesity and diabetes through increasing insulin sensitivity and 
changing the lipid profile (Francis, 1998, Gill and Cooper, 2008). However, the 
molecular basis for the effects and interactions of exercise and atherosclerosis is 
not completely clear (Golbidi and Laher, 2011).  
Extension of collateral circulation is one of the important determinants in CVDs. 
Controlled angiogenesis expands the vascular network by formation of new 
vessels (Distler et al., 2003). Uncontrolled angiogenesis is dangerous in 
atherosclerotic plaque, as it increases the size of plaque and can make it 
vulnerable to rupture (O'Brien et al., 1994). During such conditions, the roles of 
angiostatic mediators become important, as they tend to halt the process. 
Exercise also affects the angiogenesis by increasing or decreasing the circulating 
levels of angiogenic mediators. The over expression of circulating VEGF (key 
angiogenic mediator) in myocardium (Isner and Losordo, 1999), skeletal muscles 
(Olenich et al., 2013) and plasma (Suhr et al., 2007) after exercise has been 
reported. Similarly, influence of exercise on endostatin (Key angiostatic 
mediator) has also been shown (Sponder et al., 2014). 
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Endostatin has emerged as one of the potent inhibitors of angiogenesis and has 
been extensively studied for its different properties as mentioned previously in 
section 1.3.6. In a pilot study, exercise has been reported to increase the 
endostatin concentration by 73% in young healthy male participants (Gu et al., 
2004). Later on, another study also reported 23% increase in endostatin 
concentration after cycling. Additionally, increase was more pronounced in 
young healthy volunteers than diabetics and smokers (Sponder et al., 2011). 
However, Brixius and his colleagues reported a decrease in endostatin 
concentration after 6 months of endurance exercise in middle to old age 
individuals (Brixius et al., 2008). Although the exact mechanism, by which 
exercise influence endostatin is not completely, understood, the differences in 
exercise protocols, durations and physical status of the participants could be 
considered for these variations in results. 
4.3 Rationale of the present study 
The effect of exercise on circulatory endostatin concentration is still poorly 
understood. The studies which have reported the effects of exercise on plasma 
endostatin have used different intensities of exercise with different modes 
(treadmill, cycling, climbing etc.). The durations of the exercise has also not 
been related properly to changes in circulatory endostatin. In order to have a 
better understanding of how exercise influences the circulatory endostatin 
concentrations, it was proposed to use 3 exercise protocols with different 
intensities. The purpose of using a range of intensities is to replicate the dose 
response relationship between health benefits and physical activity. The over 
load principal of exercise suggests that exercise below certain threshold 
intensity will not affect the physiological parameters of the body (ACSM, 2013).  
The proposed types of exercises are as follow; 
i. Light intensity exercise at 60% of the predicted maximum heart rate 
ii. Moderate intensity exercise at 70% of the predicted maximum heart rate 
iii. Vigorous exercise at 80% of the predicted maximum heart rate 
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The energy consumption during each session of exercise was kept constant at 
200 kcal and the duration for each session was adjusted to keep the same energy 
expenditure in each individual. 
In this study the hypotheses to be tested were:  
i. Exercise will increase the endostatin concentration in plasma. 
ii. Different intensities of the exercise will have different effects on the 
endostatin concentration in plasma. 
iii. Different intensities of exercise will have different effects in males and 
females. 
 
4.4 Aims of the study  
This study has the following aims; 
I. To determine the effects of different intensities of exercise on the 
endostatin concentrations in plasma. 
II. To determine if the change in endostatin concentration after exercise is 
affected by gender or exercise mode (walking and running). 
III. To determine the correlation between change in endostatin and different 
exercises parameters. 
IV. To determine if the basal endostatin concentration corresponds to study 
in chapter 3. 
 
4.5 Material and methods 
Approval for this experimental study was granted by the University of Glasgow, 
College of Medical, Veterinary and Life Sciences Ethics Committee. The ethical 
approval is attached in appendix “A2”. The recruitment of volunteers and the 
exercise sessions were carried out in different exercise laboratories of School of 
Life Sciences. For the analyses of the blood samples metabolic suites in School of 
Life Sciences were used. 
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4.5.1 Volunteer recruitment 
Volunteers were recruited through posters around the University of Glasgow and 
public places in the west end of Glasgow. In some cases, personal contacts were 
also made. Most of the volunteers were students of the Glasgow University. 
The purpose and potential risks during the participation were explained to the 
participants and any questions asked, were answered. The volunteers were told 
that they are entirely free to drop out of the trial at any point, if they do not 
want to participate. Volunteers were screened before enrolment into the study. 
2 pre-participation health screening questionnaires were completed by each 
participant; the Physical Activity Readiness Questionnaire (PAR-Q) and the 
adopted form of health fitness facility pre- participation health screening 
questionnaire of the American College of Sports Medicine (ACSM) (ACSM, 2013). 
Both of these questionnaires are given in appendix “D2” & “D3”. In addition, 
blood pressure and basal heart rates of the participants were recorded. 
Volunteers in the age group 18-45 years, non smokers with no relevant cardiac 
history, not on medication, not pregnant or lactating and asymptomatic 
otherwise were enrolled into the study. 22 male and female volunteers were 
recruited. Their characteristics are given in table 4-1. 
 
 Total Male Female P-value 
Number (n) 22 16 6  
Age (Yrs) 29.4 ± 7.2 30.6 ± 7.8 26.5 ± 5.0 0.30 
Height (m) 1.69 ± 0.10 1.73 ± 0.07 1.58 ± 0.01 <0.001 
Weight (kg) 69.7 ± 14.2 75.7 ± 10.8 53.6 ± 8.5 <0.001 
BMI 24.2 ± 3.33 25.3 ± 2.8 21.34 ± 2.9 0.02 
SBP (mm of Hg) 115 ± 0 118 ± 9 107 ± 10 0.04 
DBP (mm of Hg) 77 ± 7 78 ± 6 74 ± 7 0.20 
HR (bpm) 77 ± 5 77 ± 6 80 ± 3 0.10 
Table 4-1; Characteristics of the participants 
The differences in variables for males and females were determined with independent sample t-
tests. P-value <0.05 shows significant difference. Significant difference between males and female 
were observed for height, weight, BMI and systolic blood pressure. BMI; Body Mass index, SBP; 
Systolic blood pressure DBP; Diastolic blood pressure, HR; Heart rate (values are presented as 
mean ± SD)  
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4.5.2 Protocol of the study 
The participants visited the lab on 4 occasions. 7 days elapsed between visits. 
The day by day lab activities are discussed in the following sections and a 
schematic presentation of protocols is shown in figure 4-1. The order of visits 2, 
3 and 4 were randomised, so that exercise intensities did not come in an 
ascending or descending sequence.  The participants were paid £40 each, after 
completing the trials. 
4.5.2.1 Visit 1 
The participants attended the lab. After completing the consent forms and 
questionnaires about health status, their blood pressure, heart rate, height and 
weight were recorded, as described in chapter 2 sections 2.5. Each volunteer 
performed a sub maximal exercise test, using a walking or running protocol. This 
choice was based on their individual fitness levels, as described earlier in 
chapter 2 section 2.6. In the walking protocol, the speed was kept constant and 
the gradient was increased every 5 minutes. In the running protocol, the speed 
was increased by 1km/hr every 5 minutes while keeping the gradient at 0%. The 
maximum duration of the test was 20 minutes but stopped if the volunteer’s 
heart rate reached 85% of predicted maximum heart rate. This happened with 
only one volunteer. 
During each test, expired air was collected using Douglas bags and analysed to 
elicit the speeds and durations to be used in the subsequent 3 exercise 
protocols. The methods for calculating expired air gases and determining the 
exact speed and duration at specific heart rate are outlined, in chapter 2 section 
2.6.3.  
The dates and timings for the next visits were discussed with the participants 
and they were asked to abstain from physical activity for 24 hours before each 
trial. 
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4.5.2.2 Visit 2 
On the 2nd visit, the measurements for weight, height, blood pressure and heart 
rate were repeated. A cannula was passed in the ante-cubital vein and a pre-
exercise blood sample was taken. The participants initially stood quietly on 
treadmill for 5 minutes and their expired air was collected in the last minute. 
This was used to calculate their oxygen consumption and substrate utilization at 
rest and to confirm that participants are not hyperventilating. After this, the 
participants walked on the treadmill on pre-calculated speed capable of eliciting 
60% of the expected maximum heart rate. The duration of the exercise was set 
so, that the predicted energy expenditure of each participant was 200 kcal. This 
prediction was confirmed by expired gas collection in Douglas bags, after 5 
minutes of exercise. Where participants were consuming less or more energy, 
the work rates were increased or decreased.  The maximum increase or decrease 
for a participant was 0.4 km/hr. A second measurement of expired air gas was 
taken 5 minutes after any adjustment made. The rate of perceived exertion was 
measured using Borg scale (Borg, 1973). 
After finishing exercise, participants relaxed in a chair and blood samples were 
taken at 10 and 60 minutes intervals. They were only offered water during this 
time. After the final blood sample, cannula was removed and participants left 
the lab. 
4.5.2.3 Visit 3 
The sequences of events were the same, as on visit 2, except that participants 
ran at speed eliciting 70% of the predicted maximum heart rate. The duration of 
the exercise period was shorter than visit 2. 
4.5.2.4 Visit 4 
Participants repeat the same sequence of events as in visits 2 & 3. During this 
visit the participant ran at 80% of their predicted maximum heart rate. Again, 
the duration of the exercise was shorter. 
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Figure 4-1; Schematic diagram of study protocol 
Protocol of the study is schematically presented. Sub maximal oxygen consumption test is done on 
day 1 to measure the intensities and duration for the main trial. The volunteers then performed 3 
exercises at 60%, 70% and 80% of predicted maximum heart rate. The sequence of visit 2, 3 & 4 
were randomised. Blood samples were taken before and 10 and 60 minutes after exercise on visit 
2, 3 & 4. 
4.5.3 Measurements made during exercise 
Different features of the response to exercise at each intensity are given in 
tables 4-2, 4-4, 4-6 and other tables in this chapter. They are:  
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Speed 
The speed of the treadmill belt was measured in km/hr. The intensity of 
exercise was adjusted by changing the speed.  
Duration 
This is the duration for which participant actually exercised on the treadmill. It 
is given in minutes. 
 
Distance 
The distance covered during each exercise session was recorded and is given in 
kilometres. It does not include the distance covered during warm-up and 
recovery periods of the exercise. 
 
Oxygen consumption (VO2) 
Values for oxygen consumption at rest (BVO2) and at exercise (VO2_60, VO2_70, 
VO2_80,) were determined from sub-maximal values, as discussed in section 2.7. 
The difference in oxygen consumption was calculated by subtracting the oxygen 
consumption at rest (BVO2) from oxygen consumption at exercise and is denoted 
as ∆VO2. All these values are given in ml/kg/min. 
 
Carbon dioxide production (VCO2) 
This denotes the amount of carbon dioxide produced during the exercise. It is 
also measured in ml/kg/min. 
 
RER 
This is the ratio of carbon dioxide produced and oxygen consumed during one 
breath. It is called as respiratory exchange ratio and is determined as follows; 
    RER = VCO2/ VO2 
The RER values in table 4-2, 4-4 and 4-6 refers to RER values at respective 
exercise intensity. 
 
Rate of energy expenditure (EE) measured in kcal/min, rate of carbohydrate 
oxidation (RCHO) and rate of fat oxidation (RFO) 
All these values are derived from RER during the exercise stage and are 
discussed in section 2.7.4. 
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Rate of perceived exertion (RPE) 
This refers to the exercise intensity as perceived by the participants after 
performing exercise at different intensities. These were determined by asking 
participant reaction to exercise intensity on Borg scale (Borg, 1973). 
 
4.5.4 Blood sample collection  
A 20G cannula (Versatus W, Leuven, Belgium) was passed before the exercise 
and pre exercise blood sample was collected into 6ml EDTA tube. The blood 
samples were put on ice immediately after collection. They were spun at 1000 
RPM for 15 minutes, using a Universal 320 centrifuge (Universal 320R, Tuttlingen, 
Germany), within 30 minutes of collection. The plasma was transferred into 1 ml 
Eppendorf tube. 3 aliquots of plasma were made and stored at -80◦C in an ultra 
low temperature freezer (New Brunswick Scientific, U725-86, US) for up to one 
month before being analysed. 
4.5.5 Sample analysis 
The frozen samples were thawed and analysed for plasma endostatin 
concentration using QuantikinR ELISA kit of the R&D systems, as discussed in 
detail in section 2.11.1. 
4.5.6  Statistical analyses of the data 
Statistical analyses were carried out using SPSS 17 and MINITAB 16 statistical 
software. The distributions of all the variables were checked using Kolmogorov- 
Smirinov and Shapiro-Wilk tests of normality.  Log transformations of the data 
were done where appropriate. 
Descriptive statistics were carried out for all the variables and are presented as 
mean ± standard deviation (SD). Independent sample T-tests were applied to 
find out the differences between the means for male/female and 
running/walking groups.  One-way ANOVA with Bonferroni post hoc analyses with 
repeated measures was applied to determine the changes over time, before and 
after exercise.  
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 Box plots and independent line plots were produced for graphical demonstration 
of the data. Correlations of different variables with plasma endostatin 
concentration were done using Pearson correlation tests. Simple linear 
regressions were carried out for uni-variate and multivariate analyses to check 
any association of change in mean endostatin concentration with different 
exercise indices. 
4.6 Results 
4.6.1 Overview of the results 
As this study involved 3 different exercise interventions, which were carried out 
at 3 different intensities i.e. light, moderate and vigorous, as discussed in 
section 4.3. For convenience we will refer these interventions as follow: 
I. Protocol 1 refers to exercise at intensity of 60% of the maximum heart 
rate 
II. Protocol 2 refers to exercise at intensity of 70% of the maximum heart 
rate 
III. Protocol 3 refers to exercise at intensity of 80% of the maximum heart 
rate 
Data were analysed separately for each protocol and where appropriate 
collective analyses were carried. 
 
4.6.2 Distributions of the anthropometric data of all individuals 
The anthropometric data of all the participants were found normally distributed. 
Blood pressures and heart rates were recorded on all visits. Analysis with 
repeated measure ANOVA showed no difference between their means. 
Independent sample T- tests were applied to check the difference in means of 
different variables for males and females.  Unsurprisingly, men were 
significantly taller (P <0.001) & heavier (P <0.001). In addition, males had higher 
systolic blood pressure (P = 0.04). These data are summarised in table 4-1. 
Chapter: 4 
119 
 
4.6.3 Exercise at (Protocol 1) 
4.6.3.1 Distribution of the data for protocol 1  
The different features of exercise like speed, gradient, duration, heart rate etc 
of exercise at 60% of the predicted maximum heart rate were calculated and 
checked for normality. The differences in means for male and female were 
determined through independent sample T-test. Table 4-2; summarize the 
different components of the exercise in protocol 1 for all individuals as well as 
for males and females.  
In summary, all the volunteers walked or ran on the treadmill to deliver low 
intensity exercise. Their mean speed was 5.01 ± 0.1 km/hr and the mean 
duration of exercise was 42 ± 15 minutes. The mean distance covered at this 
exercise was 3.5 ± 0.8 km. 
During exercise the mean heart rate of female participants was significantly 
higher than males (118 ± 5 Vs 111 ± 5, P = 0.1). However, the change in the 
heart rate between resting and exercise condition was not different in two 
groups. This is because females had a higher resting heart rate, as shown in 
table 4-2.  
As all females chose gradient protocol, their mean speed was less than males. 
Females spent significantly more time on the treadmill and walked for longer 
distance. Oxygen consumption and rate of energy expenditure (kcal/min) was 
significantly higher in males and so was the rate of carbohydrate and fat 
oxidation. The exercise was perceived as “very light” by both sexes.  
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 Total Male Female P-value 
Sample size (n) 22 16 6  
BHR_60 (bpm) 77 ± 5 77 ± 6 80 ± 3 0.10 
HR_60 (bpm) 112 ± 5  111 ± 5 118 ± 5 0.01 
∆HR_60 (bpm)  36 ± 7 35 ± 8 38 ± 5 0.36 
Speed (Km/hr) 5.01 ± 0.1 5.3 ± 0.7 4.2 ± 0.3 0.002 
Duration (minutes) 42 ± 15 35 ± 9 61 ± 11 <0.001 
Distance (km) 3.5 ± 0.8 3.1 ± 0.6 4.4 ± 0.7 0.001 
BVo2_60 (ml/kg/min) 4 ± 0.4 4.1 ± 0.4 3.7 ± 0.3 0.020 
VO2_60 (ml/kg/min) 16 ± 4 17 ± 4 13 ± 2 0.009 
∆VO2_60 (ml/kg/min) 12 ± 4 13 ± 4 9 ± 2 0.021 
VO2 max % (ml/kg/min)  39 ± 6 39 ± 7  41 ± 3 0.350 
VCO2 (ml/kg/min) 14 ± 4 15 ± 5 11 ± 2 0.020 
RER 0.86 ± 0.04 0.86 ± 0.05 0.88 ± 0.03 0.520 
EE (kcal/min) 5.4 ± 2.1 6.2 ± 1.9 3.4 ± 0.7 0.002 
RCHO_60 (gm/min) 0.82 ± .5 0.92 ± 0.6 0.53 ± 0.14 0.020 
RFO_60 (gm/min) 0.25 ± .1 0.3 ± 0.1 0.15 ± 0.05 0.005 
RPE 8 ± 2 8 ± 2 8 ± 1 0.50 
Table 4-2; Different components of exercise and their mean difference 
Table shows the different components of the exercise for all individuals and the difference between 
the means for males and females. BHR; Resting heart rate, HR_60; Heart rate during exercise, 
∆HR; Difference between resting and exercise heart rate, BVO2; Resting oxygen consumption, ∆ 
VO2; Difference in oxygen consumption at exercise and rest, EE; Rate of energy expenditure 
(kcal/min), RCHO; Rate of carbohydrate oxidation, RFO; Rate of fat oxidation, RPE; Rate of 
perceived exertion 
 
4.6.3.2 Endostatin concentration in Plasma before and after exercise at 
protocol 1 
The concentrations of endostatin in plasma was measured before and 10 and 60 
minutes after exercise. The normality tests for the plasma endostatin revealed a 
non normal distribution for concentration at 10 minutes (P = 0.024 & 0.005) and 
60 minutes (P = 0.012 & 0.05) samples as shown by Kolmogorov- Smirinov and 
Shapiro-Wilk tests. The data were subjected to log transformations (P = 0.15 & 
0.12).  
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Line plots for all individuals on different times points are illustrated in figure 4-
2. It is obvious that the individual values lie in close ranges to each other. One 
participant can be seen with higher basal endostatin concentration. 
 
 
Figure 4-2; line plots for all participants 
Individual line plots for all participants showing the plasma endostatin concentrations before (0 Min) 
and different intervals (10 Min & 60 Min) after exercise at protocol 1. Participant 3 can be seen 
clearly with high values. 
 
Some of the participants showed a reduction in endostatin concentration after 
the exercise, while others had a positive change. The line plots for all 
participants based on the increase or decrease in the endostatin concentration 
after the exercise were created, as shown in figure 4-3. It was calculated, that 
36% of the participants showed a positive change while 64% showed a negative 
change after exercise. 
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Figure 4-3; Line plots illustrating the endostatin concentration in plasma before exercise (0 
Min) and different intervals (10 Min & 60 Min) after exercise at protocol 1.  
It is obvious that 14 out of 22 volunteers showed immediate decrease in basal concentration after 
the exercise. 
 
The basal mean endostatin concentration in plasma was determined as 101 ± 20 
ng/ml. ANOVA with repeated measures revealed, no significant change in 
endostatin concentrations after exercise (P = 0.5). The mean endostatin 
concentrations were 97 ± 22 ng/ml and 98 ± 23 ng/ml, 10 and 60 minutes after 
exercise respectively. This is equal to 4% and 3% decrease in mean Endostatin 
concentration. These changes were not significant (P = 0.5 & 0.8), as shown in 
figure 4-4. 
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Figure 4-4; Endostatin concentrations before and different intervals after exercise at 
protocol 1 
Box plots illustrating the mean, median, quartile range and range of endostatin concentration in 
plasma before and 10 and 60 minutes after exercise at protocol 1.  The clear circle represents 
outlier. ANOVA with repeated measures show no significant changes in mean endostatin 
concentrations at any time point (P = 0.5). 
 
4.6.3.3 Mean endostatin concentrations in males and females  
Figure 4-5 shows interaction line plots for male and female participants. It can 
be seen that the effect of exercise on endostatin concentrations is mixed in both 
groups.  
The basal mean endostatin concentrations were 105 ± 21 ng/ml and 90 ± 13 
ng/ml for males and females respectively. The mean endostatin concentration 
for males, 10 minutes after exercise was 99 ± 25 ng/ml and 60 minutes after 
exercise was 98 ± 26 ng/ml. The mean endostatin concentration for females,10 
minutes after exercise was 90 ± 6 ng/ml and 60 minutes after exercise was 97 ± 
14 ng/ml. Independent sample T-tests was applied to investigate the difference 
in mean endostatin concentration. No significant difference between the means 
in males and females at any time point was observed. 
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Figure 4-5; Interaction line plots showing the individual values for male and female 
participants before and after exercise at protocol 1 
 
 
Repeated measure ANOVA revealed no significant changes in mean endostatin 
concentration before and after the exercise for males (P = 0.2) and females (P = 
0.5). The decrease in endostatin for the male group was 6% and 7% at 10 minutes 
and 60 minutes interval. No change in mean endostatin concentration for 
females was observed at 10 minutes interval. However, 7% increase at 60 
minutes interval was observed, as shown in figure 4-6.  
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Figure 4-6; Endostatin concentration in males and females before and after exercise at 
protocol 1 
Box plots presenting the mean, median, inter quartile range and range of endostatin for male and 
female participants before and at different intervals after exercise at protocol 1. No significant 
differences were observed at any time point between the two groups. Clear circles represent 
outliers. 
 
4.6.3.4 Mean endostatin concentrations in running and walking group 
As described in section 4.5.2.1, the volunteers followed walking or running 
protocol as determined by their fitness levels. Interaction line graphs were 
created which illustrate the individual values for participants in each group and 
shown in figure 4-7. No clear difference, in term of influence of exercise on 
endostatin concentration is visible and both groups show a mixed effect of 
increase and decrease in endostatin concentrations after exercise. 
The mean endostatin concentration at rest was 100 ± 24 ng/ml for walking group 
and 101 ± 18 ng/ml for running group. Independent sample T-test revealed no 
difference between these values.  
ANOVA with repeated measure showed no significant change in any group.  
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The individual and group data are shown in figures 4-7 and 4-8. One of the 
volunteers was a clear outlier in the walking group. No significant difference was 
observed even after removal of outlier’s data from analysis. 
 
 
 
Figure 4-7; Interaction line plots for participants in walking and running group shows the 
individual values for all participants. Mix effect of exercise in both groups can be seen. 
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Figure 4-8; Endostatin concentrations in running and walking groups before and after 
exercise at protocol 1 
Box plots presenting the mean, median, inter quartile range and range of endostatin for participants 
in running and walking groups, before and at different intervals after exercise at protocol 1. No 
significant differences were observed at any time point between the two groups. Clear circles 
represent outliers. 
 
4.6.4 Exercise at 70% heart rate (Protocol 2) 
4.6.4.1 Distribution of the data  
The normalities of data generated from different exercise indices in protocol 2 
were checked using Kolmogorov- Smirinov and Shapiro-Wilk tests. Where not 
normal, it was subjected to log transformation. Descriptive statistics were done 
for all individuals and difference between the means for males and females were 
determined using independent T-test, as shown in the table 4-3. 
In this protocol the volunteers exercised at a moderate intensity. The mean 
speed on the treadmill was 5.8 ± 1.2 km/hr. Female volunteers exercised only 
with the gradient protocol, so their speed was less than males. The mean 
duration for the exercise was 30 ± 11 minutes during which the volunteers 
covered a distance of 2.7 ± 0.6 km. The exercise at protocol 2 was carried out at 
55% ± 5% (mean ± SD) of the predicted maximal oxygen consumption (V
.
O2 max). 
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Significant differences in means for some variables between male and female 
participants were observed, as shown by the P values in table 4-3. There was no 
difference in resting heart rate. Female volunteers ran slower than males but 
had significantly higher heart rates during exercise. The female volunteers also 
had lower rates of oxygen consumption and energy expenditures per minute. As 
a result, females exercised for longer durations than males. Males had higher 
rates of carbohydrate and fat oxidation. The exercise was perceived as ‘light’ by 
both sexes.  
 
 Total Male Female P-value 
Sample size (n) 22 16 6  
BHR_70 (bpm) 78 ± 5 78 ± 5 78 ± 5 0.8 
HR_70 (bpm) 133 ± 7  131 ± 7 138 ± 5 0.04 
∆HR_70 (bpm)  55 ± 8 53 ± 7 60 ± 7 0.05 
Speed (Km/hr) 5.8 ± 1.2 6.3 ± 1 4.2 ± 0.3 <0.001 
Duration (minutes) 30 ± 11 24 ± 5 45 ± 8 <0.001 
Distance (km) 2.7 ± 0.6 2.5  ± 0.6 3.2 ± 0.6 0.005 
BVO2_70 (ml/kg/min) 3.7 ± 0.3 3.7 ± 0.3 3.7 ± 0.4 0.6 
VO2_70 (ml/kg/min) 22 ± 5 24 ± 5 18 ± 2 0.001 
∆VO2_70 (ml/kg/min) 18 ± 5 20 ± 5 14 ± 3 0.003 
VO2 max % (ml/kg/min)  55 ± 5 54 ± 5 56 ± 2 0.34 
VCO2 (ml/kg/min) 20 ± 5 21 ± 5 16 ± 2 0.016 
RER 0.9 ± 0.04 0.9 ± 0.03 0.89 ± 0.04 0.6 
EE (kcal/min) 7.6 ± 2.7 8.7 ± 2.2 4.6 ± 1 <0.001 
RCHO_70 (gm/min) 1.4 ± 0.6 1.6 ± 0.6 0.8 ± 0.3 0.001 
RFO_70 (gm/min) 0.27 ± .1 0.3 ± 0.1 0.18 ± 0.29 0.027 
RPE 11 ± 2 10 ± 2 11 ± 2 0.4 
Table 4-3; Different exercise indices (protocol 2) and their mean differences between males 
and females 
Table shows the different exercise indices for all individuals and for males and females at protocol 
2.BHR; Resting heart rate, HR_70; Heart rate during exercise, ∆HR; Difference between resting 
and exercise heart rate, BV
.
O2; Resting oxygen consumption, ∆ V
.
O2; Difference in oxygen 
consumption at exercise and rest, EE; Rate of energy expenditure (kcal/min), RCHO; Rate of 
carbohydrate oxidation, RFO; Rate of fat oxidation, RPE; Rate of perceived exertion. 
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4.6.4.2 Endostatin concentrations in Plasma before and after exercise at 
protocol 2 
The distribution of endostatin concentrations at rest and different time intervals 
post exercise were examined using Kolmogorov- Smirinov and Shapiro-Wilk tests 
of normality. The basal and 60 minutes endostatin data were not normally 
distributed (P = 0.007 &0.032). Therefore, all endostatin samples were 
subjected to log transformations to obtain normal distributions (P = 0.28 & 
0.12).  
The concentrations of endostatin for each volunteer before and after exercise 
are illustrated in figure 4-9. The basal endostatin concentration for all 
participants can be seen in close ranges except 2. (Panel 19 and 22 shows higher 
basal endostatin concentration of 132 ng/ml and 155 ng/ml respectively). After 
exercise, some of the volunteers had an increase in their endostatin 
concentrations while others had decrease. It was plotted in figure 4-10, which 
illustrates that 77% of the individuals exhibit a positive change after exercise 
and 23% exhibit a negative change. However, it can be seen that at 60 minutes 
interval, the concentration raises for all participants. 
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Figure 4-9; Individual line plots for all the volunteers showing the plasma endostatin 
concentrations before exercise (0 Min), and at different intervals (10 Min & 60 Min) after 
exercise at protocol 2.  
 
 
 
Figure 4-10; Line plots illustrating the endostatin concentration in plasma before exercise (0 
Min) and at different intervals (10 Min & 60 Min) after exercise at protocol 2.  
17 out of 22 participants exhibited immediate increase as shown by the right panel. On the left 
panel, the initial decrease followed by an increase can be seen. 
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Mean endostatin concentration in plasma at rest was 88 ± 22 ng/ml. Mean 
endostatin concentration was 105  ± 30 ng/ml at 10 minutes interval and 106 ± 
33ng/ml at 60 minutes interval. One-way ANOVA with repeated measures 
showed a significant difference in the mean endostatin concentration at rest and 
subsequent time points (P = 0.002). Bonferroni post hoc analyses revealed 
significant rise in plasma endostatin concentration at both time points after 
exercise (P = 0.02 & 0.004). This increase was 18% and 19% respectively, as 
shown in figure 4-11.  
 
 
 
Figure 4-11; Endostatin concentration before and different intervals after exercise at 
protocol 2 
Box plots illustrating the mean, median, quartile range and range of endostatin for all participants 
before and at 10 and 60 minutes after exercise at protocol 2. Two participants presented with high 
endostatin concentrations in plasma at rest and are shown as outlier by clear circles. The mean 
endostatin concentrations increase by 18% (P = 0.02) and 19% (P = 0.004) respectively, at 10 and 
60 minutes after exercise and shown by the dotted line with *. 
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4.6.4.3 Endostatin concentration in males and females  
Plots illustrating the individual values for male and female volunteers are shown 
in figure 4-12. The mixed effect of exercise in both groups can be seen. 
Independent sample T-test showed no difference in means for both groups at any 
time point. The mean resting endostatin concentrations were 87 ± 43 ng/ml for 
males and 90 ± 35 ng/ml for females. Two participants with unusually high 
resting endostatin concentration of 155 ng/ml and 132 ng/ml were found, one in 
each group. There was no obvious explanation for these observations. Omitting 
them from the analysis did not change the difference between the two groups. 
The mean endostatin concentration for males, 10 minutes after exercise was 108 
± 29 ng/ml and 60 minutes after exercise, it was 106 ± 30 ng/ml. The mean 
endostatin concentration for females 10 minutes after exercise was 98 ± 40 
ng/ml and 60 minutes after exercise it was 106 ± 43 ng/ml. 
 
 
Figure 4-12; Interaction line plots showing the individual values for male and female 
participants before and at 10 and 60 minutes after exercise at protocol 2. 
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One-way ANOVA with repeated measures with Bonferroni corrections were 
carried out to investigate the significance of the differences between the 
endostatin concentrations at the different time points.  In males, a significant 
increase of 24% (P = 0.04) was observed 10 minutes after exercise. After 60 
minutes the rise in mean endostatin concentration was 22%. This was also 
statistically significant (P = 0.03). In females, the endostatin concentration 
increased by 9% (P = 0.2) at 10 minutes and by 17% (P = 0.05) at 60 minutes 
interval after exercise. These data are illustrated in figure 4-13. 
 
 
 
Figure 4-13; Endostatin concentration in males and females before and after exercise at 
protocol 2 
Box plots presenting the mean, median, inter quartile range and range of endostatin concentration 
for male and female participants before and different intervals after exercise at protocol 2. Dotted 
line with * represent the significant difference at different time points after exercise with basal 
endostatin concentration. 
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4.6.4.4 Endostatin concentration in running and walking group 
Independent sample T-test revealed no significant difference between the mean 
endostatin concentrations of the running and walking group at any time point.  
Interaction line plot for all individuals in different groups were plotted, as shown 
in figure 4-14. Resting mean endostatin concentration was 89 ± 17 ng/ml for 
running cohort and 86 ± 29 ng/ml for walking cohort.  
 
 
Figure 4-14; Interaction line plots for participants in walking and running group showing the 
individual values for all participants before exercise (0 Min) and at different intervals (10 Min 
& 60 Min) after exercise at protocol 2. 
 
ANOVA with repeated measures were carried out for both the groups. The 
exercise increased the plasma endostatin concentration significantly in both 
groups (P = 0.014 & 0.017) but the increase in the running group was more 
pronounced. In the running group an increase of 28% (P = 0.05) at 10 minutes 
interval and 26% (P = 0.04) at 60 minutes interval was observed. However, in the 
walking group, the rise in endostatin concentration was 9% (P = 0.31) at 10 
minutes interval and 14% (P = 0.02) after exercise, as represented in figure 4-15. 
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Walking group contain all females, therefore the pattern of change in endostatin 
in this group is almost similar to female group. 
 
 
 
Figure 4-15; Endostatin concentration in running and walking group before and after 
exercise at protocol 2 
 
Box plots showing the mean, median, inter quartile range and range of endostatin concentration 
for participants in the running and walking groups. Data are shown for pre exercise and different 
time intervals after exercise at protocol 2. Clear circles represent outlier. A more significant 
change was observed in the running cohort than walking. Dotted line with (*) represent the 
significant difference. 
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4.6.5 Exercise at 80% heart rate (Protocol 3) 
4.6.5.1 Distribution of the data for protocol 3 
Different variables of the exercise were calculated and checked for normalities. 
The differences in means for the male and female volunteers were determined 
using independent T-test. Table 4-4 summarize the different exercise indices in 
protocol 3 for pooled data and for male and female groups. 
 
 
 Total Male Female P-value 
Sample size (n) 22 16 6  
BHR_80 (bpm) 78± 5 77 ± 5 80 ± 5 0.3 
HR_80 (bpm) 153 ± 6  152 ± 7 156 ± 4 0.2 
∆HR_80 (bpm) 75 ± 8 75 ± 9 77 ± 8 0.6 
Speed (Km/hr) 6.4 ± 1.9 7.2 ± 1.6 4.2 ± 0.3 <0.001 
Duration (minutes) 23 ± 8 19 ± 4 34 ± 7 0.002 
Distance (km) 2.4 ± 0.4 2.3 ± 0.4 2.6 ± 0.5 0.2 
BVO2_80 (ml/kg/min) 3.7 ± 0.4 3.6 ± 0.3 3.8 ± 0.5 0.3 
VO2_80 (ml/kg/min) 28 ± 6 30 ± 6 22 ± 3 0.001 
∆VO2_80 (ml/kg/min) 25 ± 7 27 ± 6 18 ± 4 0.004 
VO2 max % (ml/kg/min) 69 ± 3 69 ± 4  71 ± 2 0.3 
RER 0.92 ± 0.04 0.92 ± 0.03 0.91 ± 0.05 0.3 
EE (kcal/min) 9.8 ± 3.3 11.2 ± 2.5 5.9 ± 1.3 <0.001 
RCHO_80 (gm/min) 1.98 ± 0.8 2.25 ± 0.6 1.09 ± 0.41 <0.001 
RFO_80 (gm/min) 0.27 ± .1 0.3 ± 0.1 0.15 ± 0.05 0.2 
RPE 14 ± 2 13 ± 2 15 ± 2 0.2 
Table 4-4; Different components of exercise and their mean difference 
Table shows the different components of the exercise for all individuals and the difference between 
the means for males and females. BHR; Resting heart rate, HR; Heart rate, ∆HR; Difference 
between  resting and exercise heart rate, BVO2; Resting oxygen consumption, ∆ VO2;  Difference 
in oxygen consumption at exercise and rest, EE; Rate of energy expenditure (kcal/min), RCHO; 
Rate of carbohydrate oxidation, RFO; Rate of fat oxidation, RPE; Rate of perceived exertion. 
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During this protocol, the volunteers exercised at a higher intensity on the 
treadmill. The mean speed was 6.5 ± 1.9 km/hr. It should be noted that female 
volunteers only exercised with the gradient protocol, so their speed was less but 
the gradient was steeper. The mean duration of exercise was 23 ± 8 minutes 
during which the volunteers covered a distance of 2.4 ± 0.4 km. This exercise 
was performed at 69% ± 3 of their predicted maximum oxygen consumption (V
.
O2 
max). 
Male participants exercised at significantly higher speed with high rates of 
energy expenditure for shorter periods. Males also showed a significantly higher 
rate of substrate metabolism. Respiratory exchange ratio for both the sexes was 
almost equal. Females perceived the exercise as ‘hard’ while males perceived it 
as ‘somewhat hard’. 
4.6.5.2 Endostatin concentration in Plasma before and after exercise at 
protocol 3 
The data for endostatin concentration at different time points were found to be 
normally distributed (P = 0.2, 0.2 & 0.1).  
The endostatin concentrations at different time intervals for all participants are 
plotted in figure 4-16. It can be seen that all of the volunteers exhibited a 
positive change after exercise at this intensity. One Volunteer (Panel 3) can be 
seen with higher basal endostatin concentration. The same volunteer showed a 
higher basal endostatin concentration on one previous occasion as well. The 
reasons for high baseline values are not completely clear.  
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Figure 4-16; Individual line plots for all participants showing the plasma endostatin 
concentrations before exercise (0 Min), and at different intervals (10 Min & 60 Min) after 
exercise at protocol 3. Participant 3 can be seen clearly with high baseline concentration. 
 
 
The mean endostatin concentration at rest was 100 ± 20 ng/ml. One-way ANOVA 
with repeated measures showed a significant increase in mean endostatin 
concentration after exercise (P <0.001). The mean endostatin concentrations at 
10 and 60 minutes intervals were 138 ± 34 ng/ml and 114 ± 34 ng/m 
respectively. These increase in means are equal to 38% (P <0.001) and 14% (P= 
0.021).  Box plots of the pooled data are shown in figure 4-17. 
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Figure 4-17; Endostatin concentration before and at different intervals after exercise at 
protocol 3 
Box plots illustrating median, quartile range and range of endostatin concentration in plasma before 
and at 10 and 60 minutes after exercise at protocol 3.  Significant changes in endostatin 
concentrations were observed at 10 minutes (P<0.001) and 60 minutes (P = 0.021). Clear circles 
represent outlier. 
  
4.6.5.3 Endostatin concentration in males and females  
Individual values at different time intervals were plotted using interactive line 
plots and shown in figure 4-18. Mean endostatin concentrations at baseline were 
102 ± 20 ng/ml for males and 94 ± 22 ng/ml for females. The mean endostatin 
concentration for males raised to 140 ± 34 ng/ml (P < 0.001) at 10 minutes and 
was 114 ± 28 ng/ml (P = 0.06) at 60 minutes after exercise. The mean endostatin 
concentration for females, at 10 minutes after exercise was 131 ± 35 ng/ml (P = 
0.018) and at 60 minutes was 113 ± 44 ng/ml (P = 0.22).  
No significant differences were observed between the means of both groups at 
any time point. Exercise changed the endostatin concentration significantly in 
both groups, as shown in the figure 4-19. 
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Figure 4-18; Interaction line plots showing the individual values for male and female 
participants before and at 10 and 60 minutes after exercise at protocol 3. All participants 
showed a positive change after exercise.  
 
 
Figure 4-19; Endostatin concentrations in males and females before and after exercise at 
protocol3 
Box plots presenting the mean, median, Inter quartile range and range of endostatin concentration 
for male and female participants before and different intervals after exercise at protocol3. 
Significant difference in endostatin concentration can be seen at 10 minutes interval for both 
groups. Clear circle represents outlier. 
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4.6.5.4 Endostatin concentration in running and walking group 
The data for the participants in the walking and running group was also 
analysed. Interaction line plots showing the individual values for all participants 
can be seen, in figure 4-20. Independent sample t-test reported no difference in 
the mean endostatin concentrations in both groups at different time points. 
Mean basal endostatin concentration for running group was 101 ± 19 ng/ml and 
for walking group was 99 ± 23 ng/ml. 
The mean endostatin concentration for running group raised to 139 ± 29 ng/ml 
at 10 minutes after exercise (P < 0.001) and dropped back to 111 ± 20 ng/ml at 
60 minutes interval (P = 0.3 with basal and 0.001 with 10 minutes sample). The 
mean endostatin concentration for walking group, 10 minutes after exercise was 
136 ± 42 ng/ml and 117 ± 46 ng/ml at 60 minutes (P <0.001 and 0.3 
respectively), as shown in figure 4-21.  
 
 
Figure 4-20; Interaction line plots for participants in walking and running group showing the 
individual values for all participants in each group before and after exercise at protocol 3.  
Chapter: 4 
142 
 
 
Figure 4-21; Endostatin concentration in walking and running group before and after 
exercise at protocol 3 
Box plots presenting the mean, median, inter quartile range and range of endostatin for participants 
in running and walking group, before and different intervals after exercise in protocol 3. Significant 
increase is observed immediately in both groups (P <0.001 for walking and running group, 
respectively) at 10 minutes interval which decreases in both groups at 60 minutes interval (P= 
0.001 & 0.13 between 10 and 60 minutes for running and walking respectively).  
 
4.6.6 Endostatin concentration and BMI at different intensities 
Within the volunteers recruited two groups could be identified on the basis of 
their BMI, 11 overweight and 11 normal. Normal individuals had a BMI less than 
25 kg/m2 and overweight individuals had a BMI of more than 25 kg/m2.  
The data from these groups were analysed to compare differences in endostatin 
concentration after exercise at all intensities.  At protocol 1, no difference 
between basal mean endostatin concentrations for both groups were observed 
(102 ± 25 Vs 99 ± 16 ng/ml for normal vs. overweight). Both groups showed an 
insignificant decrease in mean endostatin concentration (P = 0.8 & 0.2, for 
normal and overweight respectively).  
At protocol 2, again no difference between the basal endostatin concentration 
for both the groups was observed (P = 0.3). Significant increase in mean 
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endostatin concentration was observed for both groups after exercise at protocol 
2 (ANOVA P = 0.03 & 0.05 for normal and overweight) 
At protocol 3, there was no difference in basal endostatin concentration for both 
the groups. The exercise at protocol 3 significantly increased the endostatin 
concentration in plasma for both groups (ANOVA P <0.001 for both groups). 
In conclusion, the effects of exercise on endostatin concentrations in both 
groups were the same and not much different from the analyses done already. 
4.6.7 Correlations of changes in endostatin concentrations 
and the different parameters of the exercise at all 
intensities 
As the different exercise intensities changed the endostatin concentration in 
plasma differently, it was thought that some features of these exercises might 
influence the changes directly and more than others. For this reason, the 
difference in the endostatin concentration, (∆ES1) baseline and 10 minutes after 
the exercise and (∆ES2) baseline and 60 minutes were calculated for all the 3 
exercise intensities. Further statistical analyses were carried out to examine the 
Pearson correlation between features of the exercise and ∆ES1 & ∆ES2 at all 
intensities. The results are shown in the table 4-5.  
It is interesting that no particular pattern of correlation between any feature of 
exercise and the change in endostatin concentration was observed. Some of 
correlations were of statistical significance at one time point but not at others. 
For example; significant positive correlation was found between respiratory 
exchange ratio and the ∆ES1 at protocol 1 exercise but not at other time points. 
Similarly, significant negative correlations were found between the rate of fat 
oxidation and ∆ES1 & ∆ES2 at protocol 1 but not at protocol 2 or 3. It might be 
possible that these correlations are by chance and not true. 
However, other components of the exercise like change in heart rate, duration 
of the exercise, distance covered, oxygen consumption, change in oxygen 
consumption, energy expenditure, rate of carbohydrate oxidation and rate of 
perceived exertion showed no significant correlations with the changes in 
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endostatin concentration after exercise at different intensities.  Some of the 
variables and their correlation values with linear regression lines are shown in 
appendix “I”. 
  
Variables ∆ES1-60 ∆ES2-60 ∆ES1-70 ∆ES2-70 ∆ES1-80 ∆ES2-80 
Heart Rate (bpm) 
  
0.216 0.386 -0.158 -0.120 -0.143 -0.088 
0.334 0.076 0.483 0.595 0.525 0.696 
∆ Heart rate (bpm) 
  
0.156 0.109 -0.261 -0.131 0.083 -0.014 
0.489 0.630 0.241 0.562 0.713 0.952 
Speed (km/h) 
  
-0.038 -0.090 0.312 0.061 0.142 -0.008 
0.868 0.690 0.157 0.787 0.528 0.972 
Gradient (%) 
  
-0.151 -0.146 -0.687 -0.505 -0.116 0.130 
0.698 0.708 0.041 0.165 0.766 0.738 
Duration (Min) 
  
0.170 0.211 -0.090 0.142 -0.070 0.124 
0.448 0.347 0.690 0.529 0.757 0.581 
Distance (km) 
  
0.102 0.187 0.116 0.378 0.157 0.262 
0.651 0.404 0.608 0.082 0.484 0.240 
Basal VO2  
  
0.052 -0.227 -0.333 -0.134 -0.114 -0.117 
0.818 0.310 0.130 0.551 0.614 0.603 
Actual VO2 (ml/kg/min) 
  
0.048 -0.020 0.059 -0.195 0.144 0.154 
0.830 0.931 0.793 0.385 0.522 0.493 
∆VO2 (ml/kg/min) 
  
0.044 0.002 0.077 -0.184 0.149 0.159 
0.844 0.992 0.734 0.412 0.508 0.479 
VO2 Max (%) 
  
0.330 0.232 0.005 -0.243 -0.099 0.128 
0.133 0.299 0.981 0.276 0.663 0.570 
Resp. Exch. Ratio 
  
0.535 0.396 0.076 0.035 -0.108 0.184 
0.010 0.068 0.735 0.876 0.632 0.413 
 EE (kcal/min) 0.051 -0.024 0.122 -0.280 0.159 -0.044 
0.823 0.914 0.588 0.207 0.480 0.847 
Rate of Fat Oxidation  
  
-0.528 -0.466 -0.032 -0.234 0.154 -0.196 
0.012 0.029 0.888 0.295 0.495 0.381 
Total Fat Oxidation (g) 
  
-0.531 -0.390 -0.086 -0.037 0.087 -0.175 
0.011 0.073 0.705 0.870 0.702 0.436 
Rate of Carb. Oxidation  
  
0.332 0.228 0.160 -0.193 0.118 0.042 
0.131 0.307 0.476 0.391 0.601 0.853 
Total Carbohydrate (g) 
  
0.522 0.413 0.048 0.021 -0.124 0.190 
0.013 0.056 0.830 0.927 0.583 0.397 
Rate of Perceived 
Exertion  
0.193 0.235 -0.053 -0.067 0.128 0.095 
0.389 0.293 0.815 0.766 0.571 0.673 
Table 4-5; Pearson Correlation of change in plasma endostatin concentration at 10 (∆ES1) 
and 60 minutes (∆ES2) of exercise at all protocols with different components of exercises at 
all intensities 
 
Pearson correlation values (Upper values) and P value (Lower values) for change in endostatin at 
10 minutes and 60 minutes interval at each exercise to the different components of exercise at 
respective intensities. ∆ Heart rate; Change in heart rate, VO2; (Oxygen consumption), ∆VO2; 
change in oxygen consumption from resting to exercise, Resp. Exch. Ratio; Respiratory exchange 
ratio, Rate of Carb Oxidation; Rate of carbohydrate oxidation. EE; Rate of energy expenditure 
(kcal/minute) 
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4.6.8 Regression analyses  
Linear regressions were carried out to determine any association of different 
anthropometric and exercise components with the change in endostatin 
concentration (∆ ES1) at 10 minutes and (∆ ES2) at 60 minutes during all exercise 
intensities. Uni-variate analyses were carried out for all the predictors including 
anthropometric characteristics and exercise parameters at all intensities- Beta 
Coefficient values, P values and R2 adjusted values were calculated. No 
association in uni-variate analyses were found between any predictors and ∆ ES1 
and ∆ ES2 at protocol 3. However, the variables with P value less than 0.1 in uni-
variate analyses at protocol 1 and 2 were identified as predictors of interest and 
included in the table 4-6. 
The predictors of interest were further analysed in multivariate linear regression 
model, as shown in table 4-7. Distance covered during the exercise and diastolic 
blood pressure at protocol 2 were found to be significantly associated (P = 0.053 
& 0.043) with the ∆ ES2 for the pooled data. When adjusted for gender and 
walking/running group, the distance covered during the exercise was 
significantly associated with the ∆ ES2 for both the adjusted groups (P = 0.011 & 
0.022). However, association between diastolic blood pressure and change in 
endostatin concentration ∆ ES2 was approaching significance (P = 0.069 & 
0.081), as shown in the table 4-7. These are likely to be chance findings as they 
could not be confirmed for the data set at other protocols.
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Predictors ∆ES1-60 ∆ES2-60 ∆ES1-70 ∆ES2-70 
 β-coef p R2-adj β-coef p R2-adj β-coef p R2-adj β-coef p R2-adj 
Age (years)             
Weight (kg)             
Height (m)             
BMI (kg/m2)             
Systolic BP (mmHg)      1.648 0.018 21.30    
Diastolic BP (mmHg)      1.419 0.109 08.00 1.206 0.105 08.30 
Heart Rate (bpm)            
Work Rate (km/h)            
Gradient (%)       -3.715 0.041 39.70    
Duration (Min)            
Distance (km)          14.91 0.082 10.00 
VO2 Max (%)             
Resp. Exch. Ratio 154.6 0.010 25.00 159.52 0.068 11.40       
Rate of energy exp. 
(kcal/min) 
          
Rate of Fat Oxidation  -65.99 0.012 24.20 -81.25 0.029 17.80       
Total Fat Oxidation (g) -2.047 0.011 24.60 -02.10 0.073 11.00       
Rate of Carb. Oxidation             
Total Carb. (g) 0.819 0.013 23.60 0.903 0.056 12.90       
Rate of Perceived 
Exertion  
          
Table 4-6; Uni-variate regression analysis of change in endostatin concentration with anthropometric and exercise predictors 
 
∆ES; change in endostatin levels between resting and 10 minutes (called as ∆ES1) or 60 minutes (called as ∆ES2) after exercise, Β-coef; beta coefficient, p; p-
value, R2-adj; R2 adjusted, BMI; body mass index expressed as kg/m2, VO2; oxygen consumption, Resp. Exch. Ratio; respiratory exchange ratio, Energy Exp.; rate 
of energy expenditure expressed as kcal/min, carb.; carbohydrate in g 
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 ∆ES1-60 ∆ES2-60 ∆ES1-70 ∆ES2-70 
  β-coef p R2-adj  β-coef p R2-adj   β-coef p R2-adj   β-coef p R2-adj   
Unadjusted multivariate analysis 
Systolic BP (mmHg)             0.418 0.433 49.32%       
Diastolic BP (mmHg)             0.501 0.245   1.35 0.053 22.60% 
Gradient (%)             -3.210 0.070         
Distance (km)                   16.491 0.043   
Resp. Exch. Ratio 2555.8 0.301 23.97% -4220.8 0.251 14.20%             
Rate of Fat Oxidation -31.62 0.379   -75.16 0.166               
Total Fat Oxidation (g) 17.17 0.422   -29.87 0.348               
Total Carb. (g) -6.350 0.256   11.03 0.186               
Adjusted multivariate analysis for Gender 
Systolic BP (mmHg)             0.698 0.258 52.82%       
Diastolic BP (mmHg)             0.399 0.350   1.218 0.069 29.80% 
Gradient (%)             -3.723 0.058         
Distance (km)                   25.129 0.011   
Resp. Exch. Ratio 2732.6 0.325 19.36% -3796.8 0.355 9.260%             
Rate of Fat Oxidation -25.25 0.638   -59.65 0.454               
Total Fat Oxidation (g) 18.72 0.436   -26.11 0.462               
Total Carb. (g) -06.64 0.272   10.32 0.249               
Adjusted multivariate analysis for Walking/Running  
Systolic BP (mmHg)             0.418 0.433 49.32%       
Diastolic BP (mmHg)             0.501 0.245   1.192 0.081 26.92% 
Gradient (%)             -3.209 0.070         
Distance (km)                   19.102 0.022   
Resp. Exch. Ratio 2562.7 0.315 19.45% -4222.7 0.266 8.850%             
Rate of Fat Oxidation -25.62 0.582   -76.79 0.274               
Total Fat Oxidation (g) 17.68 0.425   -30.01 0.363               
Total Carb. (g) -06.15 0.292   10.97 0.209               
Table 4-7; Multivariate regression analyses of change in endostatin concentration with anthropometric and exercise predictors  
Predictors which had a p≤0.1 in uni-variate analysis were analysed in multivariate analysis. ∆ES; change in endostatin levels between resting and 10 minutes (called as 
∆ES1) or 60 minutes (called as ∆ES2) after exercise, Β-coef; beta coefficient, p; p-value, R
2
-adj; R2 adjusted, Resp. Exch. Ratio; respiratory exchange ratio, carb.; 
carbohydrate in g.
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4.6.9 Baseline endostatin concentration on different days 
during the trial 
The baseline endostatin concentrations on each of the 3 lab visits were analysed 
to investigate the consistency of the data. Independent sample T-test revealed 
no significant difference between mean endostatin concentration for males and 
females on each experimental day. These data are shown in table 4-8. 
 
  Gender Mean Endostatin(ng/ml) ± SD P Value 
week 1 Female 90 ± 14 0.068 
 Male 105 ± 21 
All 101 ± 20  
week 2 Female 90 ± 35 0.844 
 
 
Male 87 ± 17 
All 88 ± 22 
week 3 Female 94 ± 22 0.421 
Male 102 ± 20 
All 100 ± 20 
Table 4-8; Baseline endostatin concentrations for male, female and all individuals on 
different weeks 
Mean basal endostatin concentrations in plasma of male and female individuals on all 3 weeks. 
The data for males and females were not significantly different on 3 weeks. SD; Standard deviation 
 
The differences in the mean on the 3 weeks were determined using repeated 
measures ANOVA with Bonferroni post hoc analysis. No significant difference 
between the endostatin concentration at week 1 with week 2 or week 3 were 
observed (P = 1.0 and 0.16 respectively). However, the Difference between 
week 2 and 3 was borderline significant (P = 0.049).  
Box plots showing the mean, median, individual values and the difference 
between the means on all visits are given in figure 4-22. 
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4-22; Baseline endostatin concentration on 3 visits 
Box plots presenting basal endostatin concentration on all 3 weeks with mean, median and 
individual values. Dotted line above the box plot shows the significant difference between week 2 & 
week 3 concentration (P value 0.049). 
In males, the difference in mean endostatin concentrations between week 2 and 
week 3 were significant (P = 0.014). There was no significant difference between 
week 1 and week 2 (P = 0.068) and week 1 and week 3 (P = 1.0). 
However, no differences in basal endostatin concentrations were observed for 
females on all 3 weeks (Anova P = 0.93). The data is shown in figure 4-23. 
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4-23; Baseline endostatin concentrations in males and females on all 3 visits 
Box plots presenting the mean, median, inter quartile range, individual values and significant 
difference in the basal endostatin concentration on different weeks for males and females. Female 
participants can be seen with almost the same mean concentrations on all the three weeks. Solid 
arrows with * shows the difference for males participants. (* = P value 0.068, ** = P value 0.014) 
 
4.6.10 Correlations of basal endostatin concentration with 
anthropometric and resting variables 
Basal endostatin concentrations on all 3 weeks and the different anthropometric 
and other baseline variables were checked for any correlation between them. 
Moreover, mean endostatin values for all individual from the basal endostatin 
concentrations on 3 weeks were determined and correlated as well. These 
correlations are shown in table 4-9. Age show significantly positive correlation (P 
= 0.008, r = 0.55) with basal endostatin concentration only at week 1 but not 
week 2 or week 3. However, when correlated with the mean data of all weeks, it 
was approaching statistical significance (P = 0.053, r = 0.24).  
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Variables ES-Week 1 ES-Week 2 ES-Week 3 ES-All weeks 
 r p r p r p r p 
Age (years) 0.553 0.008 0.009 0.967 0.207 0.356 0.240 0.053 
Weight (kg) 0.114 0.615 0.015 0.946 0.312 0.157 0.137 0.272 
Height (m) 0.017 0.939 0.047 0.836 0.348 0.113 0.129 0.303 
BMI (kg/m2) 0.185 0.410 -0.028 0.901 0.202 0.367 0.111 0.376 
Systolic BP 0.273 0.220 0.170 0.450 0.142 0.530 0.186 0.134 
Diastolic BP -0.053 0.815 0.226 0.312 0.209 0.350 0.124 0.319 
Basal HR -0.389 0.074 -0.024 0.917 -0.172 0.444 -0.207 0.095 
Basal VO2  -0.091 0.689 0.128 0.569 -0.218 0.329 -0.015 0.903 
∆ES1 -0.228 0.308 -0.251 0.259 0.210 0.349 -0.074 0.556 
∆ES2 -0.288 0.193 0.089 0.694 0.008 0.972 -0.114 0.360 
4-9; Correlations of baseline endostatin concentration on all visits with anthropometric and 
physical characteristics  
Pearson correlations for different anthropometric measures and basal endostatin concentration on 
different weeks are shown. ES; basal endostatin concentration, r; Pearson correlation value, P; P 
value, ∆ES1; difference in endostatin concentration between basal and 10 minutes sample, ∆ES2; 
difference in endostatin concentration between basal and 60 minutes sample, BP; blood pressure 
as mmHg, HR; heart rate as bpm, VO2; oxygen consumption in ml/kg/min 
 
4.6.11 Correlation of the baseline endostatin concentration 
with the changes in endostatin concentration on 
respective days 
It was thought that basal endostatin concentration might affect the change in it 
after exercise on respective trials. To answer this, Pearson correlation between 
the basal endostatin concentrations on different days with respective changes 
(∆ES1 & ES2) were carried out, as shown in the table 4-9. No correlations of 
statistical significance were observed between basal endostatin concentration 
and ∆ES1 & ES2 on all weeks, as illustrated in the figure 4-24.  
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4-24; Correlations with linear regression lines of basal endostatin concentration on all 
weeks with changes in endostatin concentration on respective days 
No significant correlation can be appreciated. Delta ES1; difference between basal ES 
concentration and 10 minutes sample, Delta ES2; difference between basal ES concentration and 
60 minutes sample. ES; Endostatin, values in red; male volunteers, values in black; female 
volunteers 
 
4.6.12 Collective data of all individuals on all visits 
Finally the data for all individuals were plotted in the same interactive line 
graphs, as shown in figure 4-25, to observe any specific trend with naked eye. 
Mixed pattern of increase and decrease in endostatin concentration after 
exercises were observed for all individuals except;  participant no 3 who had 
high basal endostatin concentrations on 2 occasions and participants 18, who 
showed no changes in endostatin concentration after exercise on all 3 occasions.  
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4-25; Individual line graphs for all participants on all days. Participant 3 presented with a 
clear outlier data for basal endostatin on week 1 and week 3. Participant 18 can be seen with 
almost no change after the exercise on all occasions. 
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4.7 Discussion  
Prevalence of cardiovascular disease is on the rise in the recent era and certain 
ethnicities are at higher risk than others. For example, the South Asian 
population have a higher incidence of premature onset of the CVDs as well as 
increased mortality and morbidity (Gholap et al., 2011). Research has 
established the beneficial effects of exercise on decreasing the development, 
mortality and morbidity due to cardiovascular diseases, although the 
mechanisms for these beneficial effects are poorly understood (Thompson et al., 
2003, Golbidi and Laher, 2012). Therefore, health organizations such as WHO has 
suggested a minimal recommendation of quantitative and qualitative physical 
activity to diminish the risk of CVD (World Health Organization, 2011). In some 
cases these physical activities are structured while in other cases vigorous. 
In general, this study was designed to investigate the impact of structured 
exercise activities on the endostatin concentration which is one of the key 
regulators of angiogenesis. In more specific terms, this study examined the 
impact of 3 different exercise intensities (mild, moderate and vigorous) on the 
concentration of endostatin in plasma of young healthy adult males  and 
females. It was proposed that different exercise intensities might influence the 
endostatin concentration in plasma differently. Moreover, it was also proposed, 
that gender and variations in physical characteristics might be differently 
influenced. 
4.7.1  Summary of findings of the study 
22 young healthy volunteers completed the exercise within the time schedule 
without any dropout. It includes 16 males and 6 females. No difference in 
anthropometric characteristics and age between males and females were 
observed, as shown in table 4-1. 
The results in this chapter reported different effects of exercise on endostatin 
concentration in plasma. The changes in the circulatory endostatin with 
different intensities were different. With the mild intensity exercise a non 
significant negative change was observed, while with higher intensities the 
increase in endostatin was significantly high. The moderate intensity exercise 
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reported mixture of effects but all the participants showed an increase in 
endostatin concentration at 60 minutes interval.  
The exercise in protocol 1 was of light intensity i.e. at 60% of the predicted 
maximum heart rate. After exercise, the plasma endostatin concentration was 
reduced by ~5%, as shown in figure 4-4. The effect was however not significant. 
The exercise in protocol 2 was of moderate intensity i.e. at 70% of the predicted 
maximum heart rate. The mean endostatin concentration after exercise changed 
significantly by 18% at 10 minutes after the exercise and 19% at 60 minutes after 
the exercise, as shown in figure 4-11.  
The exercise in protocol 3 was of high intensity i.e. at 80% of the predicted 
maximum heart rate. The mean endostatin concentration changed significantly 
(P <0.001) at 10 minutes and 60 minutes (P = 0.021) after the exercise, as shown 
in figure 4-17. This change was equal to 38% and 14% respectively.  
Changes in endostatin concentration at these respective exercises were never 
strongly influenced by gender, exercise mode (walking/running) and BMI of the 
individuals. 
 Moreover, changes in endostatin concentration could not be correlated with 
different anthropometric characteristics and different exercise features. 
4.7.2 Study design 
To the best of author’s knowledge, this is the first study to demonstrate the 
effect of 3 different structured physical activities of different intensities on the 
endostatin concentration in plasma of young healthy volunteers. 
The main aim of the study was to investigate the impact of different intensities 
of exercise on the endostatin concentration in plasma with the hypothesis that 
different intensities will affect endostatin concentration differently. The 
intensities of the exercise, according to the American College of Sports Medicine 
(ACSM, 2013) were equivalent to light, moderate and vigorous. The participants 
were divided in to 3 groups and the orders of the exercise were randomised.  
Chapter: 4 
156 
 
Male participants were significantly heavier and taller than females, as shown in 
table 4-1. The participants were asked to refrain from any physical activity for 
24 hours before the main trial. It served two aims; firstly the university students 
are more active than common individuals due to their involvement in different 
sports and secondly, prior exercise might interfere with the actual effects. 
Recruitment of the participants was not easy due to number of visits. However, 
it was encouraging that all the participants after recruitment followed the full 
protocol and no drop outs were observed.  
For standardization of the experiment, the exercise activities of all the 
participants at all the visits were monitored and recorded by the same 
researcher with the help of the same lab technician. Moreover, the same 
treadmill was used for all participants in the same lab. Same heart rate monitor 
and Douglas bags were used for participant on all occasions. Only one type of gas 
analyser was used for all measurements. The lab temperature was kept constant 
during all trials. However, the researcher was unable to control the barometric 
pressure. Moreover, due to very high time consumption of the ELISA (6 to 7 
hours), only one plate per day was analysed.  
The sample size of the study was 22. It was calculated based on the results of 
the study in chapter 3. Using the mean and standard deviation of endostatin 
concentration, it was assumed that exercise will change the mean endostatin 
concentration by 10 ng/ml. Applying this data to the nomogram designed by 
Altman (Altman, 1990) and Eng (Eng, 2003), it was predicted that recruiting 18-
22 individuals will provide a chance of 90% success. This study sample was bigger 
than that by Gu (Gu et al., 2004) who investigated 7 individuals, Suhr who 
studied twelve and thirteen participants (Suhr et al., 2007, Suhr et al., 2010) 
and Brixius, who recruited 21 individuals (Brixius et al., 2008).  However, the 
sample size was smaller than those used by Sponder (Sponder et al., 2013) who 
studied 42 Type 2 diabetic patients and 45 controls in his study, and Makey who 
tested 72 female breast cancer patients (Makey et al., 2013). Nonetheless, their 
study protocol was different in 2 respects; firstly they use single interventional 
exercise and secondly their studies involved cohort of patients. 
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4.7.3 Comparison with published studies 
This study investigates the impact of 3 different exercise intensities on 
endostatin concentrations in young healthy individuals. In simple terms, the 
intensities corresponded to walking, jogging and running at a moderate speed. 
Very high intensities i.e. more than 80% predicted maximum heart rate, were 
not selected due to 3 main reasons; firstly it would be reasonably impractical for 
sedentary population to run at high intensity as individual tends to adhere to 
lower intensity programme (Duncan et al., 2005), secondly low intensities are 
easy to incorporate with long term compliance into one’s life style (Choi et al., 
2007) and thirdly low intensity activities could be implied clinically with ease in 
patients (Johnson et al., 2009).  
4.7.3.1 Exercise at protocol 1 
This study found that endostatin concentration was negatively but not 
significantly altered with low intensity exercise.  During this exercise the 
participants lightly walked for relatively longer distance over reasonably longer 
durations. Though exercise minimally decreases the mean endostatin 
concentration but 64% of the individuals showed a transient decrease after the 
intervention, as shown in the figure 4-3. The decrease in endostatin 
concentration acutely after exercise has not been reported previously.   
However, Brixuis reported a significant decrease in the basal endostatin 
concentration after 6 months of endurance training in overweight men (Brixius 
et al., 2008). This 6 month interventional exercise programme included 3 
episodes of walking for 90 minutes at 2-4 mmol/l lactate levels or biking for 60 
minutes at the 2-4 mmol/l per week. Nonetheless, this study fails to report the 
time duration between the last exercise session and the blood samples taken for 
endostatin analyses. Moreover, Bruserud and his colleagues also reported no 
difference in endostatin concentrations for healthy adults after high mountain 
climbing (Bruserud et al., 2005). A more recent study reported a non significant 
and minimal increase in the plasma endostatin concentration after 30 minutes of 
walking on treadmill at 55-59% maximum heart rate intensity (Makey et al., 
2013). The decrease in endostatin concentration in the skeletal muscles of the 
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mice, after 4 weeks of moderate exercise for 30 minutes a day for 7 days a week 
was reported by Gu (Gu et al., 2006).  
The exact mechanism of why endostatin concentration decreases after low 
intensity exercise is, however, poorly defined.  Gu speculated that because 
endostatin is inversely correlated with the capillary density in the skeletal 
muscles and that exercise tends to improve the capillary density, in turn 
decreases the endostatin concentration in the skeletal muscles (Gu et al., 2006). 
Whereas, Brixius postulated that long term exercise decrease the circulating 
endostatin with two possible effects; firstly with the decrease in endostatin 
concentration a more angiogenic phenotype in body muscles is enhanced  and 
secondly in case of high intensity physical activity, a rapid increase in the 
circulatory endostatin provides the beneficial effects against atherosclerosis 
(Brixius et al., 2008). However, no evidence is there to back this hypothesis and 
further experimental work would be required to prove this.   
In Bruserud’s study no significant difference in endostatin concentration in 
healthy adults was reported after mountain climbing. It could possibly be due to 
many reasons including age of the participants (Mean age 74 years), co-morbid 
conditions, intensity of the exercise and timing of the blood samples. Moreover, 
it is hard to know the extent of change in endostatin concentration in his study, 
as only P values are reported. However, when manually calculated from the 
graph, 40% of the individuals showed a decrease in endostatin concentration 
after climbing. Though the design of the study differs to our study (Unstructured 
physical activity, 30 minutes break during climbing), the results are in line with 
our study (Bruserud et al., 2005).  
Based on the results in this chapter, we can say that a threshold mechanism 
required for the release of endostatin after exercise, does exist and low 
intensity does not affect that threshold. Person to person variation in this 
threshold mechanism might explain the difference in influence by the same 
intensity of exercise. Moreover, it is also possible that decrease in venous 
endostatin concentration after exercise may be due to uptake of endostatin by 
tissue from circulation.   
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This study also finds that the change in males and females is not uniform after 
the exercise. In fact, the males showed a negative change at 10 and 60 minutes 
after the exercise while females showed no change in the mean concentration, 
10 minutes after the exercise and positive change of 7% at 60 minutes.  This 
finding is interesting, because male participants exercised comparatively at 
higher speed with higher oxygen consumption and metabolic variables, as shown 
in table 4-2.  
In a recent study, endostatin concentration at base line as well as after exercise 
was shown to be higher in females and a hormonal influence was suggested as 
the possible cause (Sponder et al., 2013). Menstrual history of the female 
participants in our study was not taken and the hormonal influence on 
endostatin concentration or the change in it could not be excluded completely. 
However, it could be implied that females can benefit even from low intensity 
exercises. 
4.7.3.2 Exercise at protocol 2 and protocol 3 
A steady and significant increase in endostatin concentration in plasma was 
observed after the exercise at protocol 2. The increase in the mean endostatin 
was 18% and 19%, 10 minutes and 60 minutes after the exercise respectively (P = 
0.02 & 0.001). There was no sex specific difference in increase, although the 
pattern of increase between males and females was slightly different. Male 
showed an initial significant increase of 24% followed by a slight decrease to 22% 
at 60 minutes interval while females showed a steep increase of 9% initially 
which increased to 17% at 60 minutes. Contrasting to the results in previous 
section, 77% of the participants exhibited a positive change in endostatin 
concentrations after exercise while 23% showed a negative change, as illustrated 
in figure 4-10. However, it can be seen that after initial decrease, all 
participants exhibited positive changes. 
Similar results were obtained when the volunteers performed the 3rd physical 
activity at higher intensity (protocol 3). The increase in mean endostatin was 
38% at 10 minutes interval which remained higher even after 60 minutes of the 
exercise. There was no sex specific difference in mean concentrations. 
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Concurrently, no differences between the running and walking groups were 
observed. 
The results in this section of the study confirm and expand the earlier 
observations of increase in plasma endostatin concentration after a moderate to 
high intensity exercise by different research groups (Sponder et al., 2013, 
Sponder et al., 2011, Gu et al., 2004, Suhr et al., 2007). Gu and his colleagues 
were the first to demonstrate significant increase in plasma endostatin 
concentration, when 7 healthy individuals performed exercise at 80-93% 
predicted maximum heart rate on treadmill for 4 to 10 minutes. The mean 
endostatin concentration raised by 43%, 73% and 33% at 30 minutes, 120 minutes 
and 360 minutes after exercise while in our study the maximum increase after 
the high intensity exercise was 38% at 10 minutes. The difference could possibly 
be due to the small sample size by Gu (n = 7) and only male participants in the 
study. If male to male comparison is carried out, the highest increase for males 
in our study was 38% at 10 minutes interval.  
In a recent study, when a cohort of twelve healthy males undertook exercise 
protocols under different conditions including normoxic and normobaric hypoxic 
conditions with or without vibrations, the significant raise in endostatin 
concentration was observed in all groups up to 1 hours post exercise (Suhr et al., 
2007). The participants in this study were males and most of them were national 
levels cycling athletes. 
In a better structured study with both healthy & type 2 diabetic male and 
female volunteers, an increase in endostatin concentration after performing 
bicycle stress test was also shown (Sponder et al., 2013). Our results can be 
compared to this study, because this study also reported slightly higher increase 
in males than females. However, the highest increase reported by Sponder was 
only 15% observed in healthy males. 
Results in this study are different from the study done by Brixius (Brixius et al., 
2008),who reported a decrease in plasma endostatin concentration after 6 
months of exercise training and Makey who did not find any increase in 
endostatin concentration after exercise at 55-59% heart rate in females (Makey 
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et al., 2013). The difference in design, intensity and timings of the samples 
taken could possibly explain the difference in results. 
Just as the walking and running groups, analyses were also carried out on the 
bases of BMI. Participants were divided into normal (BMI < 25) and overweight 
(BMI > 25) groups. No differences in endostatin concentration of plasma were 
found between the two groups before or after the exercise at any time point 
during all the trials. Only one previous study has compared the increase in 
endostatin concentration for normal and obese females without any difference 
(Sponder et al., 2013).  
Moreover, as the change in endostatin with high intensities of exercise was 
significant, correlations of the different components with the change at 
different intervals after exercise were carried out, as shown in table 4-5. No 
prominent pattern of correlation was observed.  Though, respiratory exchange 
ratio and rate of fat oxidation showed significant negative correlation with 
change in endostatin concentration at low intensity exercise. But these could 
not be reproduced for other exercise intensities. It seems that these are only 
chance findings. However, Gu find a strong positive significant correlation (R2 = 
0.9388) between peak oxygen consumption and % change in endostatin 
consumption (Gu et al., 2004), a finding which is in dispute with this study.  
The data was further analysed through linear regressions, to find any association 
between the change in endostatin concentration and different anthropometric 
and exercise variables, as shown in table 4-6. In order to find a true association 
all the prominent predictors in uni-variate analysis (P <0.1) were put in multiple 
regression models, as shown in table 4-7. The association was checked un-
adjusted as well as adjusted for gender and walking/running. It is not clear, that 
why despite a significant change in endostatin concentration, no correlations or 
associations of statistical importance were found in the analyses.  It might be 
possible that exercise, through other mechanisms like increasing MMP 
concentrations, influence the endostatin concentration (Suhr et al., 2010). 
The last aim of our study was to find, if the basal endostatin concentrations on 
different weeks are relevant and consistent with the results in chapter 3. The 
mean basal endostatin on week 1 and week 3 are nearly the same i.e. 101 ng/ml 
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and 100 ng/ml, which are almost replicating the mean endostatin concentration 
of 105 ng/ml in chapter 3. However, these were different from mean endostatin 
concentration of 87 ng/ml on week 2. The reason for this difference is not clear, 
but one participant with a distinctly high endostatin concentration (treated as 
outlier on week1 and week 3) had less concentration by almost 70 ng/ml on 
week 2. 
In order, to get a better picture, the individual values on all occasions for all 
participants were plotted, as shown in figure 4-25. Individual 3 can be seen 
clearly with high basal endostatin concentration. His health questionnaires and 
anthropometric variables were checked again to find any issue that could 
potentially cause the unexplained high basal endostatin concentration. No 
discrepancy was found in his health questionnaire or anthropometric measures. 
However, when contacted recently, to take part in another study given in 
chapter 6 of this thesis, the participant reported a health problem of serious 
nature for which he is under investigation. It is possible that during participation 
in our study, the participant was in subclinical stage. 
The basal endostatin concentration was also correlated to the anthropometric 
characteristics of all the volunteers, as shown in table 4-9. The results were 
consistent with chapter 3 and no significant correlation was found for any 
variable except age. Age showed strong positive correlation with endostatin 
concentration only at week 1. Final analyses were carried out by correlating the 
average of basal endostatin concentration with the different variables. As 
expected no significant correlations were found. 
Due to the difference in basal endostatin concentration on week 2, the degree of 
changes in endostatin concentrations were correlated with the basal 
concentrations on respective days, to check if basal endostatin concentration is 
affecting the change. The changes in endostatin concentration were found 
independent of basal concentrations, as shown in figure 4-24. 
4.7.4 Limitations of the study 
The data was anonymised by using serial numbers for a participant’s data, but as 
all the experimental procedures including recruitment, laboratory and statistical 
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analyses were carried out by the author, complete blinding of the data was not 
possible. 
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5 Effects of different exercise intensities on 
concentration of VEGF in plasma of healthy 
volunteers 
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Introduction 
It has been established that endostatin inhibits angiogenic signals by VEGF 
(Yamaguchi et al., 1999, Ling et al., 2007, Eriksson et al., 2003, Kim et al., 
2002). It has also been reported that exercise induces an angiostatic phenotype 
by increasing the endostatin concentration and by decreasing the VEGF 
concentration in circulation of humans (Gu et al., 2004), as well as mice (Gu et 
al., 2006). The same study also correlated high endostatin concentration with 
low VEGF concentration in plasma and vice versa. 
The data reported in the previous chapter of this thesis, showed different and 
opposite effects of low and high intensity exercise on plasma endostatin 
concentration. This was unexpected.  It raised the possibility that low and high 
intensities of exercise might also influence the VEGF concentration in plasma 
differently. To investigate this, a small scale study was carried out using the 
remaining volume of plasma samples from the experiments reported before. 
Samples of all participants at low (protocol 1) and high (protocol 3) intensities 
exercise were analysed for VEGF. 
5.1 Rationale of the study 
It was proposed that, as endostatin opposes VEGF by interrupting the angiogenic 
signalling mechanism, the effects of exercise on VEGF concentration in plasma 
may be opposite to that of endostatin. The intensities of exercise used in 
previous section revealed contrasting influence on endostatin concentration. 
Therefore, it was hypothesized that  
i. Exercise at protocol 1 will increase the VEGF concentration in plasma. 
ii. Exercise at protocol 3 will decrease the VEGF concentration in plasma. 
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5.2 Aims of the study 
The aims of this study were: 
i. To determine the effects of two different intensities of the exercise on 
the VEGF concentration in plasma. 
ii. To determine if there is any gender difference in effects of the exercise 
on VEGF. 
iii. To determine if there is any difference between the effects of exercise on 
VEGF for walking and running group. 
iv. To determine whether the changes in VEGF concentration are correlated 
or associated with respective changes in endostatin. 
5.3 Material and methods 
The Research Ethics Committee of the College of Medical, Veterinary and Life 
Science was requested to grant permission to use the archived samples from the 
previous experiment. Permission was approved and it is shown in appendix “A3”. 
5.3.1 Sample analysis 
Unused frozen samples from the previous trial were thawed. The samples were 
analysed for VEGF concentration using QuantikinR ELISA kit for human VEGF, of 
the R&D systems, as discussed in detail in section 2.11.2. All analyses were 
carried out in the lab at West Medical Building, University of Glasgow. The time 
between the samples collection and analyses were roughly 6 months. 
5.3.2 Statistical analyses of the data 
Statistical analyses were carried out using SPSS 17 and Minitab 16 statistical 
software. Normalities for distribution were carried out. 
Descriptive statistics were determined for VEGF as mean ± SD. Independent 
sample T-tests were applied to find out the difference between the means for 
male /female and walking/ running groups.  One-way ANOVA with repeated 
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measures were applied to determine the difference between the means before 
and at different intervals after exercises. 
Box plots were produced to demonstrate the difference between the mean VEGF 
concentrations.  Pearson correlations between different variables and plasma 
VEGF concentration were determined. Simple linear regressions were carried out 
for uni-variate and multivariate analyses, to check the association of change in 
VEGF concentrations with respective change in endostatin concentrations.  
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5.4 Results  
5.4.1 VEGF after exercise at protocol 1 
VEGF concentrations at rest and different intervals after exercise were checked 
for normalities using Kolmogorov- Smirinov and Shapiro-Wilk tests and found 
normally distributed. Individual line graphs in a single panel are shown for all 
participants in figure 5-1. It can be seen that most of the participants exhibited 
an increase in the VEGF concentration after exercise. 
 
 
Figure 5-1; Individual line plots for all the volunteers showing  
VEGF concentrations before (0 Min) and different intervals (10 Min & 60 Min) after exercise at 
protocol 1 are shown. The effect of the exercise is mixed but most of the participants can be seen 
with an immediate increase in plasma VEGF. 
 
The basal VEGF concentration was 75 ± 36 pg/ml. It rise to 89 ± 47 pg/ml at 10 
minutes and was 84 ± 41 pg/ml at 60 minutes interval after the exercise. A one-
way ANOVA was applied to test the difference in means before and after 
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exercise. No significant difference (P = 0.28) was observed. Box plot showing the 
mean and median concentrations of VEGF before and different intervals after 
exercise are shown in figure 5-2. 
 
 
Figure 5-2; VEGF concentration before and different intervals after exercise at protocol 1 
Box plot illustrating the mean, median, quartile range and range of VEGF data for all individuals, 
before and at 10 and 60 minutes after exercise at protocol1. No significant difference between 
means was observed. 
 
5.4.1.1 VEGF concentration in males and females 
The individual values for males and females VEGF concentrations, before and 
after exercise are plotted in figure 5-3.The VEGF concentrations before and 
after exercise in both groups can be seen with no obvious difference, which was 
confirmed statistically. 
Resting mean VEGF concentration for males was 73 ± 36 pg/ml. Mean 
concentrations after exercise were 94 ± 47 pg/ml and 88 ± 41 pg/ml, at 10 and 
60 minutes respectively. 
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The mean VEGF concentration for females at rest was 81 ± 42 pg/ml. The mean 
concentrations ,10 minutes and 60 minutes after exercise were 74 ± 48  pg/ml 
and 88 ± 41 pg/ml respectively.  
 
 
Figure 5-3; Interaction line plots showing the individual values of VEGF for male and female 
participants before and at 10 and 60 minutes after exercise at protocol 1. 
 
One-way ANOVA with Bonferroni post hoc analyses revealed no significant 
difference between the mean VEGF concentration at different time points 
before and after exercise for both groups (P = 0.12 & 0.8 for males and females 
respectively), as shown in the figure 5-4.  
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Figure 5-4; VEGF concentration in males and females before and at different intervals after 
exercise at protocol 1 
Box plot presenting the mean, median, inter quartile range and range of VEGF concentrations for 
male and female participants before and at different intervals (10 & 60 minutes) after exercise at 
protocol 1. No significant differences were found between the means of the groups or time points. 
 
5.4.1.2 VEGF concentrations in running and walking groups  
Interaction line graphs showing the individual values for VEGF are plotted in 
figure 5-5. Mean basal VEGF concentrations were 69 ± 36 pg/ml and 84 ± 38 
pg/ml for running and walking group respectively. No significant differences 
were found in the means between the groups (P = 0.2) or time points (P = 0.8). 
This is shown in figure 5-6. 
In summary; the running group showed a non significant 23% increase in mean 
VEGF concentration at 10 minutes interval after exercise. The difference 
remained only 14% at 60 minutes interval after the exercise. On the other hand 
an increase of 10% and 8% in mean VEGF concentration was observed in the 
walking group.  
 
 
Chapter: 5 
172 
 
 
Figure 5-5; Interaction line plots showing the individual values of VEGF for participants in 
running and walking group before and at 10 and 60 minutes after exercise at protocol 1 
 
 
 
Figure 5-6; VEGF concentrations in running and walking groups before and after exercise at 
protocol 1 
Box plots presenting the mean, median, Inter quartile range and range of VEGF concentration in 
running and walking groups before and at different intervals after exercise at protocol1. No 
significant change was observed at any time point. 
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5.4.2 VEGF after exercise at protocol 3 
The VEGF samples at rest and different intervals after exercise at protocol 3 
were found to be normally distributed.  Interaction line plots for all individuals 
are illustrated in figure 5-7. Intra-personal variations in the basal VEGF 
concentration and initial rise after exercise can be seen, in most of the samples. 
The mean VEGF concentration at rest was 77 ± 33 pg/ml. Mean VEGF 
concentration 10 minutes after exercise was 100 ± 45 pg/ml, while at 60 
minutes, it was 85 ± 38 pg/ml. One-way ANOVA showed that the change after 
exercise was significant (P = 0.017). The mean VEGF concentration increased 
significantly by 30% after10 minutes (P = 0.02). At 60 minutes, the increase 
above baseline was 10% with no statistical significance (P = 0.53). Figure 5-8 
shows box plots for this data. 
 
Figure 5-7; Individual line plots for all volunteers showing the plasma VEGF concentrations 
before (0 min) and at different intervals (10 min & 60 min) after exercise at protocol 3. It can 
be seen that some participants have low basal VEGF concentration compared to others. 
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Figure 5-8; VEGF concentration before and after exercise at protocol 3 
Box plots illustrating the mean, median, quartile range and range of pool data before and at 10 and 
60 minutes after exercise at protocol 3. Significant difference for mean VEGF between baseline 
and 10 minutes samples were observed, as shown by the dotted line with * (P = 0.02). 
 
5.4.2.1 VEGF concentrations in males and females 
The individual values for males and females are plotted in figure 5-9. The basal 
VEGF concentration for males was 77 ± 31 pg/ml. It was 99 ± 39 pg/ml and 91 ± 
38 pg/ml at  10 and 60 minutes respectively. The mean VEGF concentration for 
females at rest was 78 ± 40 pg/ml. The mean VEGF concentrations 10 and 60 
minutes after exercise were 103 ± 64 pg/ml and 71 ± 38 pg/ml respectively. The 
SD of 64pg/ml for female participants is high at 10 minutes interval. It is due to 
less participants with variations in basal concentrations and high increase by 
some of the participants acutely after exercise, as shown in figure 5-9 & 5-10. A 
one-way ANOVA was carried out. No significant differences were observed 
between the means at basal and different intervals after exercise for females. 
However, a significant increase in mean VEGF concentration in males was 
observed at 10 minutes (P = 0.024). 
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Figure 5-9; Interaction line plots showing the individual values of VEGF for male and female 
participants before and at 10 and 60 minutes after exercise at protocol 3. Variations in basal 
VEGF concentration and high increase in some of the participants immediately after 
exercise is visible. 
 
 
Figure 5-10; VEGF concentrations in males and females before and after exercise at 
protocol 3 
Box plots presenting the mean, median, Inter quartile range and range of VEGF concentrations for 
males and females before and different intervals after exercise at protocol 3. Males showed a 
significant increase at 10 minutes interval after exercise (P = 0.024). 
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5.4.2.2 VEGF concentrations in running and walking groups  
Individual values of VEGF concentration at rest and different intervals after 
exercise are shown in figure 5-11. The basal VEGF concentrations were 82 ± 30 
pg/ml and 71 ± 37 pg/ml for running and walking group respectively.  
 
Figure 5-11; Interaction line plots showing the individual values of VEGF for participants in 
running and walking groups before and at 10 and 60 minutes after exercise at protocol 3. 
 
Briefly; the running group showed 17% increased in mean VEGF concentration at 
10 minutes interval after exercise. The difference increased further to 21% at 60 
minutes interval after the exercise. However, the walking group showed a 
significant increase by 52% in mean VEGF concentration at 10 minutes interval (P 
= 0.04). The mean VEGF concentration dropped down significantly, and at 60 
minutes interval it was higher by only 7% from the basal mean (P = 0.66). Figure 
5-12 demonstrate this data graphically. 
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Figure 5-12; VEGF concentrations in males and females before and after exercise at 
protocol 3 
Box plots presenting the mean, median, inter quartile range and range of VEGF concentrations in 
running and walking groups before and at different intervals after exercise at protocol 3. Significant 
increase was observed in the walking group at 10 minutes interval which dropped down 
significantly at 60 minutes samples, as shown by the dotted line with * (P =0.04) . 
 
5.4.3 Correlation of changes in VEGF concentrations with the 
changes in Endostatin concentrations 
Changes in VEGF at different intervals after both intensities of exercise were 
determined and correlated with respective changes in endostatin. Scatter plots 
with linear regression lines were plotted and shown in figure 5-13. No significant 
correlations between the two mediators were observed, as shown by the linear 
regression coefficient (r) and significance of the correlation (P) values in the 
respective panels. 
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Figure 5-13; Pearson correlations for changes in endostatin with changes in VEGF 
Scatter plots illustrates the correlations between the changes in endostatin from baseline (shown 
as delta ES1-60, delta ES2-60, delta ES1-80, delta ES2-80) with respective changes in VEGF from 
baseline (shown as delta VEGF1-60, delta VEGF2-60, delta VEGF1-80, delta VEGF2-80). The 
linear regression (r) and significance of the correlation (P) are given in each figure. No correlation 
of statistical significance was observed at any time point. 
10 Minutes 60 Minutes 
60 Minutes 10 Minutes 
Protocol 1 
Protocol 3 
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5.5 Discussion 
The main aim of the study was to determine the influence of low and high 
intensities of exercise on concentrations of VEGF in plasma and to correlate it 
with endostatin concentrations. 
5.5.1 Findings of the study 
The plasma samples of all participants were analysed using the ELISA technique. 
The plasma VEGF concentrations for all participants were successfully 
determined. On the day of light exercise, mean VEGF concentration for all 
volunteers was 75 ± 36 pg/ml. The mean VEGF concentration in this study is in 
line with the concentrations of 91 pg/ml in healthy volunteers  (Czarkowska-
Paczek et al., 2006). However, huge person to person variability in plasma VEGF 
concentrations exist (Gunga et al., 1999). Concentrations as low as 10 pg/ml 
(Hiscock et al., 2003) to as high as 485 pg/ml  have been reported (Gunga et al., 
1999). It could be assumed that quantifying influence of exercise on VEGF 
concentrations in plasma would be difficult due to inter and intra personal 
variations.  
A non significant increase of 19% and 14% in mean VEGF was observed at 10 and 
60 minutes interval after light intensity exercise, as shown in figure 5-2. 
High intensity exercise increased the mean VEGF concentration of 77 ± 33 pg/ml 
significantly by 30% which dropped down to 10% at 60 minutes interval, as shown 
in figure 5-8. There was not a huge difference between the patterns of influence 
of exercise on plasma VEGF, in male/female or walking/running groups.  
Findings in this study are in line with the published data from many research 
groups. For example, an increase of 80% in the serum VEGF was observed 
immediately, when 14 young healthy individuals performed a high intensity 
exercise to exhaustion on graded cycling. The rise in mean VEGF concentration 
remained 49% at 2 hours interval after the exercise (Czarkowska-Paczek et al., 
2006). Similarly, significant increase in VEGF, after 50% VO2max test immediately 
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and 2 hours after exercise in endurance athletes has been reported. However, 
the same study showed no increase in sedentary group subjected to same 
exercise protocol (Kraus et al., 2004). Another study reported a 2.4 fold increase 
in VEGF concentration in marathon runners, after 67 km marathon at moderate 
altitude of 2300 meters. The immediate significant increase in VEGF 
concentration after the exercise remained persistent until 5 days after exercise 
(Schobersberger et al., 2000). Low activity exercise for a longer duration has 
also been reported with increased expression of VEGF mRNA in skeletal muscles 
(Hiscock et al., 2003). 
However, the results in this study are different from other published studies 
reporting a decrease in VEGF concentrations after exercise. A decrease in 
arterial and venous plasma VEGF concentrations by 12% and 15% have  been 
reported after short bouts of exercise for 10 days (7 sessions of 45 minutes one 
legged knee extensions) (Gustafsson et al., 2002).  Gu and his colleagues also 
reported a significant decrease in VEGF concentration after high intensity 
exercise lasting 4 -10 minutes. The VEGF concentration was on decline 
consistently up to 6 hours after exercise and the maximum 53% decrease was 
observed at 2 hours interval (Gu et al., 2004). A transient decrease in VEGF has 
also been reported in hypobaric hypoxic condition in marathon runners (Gunga et 
al., 1999). In line with these, no influence of the endurance exercise on plasma 
VEGF was seen after 6 months exercise training programme in middle aged 
individuals (Brixius et al., 2008) and in females after 30 minutes exercise at 55-
59% predicted maximum heart rate (Makey et al., 2013). The difference in these 
results were attributed to many factors including the physical fitness of the 
individuals, modes and intensities of exercise, environmental conditions , 
sampling time and techniques. 
Another aim of this study was to correlate the changes in VEGF concentrations 
with respective changes in endostatin after exercise. The hypothesis was that 
exercise will increase the endostatin concentration in plasma as a result of 
enhanced catalytic activity and subsequent release into the circulation. 
Consequently, VEGF concentration will decrease partly due to uptake by the 
skeletal muscles and partly by the inhibition of endostatin. However, the results 
in this study are in contrast to what was anticipated and outlined in section 5.2 
of this study. It can be seen that at high intensity exercise the VEGF 
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concentration in plasma increased along with an increase in endostatin 
concentration. VEGF is produced locally in skeletal muscles as a result of hypoxia 
and mechanical stretch (Hiscock et al., 2003, Czarkowska-Paczek et al., 2006) 
and is subsequently released into the circulation (Rullman et al., 2007). This 
seems plausible as skeletal muscles are the main site of action for VEGF. 
However, as mentioned in section 1.3.7, VEGF is produced by many other cells 
and tissues including platelets and a local release from these cells and tissue can 
possibly cause the increase in VEGF concentration in plasma after exercise.  
No information about the half life of VEGF in plasma could be found. It has been 
shown that VEGF mRNA contains at least 2 destabilising elements due to which 
the VEGF mRNA is intrinsically labile (Levy et al., 1995). However, under hypoxic 
conditions the mRNA becomes much more stable which shows the complicated 
gene regulatory mechanism (Dibbens et al., 1999). It suggests that due to 
exercise the VEGF concentration in skeletal muscle would increase and favours 
its release to circulation which is then taken by other tissue not actively 
involved in VEGF production. 
As shown in figure 5-13, no correlations of statistical significance between the 
endostatin concentration and VEGF were observed. The results reported here 
differ from that published by Gu, who found significant negative correlations 
between VEGF and endostatin concentrations (Gu et al., 2004). 
Though the contrasting differences in VEGF concentrations after exercise in the 
published literature is not completely clear yet they are possibly due to the 
difference in the timings of the samples. Brixius and his colleagues reported no 
influence of long term exercise programme on plasma VEGF, but samples taken 
for final VEGF analyses were a day later than the last exercise session. From the 
results in this study and published literature, we can say safely that exercise 
influence the VEGF concentration transiently and 24 hours sample after exercise 
would be more or less the same as baseline VEGF concentration. 
Moreover, in this study though a transient increases is observed at 10 minutes 
after the exercise for both intensities. However, the initial increase in all cases 
follows a decrease towards the base line at 60 minutes interval. The initial 
increase in VEGF could be attributed to the compensatory mechanisms by the 
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skeletal muscles cells to exercise, by enhancing its production and subsequent 
release into circulation (Rullman et al., 2007). It is possible that the decrease in 
VEGF concentration becomes significant at later time after the exercise, as 
shown by Gu and his colleagues, who observed the decrease consistently up to 6 
hours after exercise.  
5.5.2 Strengths  
Sample size of the study was comparable to most of the published work. The 
study includes both males and females. No dropout in the study was observed 
and the experiment was completed strictly according to the protocol. The 
quality control indicators for ELISA were within the limit and samples with high 
CV values were repeated. 
5.5.3 Limitations 
Limitations of the study include uneven distribution of males and females. More 
female participants might have brought more information and would have given 
more balance to the study. Participants were asked to abstain from the physical 
activity but they may not have followed this advice.  After passing the cannula, 
baseline samples were taken immediately and the acute action of endothelial 
injury with needle, on the release of angiogenic mediators were not considered.  
Moreover, samples which were analysed for VEGF were in the freezer for a 
longer period of time (around 6 months). It may have an effect on the plasma 
VEGF concentration, as during ELISA analyses some of the samples with high 
values (beyond the reading capability of the machines) were encountered. 
Secondary ELISA analyses of these samples produced completely different results 
compared to primary analyses. Results of these secondary analyses were taken 
as actual values used in the results section of the chapter. It is unknown why the 
primary analyses yield high concentrations of VEGF in plasma.
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6 The effects of high intensity exercise to 
exhaustion on the concentrations of endostatin 
and VEGF in plasma  
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6.1 Introduction 
It is clear from the study in chapter 4, that short periods of moderate to high 
intensity exercise significantly increase the concentration of endostatin in 
plasma. The changes are different at different intensities of exercise. Moreover, 
change in VEGF concentration is not correlated with change in endostatin 
concentration. However, during those experiments samples were taken up to 
one hour after exercise during which endostatin and VEGF concentrations did not 
return to baseline. The possibility of later changes in VEGF or endostatin 
concentration could not be ruled out completely, as significant changes in 
endostatin and VEGF concentrations up to 6 hours after exercise has been 
reported (Gu et al., 2004). 
Moreover, in the previous 2 studies it has been established that basal 
concentration of endostatin could not be associated with any anthropometric or 
physical characteristics of the individuals. It was thought that factors important 
in atherosclerosis and endothelial functions should be explored to check for any 
possible association with endostatin. These factors include; body fat 
composition, fasting lipid profile, fasting blood glucose concentration and insulin 
sensitivity.  
Endostatin is a part of collagen VXIII in the basement membrane. It is in close 
proximity to the endothelium and other vascular structures. It is known that 
internal milieu strongly influences the endothelium and other vascular structure 
and their functions. For example, an increase in body fat is associated with 
activation of the renin angiotensin aldosterone system (RAAS), and subsequent 
increases in angiotensin II affects the vascular stiffness (Engeli et al., 2000).  
Moreover, increase in body fat increases the risk of type 2 diabetes (Chan et al., 
1994) which in turn increases the risk of atherosclerosis (Folsom et al., 1999).  
Similarly, insulin resistance is central to many metabolic disorders including 
diabetes and obesity. Insulin resistance is also associated with endothelial 
dysfunction and impaired vascular relaxation which in turn contributes to 
atherosclerosis and other cardiovascular events (Kim et al., 2006).  
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In addition, deranged lipid profile and hyperglycaemias are important 
determinants of endothelial dysfunction derived health problems including 
atherosclerosis and peripheral vascular diseases (Deaton et al., 2011). Thus, the 
possibility of an association of endostatin with these metabolic factors could not 
be ruled out.  
Therefore, this final experiment was designed to look for the influence of high 
intensity exercise on endostatin and VEGF concentration in plasma for a longer 
duration (24 hours) after exercise and to investigate their association with 
metabolic factors discussed in the preceding paragraphs.  
6.2 Aims of the study 
The aims of the study were as follow; 
i. To determine the correlations of basal endostatin concentration and the 
change in it after exercise, with anthropometric and metabolic factors of 
young healthy volunteers. 
ii. To determine the effect of a single bout of high intensity exercise on the 
plasma endostatin concentration up to 24 hours. 
iii. To determine the effect of single bout of high intensity exercise on the 
plasma VEGF concentration up to 24 hours. 
iv. To determine the correlations between endostatin and VEGF 
concentrations in plasma and between their respective changes at pre and 
post exercise intervals. 
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6.3 Material and methods 
The Research Ethics Committee of the College of Medical, Veterinary and Life 
Sciences granted the approval for this study. The permission is attached in 
appendix “A4”. All the experiments and subsequent analyses were carried out in 
the laboratories of the School of Life Sciences, University of Glasgow.  
6.3.1 Recruitment of the participants 
The volunteers were recruited through advertisements placed around the 
University campus. Personal contacts with participants of the previous study 
were also made.  The inclusion criteria for participants were healthy 
male/female of 18 to 45 years age, non smokers, not had known heart problems, 
not on medications for any acute/ chronic illnesses and non pregnant or 
lactating. 
After indicating their interest to participate, the volunteers were contacted at a 
convenient time and taken through two pre- participation health screening 
questionnaires, to assess their physical fitness and ability to perform maximal 
exercise to volitional exhaustion. The first questionnaire was PAR-Q and the 
second was adapted form of the ACSM Health Fitness Facility Pre- Participation 
Health Screening Questionnaire (ACSM, 2013), as shown in appendix “D2” & 
“D3”. Participants meeting the inclusion criteria were recruited to the study and 
dates for attending the laboratory were identified.  
8 healthy male volunteers were recruited to the study. The purpose and nature 
of the experiment and potential risks during it, were completely explained. They 
were told about their right to stop the experiment at any time. Their 
anthropometric data are shown in the table 6-1 below. 
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S. no 
Age 
(Yrs) 
Ht. 
(m) 
Wt.  
(kg) 
BMI 
(kg/m2) 
SBP 
(mmHg) 
DBP 
(mmHg) 
WC 
(cm) 
HC 
(cm) 
W:H 
ratio 
1 34 1.68 75.1 26.6 112 76 79 93 0.85 
2 25 1.85 69.9 20.4 116 76 80 99 0.81 
3 36 1.61 61.3 23.6 123 76 75 79 0.95 
4 27 1.82 72.2 21.8 123 82 88 99 0.89 
5 30 1.91 70.1 19.2 118 81 74 95 0.78 
6 34 1.71 67.2 22.9 130 80 83 99 0.84 
7 22 1.75 69.7 22.8 118 62 81 96 0.84 
8 40 1.80 88.9 27.4 126 76 85 94 0.90 
Mea
n ± 
SD 
31  
± 6.1 
1.77 
 ± 0.1 
71.8  
± 7.9 
23.1 
± 2.8 
121  
± 6 
76  
± 6 
81  
± 5 
94  
± 7 
0.86 
±0.05 
Table 6-1; Anthropometric and physical characteristics of the participants 
Different characteristics of all participants with mean ± SD are illustrated. Ht; Height in m, Wt; 
Weight in kg, BMI; Body mass index, SBP; Systolic blood pressure, DBP; Diastolic blood pressure, 
WC; Waist circumference, HC; Hip circumference, W:H ratio; Waist to hip circumference ratio 
6.3.2 Study protocol 
All the volunteers attend the lab on 2 consecutive days. The total duration of 
their stay, was 6 to 7 hours on the first day and about 30 minutes on the second 
day. The activities on each day are discussed in the subsequent sections and 
schematically presented in figure 6-2. 
6.3.2.1 Day 1 
The participants were requested to visit the lab fasted. After signing consent 
forms their height, weight, blood pressure, heart rate, waist and hip 
circumference were measured, as described in chapter 2 sections 2.5. Their 
body fat percentages were estimated using air displacement plethysmography in 
a Bod Pod, as discussed in section 2.5.6.  
The fasting blood glucose concentrations of the participants were checked using 
glucometer (Accu-Chek Aviva, Manheim, Germany). A cannula was put in an ante 
cubital vein and flushed with saline, as discussed in chapter 2 section 2.10. The 
participants then rested for 20 minutes in a quiet room. This was to 
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counterbalance the effects of needle injury and physical effort on baseline 
endostatin and VEGF. After rest 3 blood samples of 5 ml were taken, one each 
for endostatin, VEGF and fasting blood lipid profile and insulin concentration. 
The participants were then given isotonic drinking solution to restore some 
energy. Hydration status of the participants was not checked at this stage which 
might have an effect on the distribution of endostatin and VEGF concentration in 
plasma prior to and after exercise. This has been discussed in the limitations 
(section 6.5.6) of this chapter. 
The participants performed maximal exercise test on the treadmill using the 
modified Taylor protocol (Taylor et al., 1955). During the test, maximal oxygen 
uptake of the participant was measured with breath by breath analyser (Medical 
Graphics Corporation, Borngasse, Germany), as discussed in chapter 2 section 
2.8. The test was completed by all the volunteers and they were encouraged to 
make a maximum effort. The effort was considered maximum, if most of the 
following criteria were observed, as per ACSM guidelines (ACSM, 2013). 
1. Achieved heart rate during the test was in the range of age predicted 
maximum heart rate ± 10 bpm. 
2. A respiratory exchange ratio of more than 1.10. 
3. A post exercise lactate concentrations of 8 mmol. 
4. A plateau in oxygen consumption (VO2) or failure in oxygen uptake by 
150ml.min-1, beside increase in work rate, as shown in the figure 6-1 from 
the data of one participant. 
5. A rating of > 17 on Borg scale of perceived exertion. 
At the end of the test all the participants walked slowly for 5 minutes till the 
heart rate dropped to 120 bpm. Blood was taken by a finger prick at 0, 3 and 5 
minutes at the end of running to measure the lactate concentrations.  
The participants then relaxed in a quiet room and more blood samples were 
taken at 10, 30, 60, 120 and 240 minutes after the exercise. During this time 
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they watched movies or videos as per their choice, while sitting on a chair. They 
were given biscuits and isotonic drinks during this time. After the final blood 
sample, cannula was removed and a full meal was served. They were asked to 
attend the lab on next day for a 24 hours sample. 
6.3.2.2 Day 2 
On day 2 the participants attended the lab for two blood samples, one each for 
VEGF and endostatin. 
 
 
 
Figure 6-1; Breath by breath oxygen consumption and carbon dioxide production 
Shows oxygen consumption (VO2) and carbon dioxide production (VCO2) from one of the 
participants during exercise. The initial 3 minutes are the resting period and the maximum effort 
was noticed at 21 minutes. The dotted line on the horizontal axis shows the maximum effort period 
during which the plateau in oxygen consumption can be seen.  
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Figure 6-2; Schematic presentation of the study protocol 
The protocol of the study is presented schematically. Physical characteristics include height, 
weight, waist & hip circumference, blood pressure and pulse rate measurements. Volunteers 
performed a running exercise according to the modified Taylor protocol on treadmill till voluntary 
exhaustion. Blood samples were collected after exercise at different intervals on the same day and 
24 hours later on next day. 
6.3.3 Collection of blood samples 
The blood was collected by putting 20G cannula (Versatus-W, Terumo®, 
Belgium) in an ante-cubital vein. The cannula was attached to 3 way valve (BD 
ConnectaTM, Sweden) and flushed with normal saline to keep it clear. Blood 
samples were collected into 6ml EDTA tubes and put on ice. They were spun in 
centrifuge within 15 minutes of the collection. The blood was centrifuged at 
1000 RPM for 15 minutes for endostatin and VEGF and at 3000 RPM for 15 
minutes for lipid profiles and insulin. Plasma was separated into 3 aliquots each 
for endostatin, VEGF and lipid profile into 1ml Eppendorf tube using disposable 
plastic pipettes (Wilford Ind. Nottingham, UK). The plasma samples were stored 
at -80◦C in an ultra low temperature freezer (New Brunswick Scientific, U725-86, 
US) for less than 1 month before analyses. 
 
Chapter: 6 
191 
 
6.3.4 Samples analyses 
After thawing, the frozen samples were analysed for endostatin and VEGF 
concentrations using QuantikinR ELISA kit of the R&D systems. Insulin was 
measured using different types of Elisa kits (Mercodia, Uppsala Sweden). The 
procedures for ELISA analyses are given in chapter 2, section 2.11.  
6.3.5 Lipid profiles 
Plasma samples for lipid profiles were analysed in another laboratory of the 
University of Glasgow, as described in chapter 2 sections 2.1 and 2.13.  Plasma 
glucose, total and high density lipoprotein, triglyceride and non- esterified fatty 
acid (NEFA) were determined using commercially available enzymatic kits. 
Friedewald equation was used for the determination of low density lipoprotein 
(LDL) as follows (Friedewald et al., 1972); 
LDL mmol.l-1 = (Total cholesterol – HDL cholesterol) – (TG /2.2) 
6.3.6 Insulin resistance 
Insulin resistance was determined using the QUICKI equation (Perseghin et al., 
2001) as follow; 
QUICKI (I.R) = 1/ (log G0 + logI0) 
Where G0 is the fasting blood glucose concentration in mg/dl, I0 is the fasting 
insulin concentration in Mu/l. 
6.3.7 Statistical analyses 
SPSS version 17 and Minitab version 16 were used for the statistical analyses. The 
normalities of all variables were determined and where necessary log 
transformations were carried out. Summary statistics were carried out for data 
and presented as mean ± SD. 
ANOVA with repeated measures was used for checking the difference between 
the mean in pre and post exercise blood samples.  Correlations between 
Chapter: 6 
192 
 
endostatin, VEGF and other variables were determined using Pearson 
correlation. Box plots were produced to graphically present the data, where 
necessary. 
6.4 Results 
6.4.1 Distributions of the different anthropometric variables and 
lipid profiles  
The anthropometric characteristics, metabolic parameters, exercise components 
and angiogenic mediators at all time points were checked for normality using 
Kolmogorov- Smirinov and Shapiro-Wilk tests.  All but 3 variables showed a 
normal distribution which were subjected to log transformation. These include 
NEFA, IR and the maximum gradients achieved during the test. As the sample 
size is small, the non normal distributions of these factors are less likely to 
affect the overall results. 
Data for the body fat composition and lipid profile of all individuals with their 
mean ± SD is tabulated in table 6-2 and 6-3 respectively. 
S. no Weight Body Fat  Body Fat% Lean weight Body density 
1 75.1 16.8 22.4 58.3 1.04 
2 69.9 5.8 8.2 64.1 1.09 
3 61.3 11.1 18.2 50.1 1.05 
4 72.2 12.4 17.0 60.5 1.06 
5 70.1 5.9 8.4 64.2 1.08 
6 67.2 8.9 19.8 58.2 1.07 
7 69.7 6.5 9.3 63.2 1.07 
8 88.9 21.5 24.1 67.4 1.04 
Mean ± SD 71.8 ± 7.9 11.1 ± 5.6 15.9 ± 6.4 60.8 ± 5.3 1.06 ± 0.01 
Table 6-2; Body composition of participants 
The body fat compositions after Bod Pod measurements are shown for all participants with their 
mean and SD. Weight, body fat and lean weight are expressed in kg. 
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S. no FBG TG Chol HDL SDLDL NEFA Insulin IR 
         
1 5.0 1.06 5.61 1.12 11.30 0.79 8.97  0.34 
2 4.7 0.59 3.33 1.14 17.00 0.65 4.24  0.39 
3 4.5 2.04 6.40 0.65 22.50 0.77 12.50  0.33 
4 4.9 1.13 5.35 1.29 25.00 0.72 6.98  0.36 
5 4.8 0.59 3.31 1.18 16.70 0.69 4.34  0.39 
6 5.1 1.54 5.72 0.78 32.50 0.81 9.71  0.34 
7 4.9 0.60 3.12 0.90 22.90 1.43 4.65  0.39 
8 5.2 1.07 5.24 1.08 23.30 0.74 9.76  0.34 
Mean ± 
SD 
4.9 ± 
0.2 
1.08 ± 
0.5 
4.76 ± 
1.3 
1.02 ± 
0.2 
21.4 ± 
6.4 
0.82 ± 
0.2 
7.64 ± 
3.07 
0.36 ± 
0.02 
Table 6-3; Fasting blood glucose, lipid profiles and insulin of participants 
Fasting lipid profile and insulin for all individuals with their mean and SD are tabulated. FBG; 
Fasting blood glucose (mmol), TG; Triglycerides (mmol), Chol; Cholesterol (mmol), HDL; High 
density lipoprotein (mmol), SDLDL; Small dense low density lipoprotein (mg/dl), NEFA; Non-
esterified fatty acids, IR; Insulin resistance. 
 
6.4.2 Response to exercise 
All the volunteers performed exercise without any complications. The mean 
duration for the test was 17.04 ± 2.6 minutes (ranging 12 to 19 minutes) during 
which the participants covered a mean distance of 2.1 ± 0.34 Km. All the 
participants run at fixed speed of 8 km/ hr with a mean maximum gradient of 11 
± 2%. The mean maximum heart rate achieved during the test was 191 ± 10 bpm 
which increased by 167% from the mean basal heart rate of 72 bpm (p < 0.001). 
A mean increase of 38 ml/kg/min in oxygen consumption (VO2) was observed 
with the mean maximum oxygen consumption (VO2max) of 42 ml/kg/min achieved 
during the test (P < 0.001). Mean lactate concentration post exercise was 7.4 
mmol (ranging 5.4 to 9.8 mmol). The individual values and mean ± standard 
deviations of the parameters of exercise are given in table below 6-4. 
In summary; all of the participants gave a maximum effort which was confirmed 
by achieving most of parameters indicated by ACSM guidelines. It can be seen, in 
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table that most participants were aerobically fit and delivered their maximal 
effort. 
S. no BHR 
Max 
HR 
Duration RR distance 
Max 
Grad 
BVO2 VO2Max RER Lactate 
1 68 180 12.04 62 1.45 7.5 3.3 33 1.20 9.8 
2 71 194 19.25 48 2.40 12.5 4.3 45 1.44 7.9 
3 68 184 18.04 39 2.20 10.0 4.8 44 1.29 7 
4 70 210 18.16 49 2.25 12.5 4.3 39 1.59 8.8 
5 82 184 19.10 35 2.38 12.5 3.9 45 1.17 5.4 
6 82 194 15.07 48 1.84 10.0 4.8 39 1.23 6.9 
7 76 196 19.28 47 2.43 12.5 5.4 47 1.34 6.9 
8 63 184 15.44 41 1.93 10.0 4.0 44 1.30 6.5 
Mean 
± SD 
72 
± 9 
191 
± 10 
17.04 
± 2.6 
46 
± 8 
2.1 
± 0.34 
11 
± 1.9 
4.3 
± 0.6 
42 
± 5 
1.3 
± 0.6 
7.4 
± 1.39 
Table 6-4; Different parameters of exercise at base levels and during exercise  
The individual values for components of exercise and mean ± standard deviation are shown. These 
indicate a maximal effort by all participants according to ACSM guidelines. BHR; Basal heart rate 
(beats per minute), Max HR;  Maximum heart rate, Max Grad; Maximum gradient (%), BVO2; 
Resting oxygen consumption (ml/kg/min), VO2Max; Maximum oxygen consumption (ml/kg/min), 
RER; Respiratory exchange ratio, RR; Respiratory rate (breaths per minutes). lactate concentration 
in mmol/l. 
 
6.4.3 Baseline endostatin concentration  
The individual line plots for endostatin concentration before and different 
intervals after exercise are plotted in figure 6-3. The entire group showed rapid 
increase in endostatin concentration after exercise. Mean endostatin 
concentration at rest for all participants was determined as 104 ± 6 ng/ml. The 
mean endostatin concentration at rest was consistent with the results in chapter 
3 and chapter 4.  
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Figure 6-3; line plots showing the endostatin concentrations for all participants before and 
after maximum intensity exercise  
Individual line plots of endostatin concentration for all participants in the study are shown. Time 
points on the horizontal axis shows the time points for blood sampling (0 = before exercise, 1= 10 
minutes, 2 = 30 minutes, 3 = 1 hour, 4 = 2 hours, 5 = 4 hours and 6 = 24 hours after exercise). The 
rapid increase in endostatin concentration after exercise for all individuals can be seen.  
 
6.4.3.1 Effect of exercise on mean endostatin concentration  
Mean concentrations of endostatin in plasma before and after exercise are 
shown in figure 6-4. It is clear, that single bout of short period of high intensity 
exercise increased the mean endostatin concentration as confirmed by ANOVA 
with Bonferroni corrections (P < 0.001). The mean values were: 126 ± 16, 139 ± 
15, 132 ± 12, 129 ± 12, 120± 23 and 107 ± 15 ng/ml respectively, at 10 minutes, 
30 minutes, 1 hour, 2 hours, 4 hours and 24 hours after the exercise.  These 
changes corresponds to increases of 21% (P = 0.003), 34% (P <0.001), 27% (P < 
0.001), 24% (P = 0.001), 15% (P = 0.07), and 3% (P = 0.883) compared to resting 
endostatin concentration. The changes at points 1-4 i.e. up to 2 hours post 
exercise were statistically significant. The highest increase was observed at 30 
minutes interval after the exercise.  
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Figure 6-4; Endostatin concentration before and at different intervals after maximal exercise 
Endostatin concentration before and at different intervals after exercise (0 = before exercise, 1= 10 
minutes, 2 = 30 minutes, 3 = 1 hour, 4 = 2 hours, 5 = 4 hours and 6 = 24 hours after exercise).  
Significant changes in mean endostatin concentrations were observed after exercise at 10 minutes, 
30 minutes, 1 hour and 2 hour intervals. (* = P value <0.05 between basal and time point, ** = P 
value <0.001 between basal and time point). Clear circle represent outlier. 
 
6.4.3.2 Correlations of endostatin concentration and the changes in 
endostatin concentration at different intervals with anthropometric, 
metabolic and exercise parameters  
Extensive Pearson correlation tests were done to investigate any link between 
endostatin concentration and the changes in it at different intervals after 
exercise with different physical and metabolic factors in detail. No conclusive or 
significant correlations of importance were observed. They are presented in 
appendix “H” in tabular forms. 
6.4.4 Baseline VEGF concentration 
Line plots showing the plasma VEGF concentration for all volunteers are 
illustrated in figure 6-5. No specific pattern of increase or decrease in VEGF 
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concentration after exercise was observed.  Three out of eight participants 
exhibited a decrease immediately after exercise. One of the volunteers barely 
showed any effect of exercise on VEGF at different time points, while 4 showed 
an initial increase followed by a decrease at some points. The mean VEGF 
concentration determined at rest was 91 ± 35 pg/ml (ranging 59 -168 
pg/ml).This is slightly higher than the VEGF concentration of 75 pg/ml in 
chapter 4. 
 
Figure 6-5; Line plots with VEGF concentration before and at different intervals after 
maximum intensity exercise for all participants  
VEGF concentrations for all participants are shown in the individual line plots. Time points on the 
horizontal axis shows the time points for blood sampling (0 = before exercise, 1= 10 minutes, 2 = 
30 minutes, 3 = 1 hour, 4 = 2 hours, 5 = 4 hours and 6 = 24 hours after exercise). Panel 8 can be 
clearly seen with no specific changes or pattern. 
 
6.4.4.1 Effect of exercise on mean VEGF concentration  
The effect of exercise on VEGF concentration was also investigated.  The mean 
VEGF concentrations were: 102 ± 46, 115 ± 35, 109 ± 40, 113 ± 38, 108 ± 53 and 
99 ± 23 pg/ml at 10 minutes, 30 minutes, 1hour, 2 hours, 4 hours and 24 hours 
respectively, after the exercise.  These changes are equal to 12% (P = 0.43), 26% 
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(P = 0.04), 19% (P = 0.32), 24% (P = 0.067), 19% (P = 0.077) and 9% (P = 0.36), 
respectively. The increase in VEGF concentration was only significant at 30 
minutes interval (P = 0.04). The VEGF concentration remained higher than basal 
at all time points up to 24 hours after exercise, as shown in figure 6-6. 
 
Figure 6-6; VEGF concentrations before and at different intervals after maximal exercise test 
Figure shows the VEGF concentrations before and at different time points after exercise (0 = 
before exercise, 1= 10 minutes, 2 = 30 minutes, 3 = 1 hour, 4 = 2 hours, 5 = 4 hours and 6 = 24 
hours after exercise).  The significant change in VEGF concentration was only observed at 30 
minutes after exercise (P = 0.04). Clear circle shows outlier in basal VEGF. 
 
6.4.4.2 Correlations of VEGF concentration and the change in VEGF at 
different intervals with anthropometric, metabolic and exercise 
factors  
Similar to endostatin, correlations for VEGF were also determined. No solid 
conclusion can be drawn from it and therefore, they are included in the 
appendix “H” in tabulated form. 
6.4.5 Correlations of changes in endostatin concentration with 
changes in VEGF 
Finally, the changes in endostatin concentrations at different time intervals 
after exercise with the respective changes in VEGF were carried out. No 
significant correlations of statistical importance were observed, as shown by the 
Chapter: 6 
199 
 
Pearson correlation coefficient (r) and significance of the correlation (P) values 
in table 6-5. 
 
  ∆VEGF10 ∆VEGF 30 ∆VEGF 60 ∆VEGF 120 ∆VEGF 240 ∆VEGF 24hr 
∆ES10 r -0.391 -0.136 -0.321 -0.588 0.004 -0.071 
 P 0.339 0.747 0.438 0.125 0.993 0.867 
∆ES30 r -0.208 0.295 0.070 -0.221 -0.005 0.304 
 P 0.620 0.478 0.869 0.599 0.990 0.463 
∆ES60 r -0.223 0.005 -0.015 -0.142 -0.178 0.108 
 P 0.596 0.990 0.973 0.738 0.673 0.799 
∆ES120 r 0.021 0.155 0.393 -0.065 -0.834 0.637 
 P 0.961 0.713 0.336 0.878 0.010 0.090 
∆ES240 r 0.110 -0.377 -0.219 -0.404 -0.583 0.017 
 P 0.796 0.357 0.602 0.321 0.129 0.968 
∆ES24 r -0.463 -0.761 -0.585 -0.790 -0.590 -0.252 
 P 0.248 0.028 0.128 0.137 0.123 0.547 
Table 6-5; Correlations of the changes in Endostatin with changes in VEGF 
Pearson correlation shows the association between changes in VEGF (∆VEGF) with changes in 
endostatin concentration (∆ES) at respective times and different time intervals. As shown by the P 
values, no correlations of statistical significance were determined. r; Coefficient value of Pearson 
correlation  
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6.5 Discussion 
This study was aimed to determine the effect of maximal intensity exercise to 
volitional exhaustion (VO2max) on plasma concentration of endostatin and VEGF in 
young healthy participants. Additional aims include the correlation of basal 
endostatin and VEGF with anthropometric, physical and metabolic 
characteristics of the individuals. Moreover, the effects of changes in endostatin 
concentration on the respective changes in VEGF were also investigated. This 
experiment followed the same approach, as in chapter 4 with some changes. It 
was hoped, that this study would provide more comprehensive results, in terms 
of bigger changes in concentration of endostatin and VEGF for longer durations 
after maximal exercise test and its association with metabolic factors. The 
following changes were made to the protocol; 
i. Exercise in this study was maximal to volitional exhaustion. 
ii. Endostatin and VEGF were measured simultaneously.  
iii. Blood samples were taken more frequently and for a longer duration. 
iv. Metabolic and lipid profiles were taken into consideration to check for the 
possible correlation with endostatin and VEGF. 
6.5.1 Major findings of the study 
This study provided more conclusive results in terms of effect of exercise on 
endostatin concentration. The change in endostatin concentration was clear and 
more pronounced than studies in chapter 4. Moreover, this study also verified 
the results in the previous studies i.e. the basal endostatin concentration 
remained consistent and higher intensity of exercise significantly increased the 
endostatin concentration for up to 2 hours. Additionally, no correlations of 
statistical significance between anthropometric characteristics including body 
fat percentages and metabolic parameters including fasting lipid profile, fasting 
blood glucose and insulin with endostatin and VEGF were observed. 
Exercise also influenced VEGF concentration transiently and only at 30 minutes 
interval increase in VEGF was statistically significant. The participants showed 
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the increase in VEGF concentration at different time points after exercise. Due 
to this variation in person to person response after exercise, quantification of 
VEGF is difficult. However, it is worth noting that even those participants who 
showed an immediate decrease in VEGF after exercise, later on exhibited a 
concentration higher than basal. 
6.5.2 Study design  
All the experiments were concluded safely. The risks associated with maximal 
exercise were managed successfully by the protocol adopted. Standardised 
protocols were followed to deliver the maximum effort of the participants.  The 
sample size calculated for this study was 16. Based on the results in previous 
chapter, it was anticipated that high intensity exercise will change the 
endostatin concentration by 20%. However, the experiment was stopped after 
recruiting 8 participants; partly due to financial and partly due to time 
constraints.  From the results obtained, the influence of exercise on endostatin 
is very clear and more than anticipated (38%). It is unlikely, that including more 
participants would drastically change the results for endostatin. 
However, the influence of exercise on VEGF was not clear and participants 
exhibited a variable pattern of response to exercise, as discussed earlier. The 
VEGF concentration increased for all participants but at different time points. It 
would require a larger study with more participants. Completing this project is 
one of the potential future work areas. 
6.5.3 Discussion of the results and comparisons with the 
published literature 
6.5.3.1 Endostatin and exercise 
High intensity exercise showed significant increase in endostatin. Although the 
endostatin concentration after exercise in plasma was higher than basal, up to 4 
hours but significantly high concentrations were observed up to 2 hours. The 
results in this study confirm the previous results in chapter 4, when the 
volunteers exercised at 70% and 80% predicted maximum heart rate. Moreover, 
these results are also consistent with previous published studies carried out by 
many researchers (Gu et al., 2004, Suhr et al., 2007, Sponder et al., 2011, 
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Sponder et al., 2013, Bruserud et al., 2005). It seems that short bouts of 
relatively high intensity exercise increase the endostatin concentration 
transiently for duration up to 2 hours.  
The extent of change in endostatin concentration was, however, different and 
can be attributed to the difference in mode, intensity and physical 
characteristics of the participants. Physical fitness seems to affect the degree of 
increase in endostatin concentration after exercising (Sponder et al., 2013). Gu 
and his colleagues have reported a significant increase up to 6 hours after 
exercise (Gu et al., 2004). It could be implied that many other reasons, such as 
easy fatigability, presences of co-morbid conditions and age of the participants 
may contribute to the extent of difference as well. This could be true as one 
study reported increase in endostatin concentration only in healthy and young 
individuals and not in old age individuals (Bruserud et al., 2005). However, our 
results can be compared with study done by Suhr, who also found significant 
increase lasting for two hours after exercise (Suhr et al., 2007). 
The effects of long term physical activity on the basal endostatin concentration 
are contradictory. Sponder and his colleagues reported significantly high basal 
endostatin concentration in athlete males and females compared to their 
controls. It was assumed, that high basal endostatin concentration is due to the 
regular physical training of the athletes (Sponder et al., 2013). In contrast, 
decrease in basal endostatin concentration after 6 months of regular physical 
training in 50 – 60 years old individuals (Brixius et al., 2008), as well as in long 
and short track elite runners  have been reported (Suhr et al., 2010). The 
mechanism behind these differences is not clear and needs further studies. 
It can be seen in section 6.4.3.1 that the maximum increase of 34% was observed 
at 30 minutes interval. This finding is interesting because in the studies outlined 
in chapter 4, the concentration of endostatin was determined at 10 and 60 
minutes intervals after exercise. It was not intentional to take only at 10 and 60 
minutes intervals. Adding more time points in this study shows the development 
of the research hypothesis. It is possible that the interval at which exercise had 
the more pronounced effect might have been missed. However, it is suggested 
for future studies that multiple blood samples at different intervals especially at 
30 minutes should be taken.  
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6.5.3.2 Correlation of endostatin concentration with metabolic profile and 
anthropometric characteristics 
The other aim of the study was to correlate the basal endostatin concentration 
with anthropometric and metabolic parameters of the participants. Good 
metabolic profile indicates healthy endothelial status and well being of the 
individual. It was hypothesised, that they might affect basal endostatin 
concentration, as well as the change in it after exercise. No correlations of 
significant importance were observed either with the basal endostatin 
concentration or the change in it at any time point after the exercise, as shown 
in tabular form in appendix “H”. To the author’s knowledge this is a complete 
novel finding. It is interesting due to the fact that deranged lipid profile, glucose 
intolerance or insulin insufficiency play important roles in early endothelial 
events leading to atherosclerosis. Despite endostatin being present in blood and 
basement membrane, it did not show any interactions with these parameters. 
However, sample size is small to appreciate any such associations and study with 
a bigger sample size will be required to draw solid conclusion. 
Finally, no correlation of statistical significance was observed between 
endostatin concentration and anthropometric measurements, which are in line 
with previous results in chapter 3 and 4. 
6.5.3.3 Correlations of endostatin concentrations with exercise parameters 
The exercise intensity in this series of experiments was higher than used 
previously. The duration of near maximal exercise was shorter and the use of 
breath by breath measurement allowed the gas exchange to be monitored in real 
time. Different features of exercise showed no statistically significant 
correlations with the changes in endostatin concentrations, at different time 
points after the exercise. These  results are different from Gu who reported a 
strong linear correlation between change in exercise and peak oxygen 
consumption (Gu et al., 2004). In author’s opinion, the results in our study are 
more reliable because the values for the peak oxygen consumption, in Gu’s 
study, were estimated by calculation rather than measured. Moreover, Gu’s 
findings could not be confirmed in later studies (Sponder et al., 2013, Sponder et 
al., 2014). It was observed consistently that moderate to high intensity exercise 
increase the endostatin concentration without direct correlations with any 
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exercise feature. From this it can be assumed, that exercise does change the 
endostatin concentration by altering different mechanisms indirectly including 
increasing expression of enzymes involved in endostatin release (Suhr et al., 
2010). 
6.5.4 VEGF and exercise 
Mean basal VEGF concentration of 91 + 34 pg/ml in this study group is higher 
than that seen chapter 4, which was 75 + 36 pg/ml. However this difference is 
not significant. It is clear from the broad ranges, shown in figure 6-6, that there 
is substantial variation in basal VEGF concentrations. A wide range of basal 
concentrations, between 98 to 485 pg/ml, has been reported and this is 
attributed to the differences in genetic regulation and makeup of individuals 
(Gunga et al., 1999). Such variations make it difficult to quantify the increase in 
VEGF after exercise.   
The mean VEGF concentration increased initially after exercise until 30 minutes. 
After this time point, a pattern of increase and decrease can be observed, as 
shown in figure 6-6. It can also be seen that mean VEGF concentration was never 
found to be lower than basal during this experiment. These results confirm our 
earlier results in chapter 4, of increase in mean VEGF concentration after 
exercise with no specific pattern.  
The literature about exercise as a regulator of VEGF is conflicting and limited. 
On one hand, increases in VEGF concentrations after exercise have been 
reported (Czarkowska-Paczek et al., 2006, Hiscock et al., 2003, Kraus et al., 
2004, Schobersberger et al., 2000, Rullman et al., 2007). The extent of increase 
in mean VEGF after exercise reported, varies from as low as 30% (Kraus et al., 
2004) to as high as 240% (Schobersberger et al., 2000) and as acutely as 30 
minutes post exercise to as long as 5 days post exercise. These changes may 
reflect different exercise modalities. 
On the other hand, a decrease in mean VEGF concentration after acute exercise 
has also been reported by (Gustafsson et al., 2002, Gu et al., 2004). Again the 
modes of exercise in the above studies were completely different.  
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In Gustafsson study, the participants performed one knee extension for 7 
sessions of 45 minutes over a period of 10 days. Timings of the blood sample 
collection are crucial, as the first sample was taken before 1st exercise session 
and the last sample was taken 24 hours after the 7th exercise session. In our 
study it was observed that exercise affect VEGF concentration transiently. The 
VEGF concentration tends to drop back towards normal at about 1 hour after 
exercise. So it is possible, that VEGF concentration 24 hours after exercise may 
be more or less the same as basal VEGF concentration.   
Similar results to Gustafsson have also been reported in another study, where 
long term endurance exercise programme for 6 months, showed no alteration in 
VEGF concentration. Interestingly, post intervention plasma samples were taken, 
on next day after the last exercise session (Brixius et al., 2008). 
However, the study done by Gu, has shown the decrease in mean VEGF 
concentration significantly up to 6 hours, a finding which could not be confirmed 
by published literature or this study. 
There is convincing evidence in the literature, that acute exercise bouts 
increase VEGF concentration in skeletal muscles and its subsequent release to 
venous circulation (Kraus et al., 2004, Hiscock et al., 2003, Höffner et al., 2003) 
but not to arterial circulation(Hiscock et al., 2003). It is plausible that after 
release from the stretched muscles during exercise into the venous system, the 
VEGF is taken by other tissues, not directly involved in the exercise. However, 
the possibility of increase in VEGF from cells like platelets and myocytes cannot 
be overruled, as electrical stimulation of cardiac myocytes has been shown to 
increase VEGF release (Seko et al., 1999).  
6.5.4.1 Correlation of endostatin and VEGF concentrations before and after 
exercise 
Finally correlations between endostatin and VEGF concentrations before and at 
all time points after exercise were carried out. Concurrently the correlations 
between the changes in both mediators at each time point were also checked, as 
shown in table 6-5. No correlations of statistical importance at any time point 
were observed. These results are in line with our earlier results in chapter 4. 
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It is established from the literature that endostatin antagonises the signalling 
mechanisms of VEGF (Eriksson et al., 2003, Yamaguchi et al., 1999). However, it 
is clear from the results, that increase in endostatin concentration after high 
intensity exercise has no negative effect on the plasma VEGF concentration, a 
finding which is in dispute with the results published by Gu and his co-workers 
(Gu et al., 2004). An increase in VEGF concentration after exercise seems more 
logical as exercise increase the expression of mRNA in skeletal muscles (Hiscock 
et al., 2003), which enhances the production of VEGF in skeletal muscles and 
favours the release of VEGF from tissue to circulation (Rullman et al., 2007). 
In conclusion, the high intensity exercise increases the mean endostatin more 
prominently and for a longer duration than VEGF without any important 
interaction between the two mediators. 
6.5.5 Strengths of the study 
This study investigated both the mediators at the same time with no delay in 
analyses compared to the previous study. Additionally, body fat compositions 
and fasting metabolic profiles of the participants were also investigated for 
correlation with endostatin and VEGF. Similarly, blood samples were taken more 
frequently for longer period after exercise, which provided more clear trends in 
distribution of these two mediators in circulation after exercise. Moreover, 
provisions of resting time between cannulation and basal sample and calculating 
the exercise parameters with breath by breath analyser were done to get more 
accurate results. 
6.5.6 Limitations of the study 
Sample size of this study is low and the results could be more reliable with the 
inclusions of more participants, especially females.  However, it was difficult to 
recruit sedentary females for high intensity exercise to volitional exhaustion. 
Non invasive techniques like flow mediated dilatation percentage (FMD) or 
reactive hyperaemia index (RHI), which give a more accurate status of 
endothelial insufficiency than metabolic profiles, should have been considered. 
FMD and RHI are the more sophisticated non invasive techniques in research and 
diagnostics to assess the endothelial insufficiency. In these techniques 
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vasodilator responses of the peripheral arteries are measured with ultrasound 
before and after applying pressure through a blood pressure cuff. The shear 
stress causes endothelium dependent dilatation. Median dilatation of more than 
10.7% signifies a normal endothelial function. Participants with less than 10.7% 
dilatation are more prone to CVD development. The tests by these methods 
correlate with invasive methods and are suitable for normal and healthy subjects 
(Raitakari and Celermajer, 2000).  
The exercise is of high intensity and relatively short duration. Thus sweat loss is 
unlikely to exceed 0.25-1% of body weight. This was offset by giving the 
participants fluids before and after exercise. The time course of changes in 
water balance is impossible to predict. The author is unaware of any potential 
effect of dehydration on endostatin concentration after exercise. 
It could be possible that endostatin correlates with the hydration status of the 
participants. Hydration status (plasma osmolailty electrolytes and haematocrit, 
urine osmolailty and specific gravity) of the participants should have been 
included and checked for any correlation with endostatin in this or the previous 
studies.  
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7.1 Overview 
In recent era, cardiovascular disease has remained a major health problem 
causing more mortality and morbidity than infectious disease. The incidence and 
prevalence of cardiovascular disease is on the rise and has placed a huge burden 
on the economy of developing and developed world equally; through cost of the 
treatment and wasting productive years of life. Cardiovascular diseases are 
associated with building up of plaque of fatty and fibrous streaks in the intimal 
layer of muscular arteries, especially coronary arteries. The process is called 
atherosclerosis which narrows the lumen of the arteries, compromises the blood 
supply to the area and causes thrombosis and major ischemic events (Griffin, 
1999). The major risk factors for CVD include; sedentary life style, smoking, 
dyslipidaemia, high blood pressure and obesity.  
Uncontrolled angiogenesis in the atherosclerotic plaque can increase the size of 
the plaque with rupture or complete occlusion of the vessel leading to major 
cardiovascular event (O'Brien et al., 1994). Angiogenesis is controlled by 
endogenous mediators, of which “VEGF” as angiogenic and “endostatin” as 
angiostatic mediators have been recognised as key players controlling 
angiogenesis. 
Sedentary life style remains one of the isolated and leading risk factors for CVD. 
The importance of physical activity in decreasing the morbidity and mortality 
due to CVD is accepted globally (Sofi et al., 2008). Regular physical activity 
decreases the CVD related events directly, through improving and activating 
different cardio protective mechanisms and indirectly through modifying other 
risk factors for CVD; including diabetes, dyslipidaemia, obesity and blood 
pressure (Golbidi and Laher, 2011). Cardioprotective mechanisms include; heat 
shock protein production, improving myocardial antioxidant capacity and 
coronary collateral circulation etc. 
The world has never witnessed as many advances in medical sciences as these 
days in the human history. Thanks to the research in science that has enabled 
humans to live longer and joyful life than ever before. Particular advances have 
been made in medicine and public health which have resulted many more people 
living longer (UNDP, 2001). In UK over the last 5 decades average life expectancy 
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has increased by 10 years for males and 8 years for females (office for National 
Statistics UK, 2010). In addition to increase in work force, the elderly population 
also faces a great risk of contracting health problems regularly and mortality of 
in this age group is 9 times higher than adults (Office for National Statistics UK, 
2013b). This problem is further complicated by lack of regular physical activity 
which is one of the major issues in this age group and needs to be addressed. 
Despite one of the best health services in world, the National Health Service 
Scotland (NHS) faces a great challenge of improving the health of poorest 
sections of society. The difference in life expectancy between affluent and non-
affluent societies in Scotland is 10 years and inappropriate diet and physical 
inactivity have been considered as some of the main root causes. The Scottish 
Government is keen in taking initiatives like healthy eating, increasing physical 
activity and tackling obesity (The Scottish Government, 2008). 
Like every other walk of life, research has extensively focused on exercise and 
the cardioprotective mechanisms. The role of physical activity and regular 
exercise on decreasing the incidence, prevalence, mortality and morbidity has 
been established. That is the reason, qualitative and quantitative regular 
physical activities are recommended by the health organisations, as preventive 
measures for CVD and to enhance quality of life. However, the mechanisms by 
which physical activities provide cardiac protection are not completely clear. It 
might be due to several causes. Exercise modifies many local cardio-protective 
mechanisms as discussed in section 1.3.9.4. In addition, it simultaneously affects 
various systemic features such as blood pressure control, cardio-respiratory 
fitness, and humoral features such as better glycaemic control, improving insulin 
sensitivity and lipid metabolism. 
Considering the problems associated with the understanding of structured 
physical activities and cardiac adaptability mechanisms, research presented in 
this thesis is aimed at, understanding and evaluating the effects of different 
intensities of exercise activities on endostatin and VEGF concentration in plasma 
in young healthy human volunteers. More precisely, acute effects of exercises of 
4 different intensities equivalent to mild, moderate, vigorous and maximal effort 
were investigated. Moreover, the association of these mediators with different 
anthropometric characteristics and exercise parameters were also determined. 
To the best of author’s knowledge, this is the first study to demonstrate not only 
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the effects structured physical activities of different intensities on endostatin 
and VEGF but also correlating them to different variables discussed, throughout 
chapter 3, 4 & 5. It also includes first study of its kind evaluating the 
bioavailability of endostatin concentration in males and females from different 
ethnic groups. 
7.2 Summary of the findings in this thesis 
This section outlines the research questions in chapter 1 of this thesis and the 
results that were obtained in the subsequent chapters (3, 4 & 5), with some 
discussions. 
7.2.1 Bioavailability of basal endostatin concentration 
Endostatin was detected in plasma of all volunteers. In chapter 3, the mean 
endostatin concentration measured for all volunteers were 105 ± 12 ng/ml. The 
concentration measured in the subsequent experiments in chapter 4 & 5 showed 
almost the same results. Considering time to time and person to person 
variations, we can safely say that basal endostatin concentration ranges 
between 80 and 120 ng/ml. 
The bioavailability of endostatin in plasma is not completely clear. Different 
mechanisms are proposed to be responsible for the endostatin concentration in 
plasma. Some of the possibilities are as under;  
Endostatin associated with collagen XVIII is the most frequently available form in 
plasma. Collagen XVIII is released by fibroblasts and hepatocytes (Seppinen and 
Pihlajaniemi, 2011). It might be possible that same cells are involved in the 
release of endostatin into the circulation.  
Endostatin has been reported to be present within the platelets and are released 
from the platelets when treated with thrombin (Ma et al., 2005) and ticlopidine 
(Ma et al., 2001). 
Similarly, collagen turn over in different tissues occurs on regular basis, which 
varies with a mean rate of 3 to 5 %  per day (Laurent, 1987). Basal levels of 
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circulating endostatin may be generated as a result of physiological collagen 
turnover, suggesting its importance in angiogenesis regulation during normal 
conditions (Gu et al., 2004).  
The release of endostatin from endothelial cell lines by exposing it to hypoxic 
stimuli and reactive oxygen species has also been reported. The release of 
endostatin was also enhanced by increased nitric oxide concentration. This 
assumes that NO signalling pathway (nitric oxide/cGMP pathway) and enhanced 
production of NO may augment the release of endostatin into circulation 
(Deininger et al., 2003). 
As mentioned earlier, the origin of endostatin is not completely understood, but 
based on the published literature; we could say that fibroblasts and hepatocytes 
cells, under general and other mechanisms listed above, under special 
circumstances, appear to be the major sources of endostatin in the circulation. 
This is because fibroblasts are the main source that synthesizes the components 
of extracellular matrix and many collagens including collagen XVIII. Additionally, 
high circulatory endostatin concentration in patients with fibrotic lung diseases 
with various degrees of fibrosis, has been reported (Hebbar et al., 2000, Seko et 
al., 1999).  On the other hand, all other mechanisms including release from 
platelets, collagen turnover and NO signalling pathway could be responsible for 
release under special circumstances like physical activity, cell stress and 
hypoxia.  
7.2.2 Difference between basal endostatin concentration in 
males and females 
It was hypothesized, that females might possess less basal endostatin 
concentration than males. Results in chapter 3, show that females have slightly 
less mean endostatin concentration of 102 ng/ml than males 107 ng/ml, but the 
difference is not significant.  
Results in chapter 3 and most of the published literature agree that females 
have non-significantly less endostatin concentration than males. Increased 
number of platelets and increased collagen turn over in males might be possible 
reasons to their higher basal endostatin concentrations. It could be true because 
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collagen is the most abundant protein present in the body and makes 20- 25% of 
the total body protein (Ricard-Blum, 2011, Kjaer et al., 2005). Furthermore it 
has been reported that the collagen turn over increases with physical activity, 
enhanced blood flow and mechanical loading (Kjaer et al., 2005). Based on our 
observation in table 4-1 males participants were significantly heavier than 
females (P<0.001) and might have more collagen mass and turn over than 
females. Enzyme like MMPs in the extracellular matrix are directly involved in 
release of endostatin (Sasaki et al., 2002). 
Only the study carried out by Sponder reported a higher basal endostatin 
concentration in females than males  and a hormonal influence was suggested 
for it(Sponder et al., 2014). Estradiol has been shown to increase endostatin 
concentration along with MMP- 2 and MMP 9 (Nilsson et al., 2007, Nilsson and 
Dabrosin, 2006). Diurnal variations (Glenjen et al., 2002) and influence of age 
(Bruserud et al., 2005) and regular physical activity on plasma concentration of 
endostatin has also been reported (Sponder et al., 2013). It is plausible that 
difference in baseline endostatin concentration is due to simple biological 
variations during the course of the day. 
7.2.3 Difference in basal endostatin concentration with age 
and other anthropometric characteristics 
It was also anticipated, that age and other anthropometric characteristics might 
influence the basal endostatin concentration. No significant differences in 
endostatin concentration were observed for different variables including age, 
weight, height, BMI, blood pressure and previous physical activity levels of the 
volunteers. The Pearson correlation analyses did not show any correlations 
between the factors mentioned above and endostatin concentration as shown in 
the result sections of chapter 3, 4 & 5. More over no difference in mean 
endostatin concentration was observed in volunteers belonging to different 
ethnic groups including European, Middle Eastern and South Asians. 
These findings are really interesting as during the whole research, we thoroughly 
investigated the correlations of endostatin with the different anthropometric 
characteristics. Age and blood pressure were the two variables, which in some 
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set of experiments showed significant positive and negative correlations 
respectively. The possibility of these findings by chance could not be over ruled 
because; firstly the findings were only determined in some data sets. For 
example in chapter 3, age showed a negative correlation for males especially 
South Asians and not for females or males belonging to other ethnic groups. 
Secondly, the patterns in correlations observed in chapter 4 were not uniform 
and despite the same participants in trials, correlation between age and 
endostatin concentration could not be observed on different days. Thirdly, as 
individual variations in endostatin concentration were observed in chapter 4, it 
would be very difficult to report any such correlations in small data set. In fact, 
experimental models with large sample size, different ages and longitudinal 
observations would be required to safely speculate about these correlations.  
7.2.4 Effect of mild intensity exercise (60% heart rate) on 
endostatin  
The results of chapter 4 show that low intensity exercise decreases the mean 
endostatin concentrations by 4% and 3% at 10 minutes and 60 minutes interval 
after exercise. These changes were not significant but unexpected. Individually 
64% of the participants showed an acute negative change after exercise. No 
differences in change on gender basis and exercise mode were observed. 
This finding is interesting, because it was hoped that exercise will increase the 
mean endostatin concentration as most of the published literature, at the time 
this study was carried out, reported increase in endostatin concentrations with 
physical activities.  Study carried out by Makey and her colleagues recently, 
reported almost the same results in females after performing exercise at 55-59% 
heart rate on treadmill for 30 minutes (Makey et al., 2013).  
As discussed in chapter 4 and 6, no correlations between exercise parameters 
and change in endostatin concentration were observed, it could be assumed that 
exercise indirectly modifies the different mechanisms concerned with endostatin 
release, such as MMP, collagen turn over, release from platelets etc. After 
looking at the effect of higher intensities of exercise on endostatin in the 
subsequent experiments, we can safely assume that low intensity of exercise 
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was not enough to initiate the release of endostatin.  However, even on that low 
intensity exercise 36% of the participants showed an increase in endostatin 
concentration. Therefore, it can be assumed, that intensity induced activation 
of the above mechanisms may have different thresholds for sensitivity which 
varies from person to person. 
7.2.5 Effect of moderate intensity exercise (70% heart rate) on 
endostatin  
Results in chapter 4 shows that exercise at intensity of 70% predicted maximum 
heart rate, increased the mean endostatin concentration significantly, by 18% 
and 19% at 10 minutes and 60 minutes intervals, respectively.  
7.2.6 Effect of high intensity exercise (80% heart rate) on 
endostatin  
High intensity exercise increases the mean endostatin concentration by 38% and 
14%, at 10 minutes and 60 minutes intervals respectively, as shown in chapter 4. 
No difference was observed between the degree and pattern of change for males 
and females.  
7.2.7 Effect of maximal intensity exercise (100% heart rate) on 
endostatin 
Exercise at maximum intensity increased the endostatin concentration 
significantly up to 2 hours after exercise. The highest increase in mean was 34% 
at 30 minutes interval after exercise. These results are shown in chapter 5 of 
this thesis. 
From the results in chapter 4,5 &6, it is clear that high intensity exercise 
increase the mean endostatin concentration in plasma up to 2 hours after 
exercise. The results in this chapter also suggest that degree of change in 
endostatin concentration is independent of gender or exercise mode 
(walking/running).  However, it is still not clear why endostatin concentration 
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increases after exercise and what physiological functions it performs. Some of 
the possible explanations are as follows; 
Endostatin is proteolytically released from collagen XVIII by the action of many 
enzymes including cathapsin L (Felbor et al., 2000) and MMPS especially MMP2 & 
9 (Ferreras et al., 2000). Exercise has been reported to increase the expression 
of these enzymes which in turn enhance the generation of endostatin (Suhr et 
al., 2010). 
Exercise has been shown to influence collagen turn over (Kovanen and Suominen, 
1989) which is thought to be one of the sources for direct increase in endostatin 
production (Gu et al., 2004). However, indirect effects of collagen turn over on 
the enzymes involved in the release of endostatin could also possibly increase 
the endostatin in circulation.  
Exercise increases the metabolic demands of the cells for oxygen (O2) for 
energy. It has also been established, that inhibition of NO synthase reduces the 
endostatin concentration (Deininger et al., 2003) and that endostatin causes 
vasorelaxation by up regulating  production of NO (Wenzel et al., 2006, Sunshine 
et al., 2012). It is possible that the increase in endostatin concentration may be 
one of the mechanisms for vasorelaxation during exercise, to ensure optimal 
oxygen and nutrients supply to the body. It can be suggested, that besides its 
role in angiogenesis, increased endostatin concentration help in maintaining 
optimal vascular tone during stress time for effective nutrients supply. 
7.2.8 Correlations of change in endostatin concentrations with 
anthropometric and metabolic factors  
Results in chapter 4 & 5 showed, that the changes in endostatin after different 
exercises were independent of anthropometric, physical and metabolic 
characteristics. 
To understand what are the possible anthropometric and metabolic factors that 
can potentially affect the physiological change in endostatin, correlations were 
carried out. No correlations of statistical importance were observed. Metabolic 
factors were also taken into consideration, due to its active involvement in the 
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early events in endothelium leading to atherosclerosis. It might be possible that 
because recruitment of only healthy volunteers with not much difference in 
their metabolic, endothelial and vascular status were carried, results are 
inconclusive. Because it was not the initial aim and these factors were included 
during the maturation of research process over the time, the sample size 
selected might not be enough to draw a solid conclusion. Large scale studies 
with the inclusion of volunteers with known endothelial and vascular status 
would be required. 
7.2.9 Effects of exercise on VEGF 
On all exercise intensities used in our experiments, increase in VEGF 
concentration in plasma was observed. In some cases, this was minimal and 
insignificant, while in other cases it was statistically significant. The impacts of 
exercise on VEGF increase were transient and for short duration without any 
specific pattern. Moreover, the change in VEGF after exercise was not much 
different in males/females or walking/running group.  
The increase in VEGF concentration acutely after exercise has been reported 
extensively and discussed in chapter 4 & 5. The possible mechanisms for this 
increase and subsequent physiological action after increase could be; 
I. Local up-regulations in skeletal muscles  as a result of tissue hypoxia by 
exercise (Kraus et al., 2004).  
II. mRNA expression and VEGF protein concentration has been shown to 
increase in skeletal muscles (Rullman et al., 2007) and interstitial spaces 
(Höffner et al., 2003), which in turn can enhance the production and 
release of VEGF in to blood.   
III. VEGF is also found in platelets (Ma et al., 2005) and local release from 
these cells could not be excluded.  
IV. It was suggested, that mechanical stress in the exercising leg could 
possibly cause the increased production of VEGF by myocytes which 
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accounts for local angiogenesis as well elevated plasma concentration 
(Hiscock et al., 2003).  
V. Additionally, it is also possible that the increased production of VEGF not 
only occurs in the skeletal muscles but in many other cells and tissues, 
which collectively increase the release of VEGF into blood and 
consequently the plasma concentration raises.   
Just like endostatin, the mechanism for the increase in VEGF concentration after 
exercise, is still not completely clear due to existence of multiple possible 
release mechanisms and the ability of exercise to influence these mechanisms 
equally. However, increase in VEGF after low intensity exercise shows that even 
this intensity is beneficial by enhancing the VEGF production and promoting 
angiogenesis at tissue levels. Hence, it can be suggested, that as hypoxia is the 
main stimulator of VEGF release, and exercise by producing hypoxia in skeletal 
muscles are responsible for production and subsequent release of VEGF into 
circulation. 
The consequential decrease in VEGF after initial increase could be due to 
simultaneous increase in binding capacity of VEGF to its receptors. 
Subsequently, they can also be used at micro-vascular levels to initiate 
angiogenesis. However, it is also possible that exercise may increase the number 
of binding sites for VEGF. Moreover, as the promotion of angiogenesis at tissue 
levels after exercise along with increase VEGF concentrations is established, it is 
equally possible that exercise induces the VEGF release from cells like platelets 
within the circulation which are then taken up by the tissues. 
7.2.10 Correlation of endostatin and VEGF 
No correlations of statistical importance were observed between plasma VEGF 
and endostatin concentrations, before or after exercise in chapter 4 & 5. The 
correlations between the extents of changes were also insignificant. 
It has been established, that endostatin inhibits VEGF induced endothelial cell 
proliferation and migration. It was thought, that as endostatin possesses anti 
VEGF properties, exercise induced increase in its concentration will conversely 
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affect VEGF concentration as reported (Gu et al., 2004). Exercise induced 
changes in endostatin concentrations were found unrelated to VEGF 
concentrations. It is possible, that exercise affects the concentration of 
endostatin and VEGF through completely different mechanisms.  
7.3 General considerations  
Though the effects of exercise on these mediators were transient, they were 
important and not trivial. Single bouts of moderate to high exercise brought 
about 20% to 40% changes in endostatin concentration with no gender 
difference. It is important to note, that the intensities of exercise were 
managed comfortably by relatively untrained individuals. As the exercises were 
carried out according to the comfort of the individuals, the least fit volunteers 
did not perform as well as fit volunteers in the trial, but even for them, the 
influence of exercise on these mediators was substantial and prominent. In fact, 
21 out of 22 volunteers showed a significant increase in endostatin concentration 
with exercise and the latter, as a beneficial tool for increasing circulatory 
endostatin concentration, can be suggested.  
The data from this study suggest that plasma concentration of endostatin is 
more profoundly influenced by exercise than VEGF. However, as angiogenesis in 
skeletal muscles as a result of exercise mediated by VEGF is an established fact, 
it can be speculated, that exercise might increase the uptake of VEGF into the 
tissue along with enhanced local production. Further research involving kinetic 
tracers may be helpful in elucidating these speculations. Kinetic tracers are used 
widely in research and mainly deal with kinetics of different substances, their 
production and transport into cells, biochemical transformation and utilization. 
For this purpose tracers like dye, labelled radioactive or stable isotopes are used 
(Wolfe, 1992). It is also worth mentioning that other mechanisms, which are not 
yet discovered, may be involved in changing the concentrations of these 
mediators after moderate to high exercise. The clarification of these 
mechanisms, though necessary, clearly would require specialised equipments 
and expertise. These factors might be an area for future research, but even 
without the knowledge of exact mechanisms, it is clear that moderate to high 
intensity exercise clearly affects endostatin in different individuals with diverse 
Chapter: 7 
220 
 
characteristics. Therefore, moderate to high intensity exercise can be 
implemented as preventive measure for atherosclerosis. 
However, the question of incorporating structured physical activity in life style 
to the intensity levels, where it influences the endostatin concentration, is a 
matter of debate. The answer to this question based on the research in this 
thesis, is “yes”; because the exercise intensity of 70% predicted maximum heart 
rate was easy to incorporate into the relatively sedentary populations, due to 
the fact that no drop outs were observed during the experimental work and the 
exercise was perceived as “light” by most of the participants. Moreover, as the 
pattern of change in endostatin was rarely influenced by mode of exercise 
(walking/running); participants with potential inability to run can also achieve 
the required intensity easily by walking uphill. 
With advances in technology in recent times, life style factors especially physical 
activity and diet has acquired a crucial role in determining the health of general 
population. The scientific evidence of physical activity on improving health 
indicators is undeniable and certain amount of different physical activities 
including cardio-respiratory fitness exercises beyond daily activities, are 
recommended and vital for every individual’s health. However, the physical 
activity of individuals can be modified according to the needs, comfort and 
health status. Physical activity less than recommended by the health 
organizations would undoubtedly prove beneficial in some respects. In ongoing 
un-published research by another group in this department, the preliminary 
results show that even interrupting long sitting intervals during work by mere 
standing periodically, improves the risk associated with CVD (Personnel 
communication September 2014).  
As CVD is a multi-factorial complex health problem. Interventions implied for 
prevention should also be multi-factorial and multi-faceted. This would include 
encouraging physical activity to the minimum recommended levels, diet 
modifications, public awareness through print and electronic media and 
addressing the cultural and religious aspect of the problem.  
Individual compliance to adhere to regular physical activity has remained one of 
the problems in implementing and prescribing physical activity. As per WHO 
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statistics, 60% of the world population do not achieve the required physical 
activity partly due to less engagement in physical activity and more work 
burden. This would require making exercise a joyful and pleasant event. 
However, behavioural orientation towards decreasing the risk of cardiovascular 
diseases by exercise, regular risk evaluations for CVD and gradual increase in 
exercise intensity over certain period may equally enhance the compliance and 
safety of exercise. 
7.4 Implications  
It is very premature to suggest clinical implications in the management of 
atherosclerosis, from the results obtained in this thesis. However, potentially 
many implications of this study can be taken into consideration. 
Endostatin has been found to be one of the key regulators in angiogenesis and its 
beneficial role in angiogenic dependent diseases, provide it with the advantage 
to be considered seriously. As shown in this thesis, plasma bioavailability of 
endostatin coupled with the increase in its concentration, after physical exercise 
also points potential application of exercise with certain intensities (70% heart 
rate and above) necessary into life style. Exercise intensity of 70% predicted 
maximum heart rate was relatively low, easily applicable and perceived as light 
by both males and females. However, due to the fact that studies were carried 
out in healthy individuals, competent enough to perform the exercise, these 
intensities might not be easy to incorporate in life style of people with different 
ages and co-morbid conditions. 
Moreover, young adults performing more than 3 sessions of endurance exercise 
(45 minutes) per week for 6 months have shown an increase in the basal 
endostatin concentration compared to sedentary controls (Sponder et al., 2014). 
It can be assumed that incorporation of regular physical activities would increase 
the basal endostatin concentration to levels, enough to counteract 
atherosclerosis.  Chances of rupture of plaque remain high due to intra- plaque 
angiogenesis and endostatin has been shown to stabilize the plaque by inhibiting 
this process. The results in this thesis contribute to the understanding of one of 
the links between physically active life style and decrease risk of 
atherosclerosis. 
Chapter: 7 
222 
 
Endostatin is the first angiogstatic mediator to reach clinical trials. It was 
reported with no toxicity and well tolerated drug showing less than expected 
results on stopping angiogenesis (Eder et al., 2002). Many reasons, including 
active form, mode of administration and optimal dose, were used to account for 
the possibilities of not getting expected results and in such cases exercise 
induced increase can be used as an alternative way of getting optimum results. 
Due to enhancing production of the NO and vaso-relaxation of the vessels, 
endostatin has been used as an alternative to Avastin (anti VEGF drug) in ocular 
retinal changes in mice (Sunshine et al., 2012). Again exercise induced increase 
could be alternatively used in humans with retinal changes and could be one of 
the potential areas for future research. 
Additionally, patients with Down syndrome have been reported with high 
circulatory endostatin concentration and low incidence of solid tumors (Zorick et 
al., 2001). Though the cause for this increase is mutations in the gene 
responsible for expression of collagen XVIII, it is speculative to mention that in 
healthy humans, endostatin can be increased with regular physical activities, 
which might conversely decrease the incidence of solid tumors. 
Despite the fact, that endostatin and VEGF play important roles in angiogenesis, 
many other mediators and molecules are also involved in angiogenesis. It is a 
matter of debate, whether these two are sufficient enough to decide the 
progression of disease. Further research is needed to quantify the effect of 
these two in the overall angiogenic process, which might help in overcoming the 
difficulties in therapeutic use of these mediators. 
It is evident from this thesis that most of the volunteers were sedentary and 
short bouts of exercises were easy to perform. So incorporating exercise 
programme of moderate to high intensities are not difficult, as part of 
interventional programmes for sedentary populations. Another striking feature of 
relative importance was, sticking of the participants to all exercises especially 
second study without any drop outs. It is clear that slight motivation is necessary 
to deliver a practical life style in sedentary populations. 
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Prophylactic changes in life style are beneficial than waiting for the disease 
onset and active treatment. However, in cases of increasing age, where diseases 
are expected, active treatment may be vital in improving quality of health. 
7.5 Conclusion 
In conclusion, angiogenesis occurs as one of the adaptive mechanisms in the 
body to compensate the increasing metabolic requirements of the body. 
Angiogenesis is regulated with a fine balance between angiogenic and 
angiostatic mediators and shift in favours of any mediators predicts the 
phenotype of angiogenesis. However, progressive angiogenesis in presence of 
pathologic conditions can be dangerous with life threatening outcomes. 
Endostatin is one of the main angiostatic factors in the body and can be 
increased in circulation with moderate to high intensity exercises. The origin of 
increase in endostatin concentration is not completely clear, and many organs 
and mechanisms may be involved in its release. However, regardless of the 
origin, results in this thesis show that exercise promotes endostatin 
concentration in plasma more than VEGF and may effectively influence 
pathological processes like atherosclerosis under pathological conditions. Under 
non pathological conditions it may be more helpful in maintaining vascular tone. 
Exercise has also shown a positive increase in VEGF less than endostatin. As the 
muscles VEGF concentrations were not measured, possibility of local increase 
cannot be excluded. However, tissue VEGF concentration seems more important 
for the increasing metabolic requirements than systemic VEGF concentration. 
7.6 Limitations  
Throughout the research described in this thesis, there were some challenges 
and limitations in conducting the different studies. 
i. Ethics approval for the first study was granted after 5 months due to some 
unexplained circumstances. The application to the committee was made 
in December 2011 and approval was granted on 25th May 2012.The delay 
was attributed to shortage of administrative staff and problems with the 
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implementation of a new electronic system. When the committee decided 
to grant the approval, the project was approved without any ethical 
reservations. This delay had a huge impact on the overall progress, as by 
the end of first year of research, we were unable to finish one simple 
study. Ethics approval for the subsequent studies, however, was straight 
forward and easy. 
ii. Reliability of ELISA technique was another issue. Due to non availability of 
skilled technical support, the reliability of the technique was questioned 
in the annual review process, although my supervisor regularly checked 
the results with me after I had learned the technique from another 
department. The review committee asked me to have more sessions on 
the technique and to cross check all results with specialised technical 
expert in other departments. Though the quality control indicators 
showed a reliable technique, special sessions with skilled technical staff 
were taken to ensure quality control. Later on all the results after each 
analysis were cross checked with Mrs Josephine Cooney. Consistency in 
results shows the accuracy of handling. Whereas, in the initial experiment 
coefficient of variance (CV) of less than 10%  for results were accepted as 
reliable, in the last experiment obtained CV for all samples were less than 
4%. 
iii. Recruitment of the healthy individuals was difficult for all experiments 
especially second one, where individual has to attend the lab 4 times. It 
was always a time consuming process. Many potential participants refused 
to participate after initial agreement. 
iv. Recruitment mainly from students of Glasgow University is really a 
limitation of this study. Results would have been truer representative of 
population with recruitments of non students. Similarly females were less 
in numbers than males. Control groups were not considered in any of the 
study. 
v. Samples for VEGF in chapter 4 were analysed more than 6 months after 
collection. 
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7.7 Future directions  
Based on the research in this thesis, future research should be focused on; 
1. Besides elucidating the mechanism of release and interactions between 
these two mediators, effective intensity with shorter duration should be 
investigated. Different individuals exercised for different duration in this 
study and successfully completed the trials, but still a large population 
will not exercise at these intensities regularly. It is therefore, required to 
design practical studies with short bouts of higher intensities to gain 
health benefits.  
2. Establishing public health recommendations of optimum physical activity. 
This could have two elements: to establish the best practice in physical 
activity to prevent future CVD and secondly to identify the optimum 
activity for patients who have developed progressive angiogenesis. 
3. Validating basal endostatin concentration as predictive marker for CVD 
and cancer with prospective studies. This may include people from normal 
and diseased population especially with cardiovascular and cancer 
problems. The model of the study would be prospective and may require 
longer duration. 
4. A longitudinal study evaluating long term effects of physical activities on 
the basal plasma endostatin and VEGF concentrations in healthy and non 
healthy population of both gender and different age groups. 
5. A prospective study model on mice, whereby comparing the effect of 
exercise induced rise in endostatin concentration against a group with 
regular high endostatin concentration (could be done through slow release 
endostatin depot), in respect of onset of atherosclerosis. 
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Appendix- B; Information sheets 
 
B1-   Information sheet for study 1 
 
 
Title of study 
Measurement of human Endostatin concentrations in the plasma of 
healthy volunteers  
Invitation to take part 
Thank you for reading this information sheet.  
This is an invitation for you to take part in a research study. It is important for you to 
understand why this study is being conducted and what it would involve before you 
decide to take part in this study. Please take time to read the following information 
carefully and discuss it with others if you wish.  If you are not clear about anything or 
would like to have more information, feels free to ask. Take time to decide whether or 
not you wish to take part. 
What is the purpose of the study? 
Endostatin is normally present in human blood. It is of interest because of its potential 
role in cardiac protection. This study aims to measure the concentration in healthy 
people.  
Why have I been chosen? 
Because you are: 
 
 A healthy normal adult individual 
 A non smoker 
 Not suffering from any chronic illness 
 Not pregnant or lactating 
 Have not performed any strenuous physical activity in last 24 hours 
 
Do I have to take part? 
It is entirely your own decision to take part or not. You will be given this information 
sheet in case you decided to take part. In case of withdrawal from the study after you 
decided to take part and giving consent, you are free to do so without providing any 
reason.  
 
 
 
 
What will happen to me if I take part? 
If you agree to take part, a member of the team conducting the study will explain the 
study at your convenient place and time. 
 
What do I have to do? 
On taking the decision to be a part of the study and signing the consent one of the 
team members will make an appointment with you. You have to fill in a questionnaire 
regarding your health status, physical activity and smoking habits. Your weight, 
height, Body Mass Index, waist circumference and blood pressure will be recorded.  
One sample of 5 ml blood will be taken from a vein according to a standard protocol 
by an experienced Physician in the laboratory of Glasgow University. 
 
What are the possible disadvantages and risks of taking part? 
There are very minimal risks or disadvantages associated with this study other than 
time loss. These are needle prick and slight bleeding. 
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What are the possible benefits of taking part? 
There are no direct benefits to the participants. However, it will provide a baseline 
about the concentrations of Endostatin in people. 
 
 
Will my taking part in this study be kept confidential? 
All the information will be kept confidential, available only to the researcher. Your data 
will be stored anonymously. Your name and address will not be stored.  
 
What will happen to the results of the research study? 
Your data will be included in a thesis, published in scientific journals and may be 
discussed in meeting and conferences. This is so that other people may know about 
the results of the study. Results can be discussed with you as well if you are 
interested to know about that. 
 
Who is organising and funding the research? 
This project is being organised by the School of Life Sciences, University of Glasgow. It 
is funded by a scholarship from Khyber Medical University, Peshawar, Pakistan. 
 
Who has reviewed the study? 
This project has been reviewed by the College of Medical, Veterinary & Life Sciences 
Ethics Committee for Non Clinical Research Involving Human Subjects.  
 
Contact for further information 
If you require further information please contact  
o Dr Inayat Shah by telephone no 07438334455 or via e-mail at 
i.shah.1@research.gla.ac.uk 
 
o Dr Ronald Baxendale by telephone at 0141 330 5344 or via e-mail at 
Ronald.Baxendale@glasgow.ac.uk  
 
 
Thank you for reading this information sheet.  
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B2-     Information sheet for study 2 
 
 
Title of study 
The effect of different exercise protocols on human plasma endostatin level 
 
Invitation to take part 
Thank you for reading this information sheet.  
This is an invitation for you to take part in a research study. It is important for 
you to understand why this study is being conducted and what it would involve 
before you decide to take part in this study. Please take time to read the 
following information carefully and discuss it with others if you wish.  If you are 
not clear about anything or would like to have more information, feel free to 
ask. Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Endostatin is normally present in human blood. It is of interest because of its 
potential role in cardiac protection. Heart diseases are quite common across the 
globe and are a leading cause of death in Scotland. Studies suggest that exercise 
enables the body to protect it from the heart problems, but we do not 
understand this mechanism completely. This study will help to increase that 
understanding. This is important because we can find exercise as treatment for 
the heart problems.  
 
Why have I been chosen? 
Because you are: 
 
 A healthy normal adult individual 
 A non smoker 
 Not suffering from any chronic illness 
 Not pregnant or lactating 
 
Do I have to take part? 
It is entirely your own decision to take part or not. You will be given this 
information sheet to help you understand what is involved.  You can stop the 
experiment at any time without providing any reason.  
What will happen to me if I take part? 
If you agree to take part, a member of the team conducting the study will 
explain the study at your convenient place and time. 
 
What do I have to do? 
You will be requested to attend the lab at 4 times. Each visit will last up to 2 
hours.  In the first visit you will be asked to sign a consent form followed by 
filling a complete confidential questionnaire regarding your health and physical 
ability. We will record your height, weight, and blood pressure and you will be 
familiarized with the whole procedure and equipments. You will be asked to 
perform a preliminary exercise test on treadmill which will help us predicting 
the exercise protocols in the subsequent visits. The test will last for about 30 
minutes and will be at speed suitable to you. On later visits you will be asked to 
walk or run on a treadmill for less than 45 minutes. Blood samples will be taken 
before and after the walk.  
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What are the possible disadvantages and risks of taking part? 
There are very minimal risks or disadvantages associated with this study other 
than time loss.  
You will give three blood samples of 5ml and these require a needle. The 
walking is a low to moderate intensity exercise and caries a low risk of changes 
in blood pressure or abnormal heart beat. 
What are the possible benefits of taking part? 
The study will give you an idea and information about your physical and health 
fitness. Moreover, this study will help us to determine the effects of exercise on 
the body own ability to protect it from heart problems.  
 
What if something goes wrong? 
The chances of something going wrong are extremely small. All of the 
procedures involved in this study are low risk and our screening tests are 
designed to ensure that you will only participate if it is safe for you to do so. In 
the unlikely event that you are harmed due to someone's negligence, then you 
may have grounds for a legal action.  
 
 
Will my taking part in this study be kept confidential? 
All the information will be kept confidential, available only to the researcher. 
Your data will be stored anonymously. Your name and address will not be stored. 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future 
research into the prevention and treatment of heart disease; this may involve 
investigating new biochemical markers that may or may not yet identified. 
Samples will be analysed anonymously and will require a new ethics application 
before they would be used for future research. If you do not wish your samples 
to be used for future research, please indicate this on the consent form. 
 
 
What will happen to the results of the research study? 
Your data will be included in a thesis, published in scientific journals and may be 
discussed in meeting and conferences. This is so that other people may know 
about the results of the study. Results can be discussed with you as well if you 
are interested to know about that. 
 
Who is organising and funding the research? 
This project is being organised by the School of Life Sciences, University of 
Glasgow. It is funded by a scholarship from Khyber Medical University, Peshawar, 
Pakistan. 
 
Who has reviewed the study? 
This project has been reviewed by the College of Medical, Veterinary & Life 
Sciences Ethics Committee for Non Clinical Research Involving Human Subjects. 
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Contact for further information 
If you require further information please contact  
o Dr Inayat Shah by telephone no 07438334455 or via e-mail at 
i.shah.1@research.gla.ac.uk 
 
o Dr Ronald Baxendale by telephone at 0141 330 5344 or via e-
mail at Ronald.Baxendale@glasgow.ac.uk  
 
 
Thank you for reading this information sheet. 
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B3-    Information sheet for study 3 
 
Title of study 
 
The effect of graded intensity exercise on human plasma endostatin and 
vascular endothelial growth factor level 
 
Invitation to take part 
Thank you for reading this information sheet.  
This is an invitation for you to take part in a research study. It is important for 
you to understand why this study is being conducted and what it would involve 
before you decide to take part in this study. Please take time to read the 
following information carefully and discuss it with others if you wish.  If you are 
not clear about anything or would like to have more information, feel free to 
ask. Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Endostatin and vascular endothelial growth factor are  normally present in 
human blood. It is of interest because of its potential role in cardiac protection. 
Heart diseases are quite common across the globe and are a leading cause of 
death in Scotland. Studies suggest that exercise enables the body to protect it 
from the heart problems, but we do not understand this mechanism completely. 
This study will help to increase that understanding. This is important because we 
can find exercise as treatment for the heart problems.  
 
Why have I been chosen? 
Because you are: 
 
 A healthy normal adult individual 
 A non smoker 
 Not suffering from any chronic illness 
 Not pregnant or lactating 
 
Do I have to take part? 
It is entirely your own decision to take part or not.  You will be given this 
information sheet to help you understand what is involved.  You can stop the 
experiment at any time without providing any reason.  
 
What will happen to me if I take part? 
If you agree to take part, a member of the team conducting the study will 
explain the study at your convenient place and time. 
What do I have to do? 
You will be requested to attend the lab twice on 2 consecutive days. On day 
first, you will be asked to sign a consent form followed by filling a complete 
confidential questionnaire regarding your health and physical ability. We will 
record your height, weight, body fat percentage, blood pressure and you will be 
familiarized with the whole procedure and equipments.  A cannula will be 
passed onto your vein to take first sample of blood before exercise, and you will 
be asked to walk on the treadmill. The speed/gradient of the treadmill will be 
increased periodically till you reach your maximum effort/ exhaustion. The 
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duration of your exercise will be less than 20 minutes. The exercise will start at 
lower speed and gradient and will be increased periodically after 3 minutes each 
till your exhaustion. After completion you will set in the lab for 4 hours and 
Blood samples will be taken at 10, 30, 60,120 and 240 minutes after exercise. 
This visit will take approximately 6 hours and you will be served with soft 
drinks/water during that time. Facilities like watching movies; internet will also 
be available to you during this time. Cannula will be removed after the last 
sample and you will be asked to attend the lab next day after 24 hours for 1 
more blood sample. The second visit will be for 30 minutes only. You will give 7 
samples each of 10 ml during the whole trial, 6 samples on day first and a final 
sample on second day of your trial. All the samples on day first will be collected 
through the cannula and final sample will need only through a small venous 
puncture. 
 
What are the possible disadvantages and risks of taking part? 
There are very minimal risks or disadvantages associated with this study other 
than time loss. During your exercise 2 staff members competent in first aid will 
always be available to you. Moreover, your heart rate will be monitored all the 
time. You will give 7 blood samples of 10 ml each which require a needle. 
 
What are the possible benefits of taking part? 
The study will give you an idea and information about your physical fitness and 
health. Moreover, this study will help us to determine the effects of exercise on 
the body own ability to protect it from heart problems.  
 
 
What if something goes wrong? 
The chances of something going wrong are extremely small. All of the 
procedures involved in this study are low risk and our screening tests are 
designed to ensure that you will only participate if it is safe for you to do so.  In 
the unlikely event that you are harmed due to someone's negligence, then you 
may have grounds for a legal action.  
 
Will my taking part in this study be kept confidential? 
All the information will be kept confidential, available only to the researcher. 
Your data will be stored anonymously. Your name and address will not be stored. 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future 
research into the prevention and treatment of heart disease; this may involve 
investigating new biochemical markers that may or may not yet identified. 
Samples will be analysed anonymously and will require a new ethics application 
before they would be used for future research. If you do not wish your samples 
to be used for future research, please indicate this on the consent form. 
 
What will happen to the results of the research study? 
Your data will be included in a thesis, published in scientific journals and may be 
discussed in meeting and conferences. This is so that other people may know 
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about the results of the study. Results can be discussed with you as well if you 
are interested to know about that. 
 
Who is organising and funding the research? 
This project is being organised by the School of Life Sciences, University of 
Glasgow. It is funded by a scholarship from Khyber Medical University, Peshawar, 
Pakistan. 
 
Who has reviewed the study? 
This project has been reviewed by the College of Medical, Veterinary & Life 
Sciences Ethics Committee for Non Clinical Research Involving Human Subjects.  
 
Contact for further information 
If you require further information please contact  
o Dr Inayat Shah by telephone no 07438334455 or via e-mail at 
i.shah.1@research.gla.ac.uk 
 
o Dr Ronald Baxendale by telephone at 0141 330 5344 or via e-
mail at Ronald.Baxendale@glasgow.ac.uk  
``   Thank you for reading this information sheet.  
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Appendix- C; Consent form (specimen) 
 
 
 
CONSENT FORM 
 
Title of Project: 
Effects of single bout of high intensity exercise on plasma Endostatin and vascular 
endothelial growth factor concentrations in healthy volunteers  
 
Name of Researcher:  
 
          Please initial box 
 
 
 
 
1. I confirm that I have read and understand the information sheet dated. .................  
(version............ ) for the above study and  have had the opportunity to ask 
questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason. 
 
3. I agree to my samples (Blood) being stored and used for further analysis to look 
at biochemical compound endostatin and VEGF (but not human DNA or RNA). 
      
 
4.    I agree to take part in the above study.       
 
 
 
           
Name of subject      Date    Signature 
 
 
1 for subject; 1 for researcher  
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Appendix- D; Questionnaires  
 
D1-  International Physical Activity Questionnaire (IPAQ) 
 
       INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives.  The questions will ask you about the time you 
spent being physically active in the last 7 days.  Please answer each question 
even if you do not consider yourself to be an active person.  Please think about the 
activities you do at work, as part of your house and yard work, to get from place to 
place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal.  Think only about those physical activities that 
you did for at least 10 minutes at a time. 
 
1. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, aerobics, or fast bicycling?  
 
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
 
2. How much time did you usually spend doing vigorous physical activities on 
one of those days? 
 
_____ hours per day  
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
Think about all the moderate activities that you did in the last 7 days.  Moderate 
activities refer to activities that take moderate physical effort and make you 
breathe somewhat harder than normal.  Think only about those physical activities 
that you did for at least 10 minutes at a time. 
 
 
3. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads, bicycling at a regular pace, or doubles 
tennis?  Do not include walking. 
 
_____ days per week 
 
   No moderate physical activities  Skip to question 5 
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4. How much time did you usually spend doing moderate physical activities 
on one of those days? 
 
_____ hours per day 
_____ minutes per day 
 
  Don’t know/Not sure  
 
 
Think about the time you spent walking in the last 7 days.  This includes at work 
and at home, walking to travel from place to place, and any other walking that you 
might do solely for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 
minutes at a time?   
 
_____ days per week 
  
   No walking     Skip to question 7 
 
 
6. How much time did you usually spend walking on one of those days? 
 
_____ hours per day 
_____ minutes per day  
 
  Don’t know/Not sure  
 
 
The last question is about the time you spent sitting on weekdays during the last 
7 days.  Include time spent at work, at home, while doing course work and 
during leisure time.  This may include time spent sitting at a desk, visiting 
friends, reading, or sitting or lying down to watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week 
day? 
 
_____ hours per day  
_____ minutes per day  
Don’t know/Not sure   
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D2-   Physical Activity Readiness Questionnaire (PAR-Q) 
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D-3 Health Screening Questionnaire Adapted from ACSM 
 
                  HEALTH SCREEN FOR STUDY VOLUNTEERS 
 
Volunteer No: __ 
 
It is important that volunteers participating in research studies are currently in 
good health and have had no significant medical problems in the past.  This is to 
ensure (i) their own continuing well-being and (ii) to avoid the possibility of 
individual health issues confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise   yes [ ] no [ ] 
(b) attending your general practitioner    yes [ ] no [ ] 
(c) on a hospital waiting list     yes [ ] no [ ] 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP      yes [ ] no [ ] 
(b) attend a hospital outpatient department  yes [ ] no [ ] 
(c) be admitted to hospital      yes [ ] no [ ] 
 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy      yes [ ] no [ ] 
(b) Asthma       yes [ ] no [ ] 
(c) Diabetes       yes [ ] no [ ] 
(d) A blood disorder      yes [ ] no [ ] 
(e) Digestive problems      yes [ ] no [ ] 
(f) Disturbance of balance/co-ordination   yes [ ] no [ ] 
(g) Numbness in hands or feet     yes [ ] no [ ] 
(h) Disturbance of vision     yes [ ] no [ ] 
(i) Thyroid problems      yes [ ] no [ ] 
(j) Kidney or liver problems     yes [ ] no [ ] 
(k) Chest pain or heart problems    yes [ ] no [ ] 
(l) Any other health problems    yes [ ] no [ ] 
(m) An allergy to soya protein or eggs  yes [ ] no [ ] 
 
4. For female volunteers only 
(a) Are you pregnant or think that you might be pregnant yes [ ] no [ ] 
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5. Have any of your family (parents, grandparents, brothers, sisters, 
children, aunts, uncles, cousins) ever had any of the following: (if yes 
please give details including age of first diagnosis) 
(a) Any heart problems     yes [ ] no [ ] 
(b) Diabetes      yes [ ] no [ ] 
(c) Stroke       yes [ ] no [ ] 
(d) Any other family illnesses    yes [ ] no [ ] 
 
6. Do you currently smoke    yes [ ] no [ ] 
 Have you ever smoked     yes [ ] no [ ] 
 If so, for how long did you smoke and when did you stop? …………………… 
 
7. How many units of alcohol do you typically drink in a week? …………………. 
 
8. Have you taken part in a research study in the last 3 months?  yes [ ]
 no [ ] 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm 
whether problem was short-lived, insignificant or well controlled.) (Use a 
separate sheet if necessary) 
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Appendix- E; IPAQ data processing guidelines 
 
Guidelines for Data Processing and Analysis of the International 
Physical Activity Questionnaire (IPAQ) 
 
– Short and Long Forms 
 
November 2005 
 
Contents 
1. Introduction 
2. Uses of IPAQ Instruments 
3. Summary Characteristics of Short and Long Forms 
4. Overview of Continuous and Categorical Analyses of IPAQ 
5. Protocol for Short Form 
7. Data Processing Rules 
8. Summary Algorithms 
At A Glance IPAQ Scoring Protocol – Short Forms 
 
1. Introduction 
 
This document describes recommended methods of scoring the data derived from 
the telephone / interview administered and self-administered IPAQ short and long 
form instruments. The methods outlined provide a revision to earlier scoring 
protocols for the IPAQ short form and provide for the first time a comparable 
scoring method for IPAQ long form. Latest versions of IPAQ instruments are 
available from 
www.ipaq.ki.se. 
Although there are many different ways to analyse physical activity data, to date 
there is no formal consensus on a ‘correct’ method for defining or describing levels 
of physical activity based on self–report population surveys. The use of different 
scoring protocols makes it very difficult to compare within and between countries, 
even when the same instrument has been used. Use of these scoring methods will 
enhance the comparability between surveys, provided identical sampling and 
survey methods have been used. 
2. Uses of IPAQ Instruments 
 
IPAQ short form is an instrument designed primarily for population surveillance of 
physical activity among adults. It has been developed and tested for use in adults 
(age range of 15-69 years) and until further development and testing is undertaken 
the use of IPAQ with older and younger age groups is not recommended. 
IPAQ short and long forms are sometimes being used as an evaluation tool in 
intervention studies, but this was not the intended purpose of IPAQ. Users should 
carefully note the range of domains and types of activities included in IPAQ before 
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using it in this context. Use as an outcome measure in small scale intervention 
studies is not recommended. 
 
3. Summary Characteristics of IPAQ Short and Long Forms 
 
1. IPAQ assesses physical activity undertaken across a comprehensive set of 
domains including: 
 
a. leisure time physical activity 
b. domestic and gardening (yard) activities 
c. work-related physical activity 
d. transport-related physical activity; 
 
2. The IPAQ short form asks about three specific types of activity undertaken in 
the four domains introduced above. The specific types of activity that are assessed 
are walking, moderate-intensity activities and vigorous-intensity activities. 
3. The items in the short IPAQ form were structured to provide separate scores on 
walking, moderate-intensity and vigorous-intensity activity. Computation of the 
total score for the short form requires summation of the duration (in minutes) and 
frequency (days) of walking, moderate-intensity and vigorous-intensity activities. 
Domain specific estimates cannot be estimated. 
 
4. The IPAQ long form asks details about the specific types of activities 
undertaken within each of the four domains. Examples include walking for 
transportation and moderate-intensity leisure-time activity. 
5. The items in the long IPAQ form were structured to provide separate domain 
specific scores for walking, moderate-intensity and vigorous-intensity activity within 
each of the work, transportation, domestic chores and gardening (yard) and 
leisure-time domains. Computation of the total scores for the long form requires 
summation of the duration (in minutes) and frequency (days) for all the types of 
activities in all domains. Domain specific scores or activity specific subscores may 
be calculated. Domain specific scores require summation of the scores for 
walking, moderate-intensity and vigorous-intensity activities within the specific 
domain, whereas activity-specific scores require summation of the scores for the 
specific type of activity across domains. 
 
4. Overview of Continuous and Categorical Analyses of IPAQ 
 
Both categorical and continuous indicators of physical activity are possible from 
both 
IPAQ forms. However, given the non-normal distribution of energy expenditure in 
many populations, it is suggested that the continuous indicator be presented as 
median minutes/week or median MET–minutes/week rather than means (such 
asmean minutes/week or mean MET-minutes/week). 
 
4.1 Continuous Variables 
 
Data collected with IPAQ can be reported as a continuous measure. One measure 
of the volume of activity can be computed by weighting each type of activity by its 
energy requirements defined in METs to yield a score in MET–minutes. METs are 
multiples of the resting metabolic rate and a MET-minute is computed by 
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multiplying the MET score of an activity by the minutes performed. MET-minute 
scores are equivalent to kilocalories for a 60 kilogram person. Kilocalories may be 
computed from MET-minutes using the following equation: MET-min x (weight in 
kilograms/60 kilograms). MET-minutes/day or MET-minutes/week can be 
presented although the latter is more frequently used and is thus suggested. 
Details for the computation for summary variables from IPAQ short and long forms 
are detailed below. As there are no established thresholds for presenting 
METminutes, the IPAQ Research Committee propose that these data are reported 
as comparisons of median values and interquartile ranges for different 
populations. 
 
4.2 Categorical Variable: Rationale for Cut Point Values 
 
There are three levels of physical activity proposed to classify populations: 
1. Low 
2. Moderate 
3. High 
 
The algorithms for the short and long forms are defined in more detail in Sections 
5.3 and 6.3, respectively. Rules for data cleaning and processing prior to 
computing the algorithms appear in Section 7. 
 
Regular participation is a key concept included in current public health guidelines 
for physical activity. Therefore, both the total volume and the number of 
days/sessions are included in the IPAQ analysis algorithms. 
The criteria for these levels have been set taking into account that IPAQ asks 
questions in all domains of daily life, resulting in higher median MET-minutes 
estimates than would have been estimated from leisure-time participation alone. 
The criteria for these three levels are shown below. 
Given that measures such as IPAQ assess total physical activity in all domains, 
the “leisure time physical activity” based public health recommendation of 30 
minutes on most days will be achieved by most adults in a population. Although 
widely accepted as a goal, in absolute terms 30 minutes of moderate-intensity 
activity is low and broadly equivalent to the background or basal levels of activity 
adult individuals would accumulate in a day. Therefore a new, higher cutpoint is 
needed to describe the levels of physical activity associated with health benefits 
for measures such as 
IPAQ, which report on a broad range of domains of physical activity. 
‘High’ 
 
This category was developed to describe higher levels of participation. Although it 
is known that greater health benefits are associated with increased levels of 
activity there is no consensus on the exact amount of activity for maximal benefit. 
In the absence of any established criteria, the IPAQ Research Committee 
proposes a measure which equates to approximately at least one hour per day or 
more, of at least moderate-intensity activity above the basal level of physical 
activity Considering that basal activity may be considered to be equivalent to 
approximately 5000 steps per day, it is proposed that “high active” category be 
considered as those who move at least 12,500 steps per day, or the equivalent in 
moderate and vigorous activities. 
This represents at least an hour more moderate-intensity activity over and above 
the basal level of activity, or half an hour of vigorous-intensity activity over and 
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above basal levels daily. These calculations were based on emerging results of 
pedometers studies. 
This category provides a higher threshold of measures of total physical activity and 
is a useful mechanism to distinguish variation in population groups. Also it could 
be used to set population targets for health-enhancing physical activity when 
multidomain instruments, such as IPAQ are used. 
 
‘Moderate’ 
 
This category is defined as doing some activity, more than the low active category. 
It is proposed that it is a level of activity equivalent to “half an hour of at least 
moderate-intensity PA on most days”, the former leisure time-based physical 
activity population health recommendation. 
 
‘Low’ 
 
This category is simply defined as not meeting any of the criteria for either of the 
previous categories. 
 
 
5. Protocol for IPAQ Short Form 
5.1 Continuous Scores 
 
Median values and interquartile ranges can be computed for walking (W), 
moderate intensity activities (M), vigorous-intensity activities (V) and a combined 
total physical activity score. All continuous scores are expressed in MET-
minutes/week as defined below. 
 
5.2 MET Values and Formula for Computation of MET-minutes/week 
 
The selected MET values were derived from work undertaken during the IPAQ 
Reliability Study undertaken in 2000-20013. Using the Ainsworth et al. 
Compendium 
(Med Sci Sports Med 2000) an average MET score was derived for each type of 
activity. For example; all types of walking were included and an average MET 
value for walking was created. The same procedure was undertaken for moderate-
intensity activities and vigorous-intensity activities. The following values continue 
to be used for the analysis of IPAQ data: Walking = 3.3 METs, Moderate PA = 4.0 
METs and 
Vigorous PA = 8.0 METs. Using these values, four continuous scores are defined: 
 
Walking MET-minutes/week = 3.3 * walking minutes * walking days 
Moderate MET-minutes/week = 4.0 * moderate-intensity activity minutes * 
moderate days 
Vigorous MET-minutes/week = 8.0 * vigorous-intensity activity minutes * vigorous-
intensity days 
Total physical activity MET-minutes/week = sum of Walking + Moderate + 
Vigorous METminutes/ week scores. 
 
5.3 Categorical Score 
 
Category 1 Low 
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This is the lowest level of physical activity. Those individuals who not meet criteria 
for Categories 2 or 3 are considered to have a ‘low’ physical activity level. 
 
 
Category 2 Moderate 
 
The pattern of activity to be classified as ‘moderate’ is either of the following 
criteria: 
a) 3 or more days of vigorous-intensity activity of at least 20 minutes per day 
 
OR 
 
b) 5 or more days of moderate-intensity activity and/or walking of at least 30 
minutes per day 
 
OR 
 
c) 5 or more days of any combination of walking, moderate-intensity or vigorous 
intensity activities achieving a minimum Total physical activity of at least 600 MET-
minutes/week. 
Individuals meeting at least one of the above criteria would be defined as 
accumulating a minimum level of activity and therefore be classified as ‘moderate’. 
See Section 7.5 for information about combining days across categories. 
 
Category 3 High 
 
A separate category labelled ‘high’ can be computed to describe higher levels of 
participation. 
The two criteria for classification as ‘high’ are: 
a) vigorous-intensity activity on at least 3 days achieving a minimum Total physical 
activity of at least 1500 MET-minutes/week 
 
OR 
 
b) 7 or more days of any combination of walking, moderate-intensity or vigorous-
intensity activities achieving a minimum Total physical activity of at least 3000 
MET-minutes/week. 
See Section 7.5 for information about combining days across categories. 
 
5.4 Sitting Question in IPAQ Short Form 
 
The IPAQ sitting question is an additional indicator variable of time spent in 
sedentary activity and is not included as part of any summary score of physical 
activity. Data on sitting should be reported as median values and interquartile 
ranges. 
To-date there are few data on sedentary (sitting) behaviours and no well-accepted 
thresholds for data presented as categorical levels. 
 
7. Data Processing Rules 
 
In addition to a standardized approach to computing categorical and continuous 
measures of physical activity, it is necessary to undertake standard methods for 
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the cleaning and treatment of IPAQ datasets. The use of different approaches and 
rules would introduce variability and reduce the comparability of data. 
There are no established rules for data cleaning and processing on physical 
activity. 
Thus, to allow more accurate comparisons across studies IPAQ Research 
Committee has established and recommends the following guidelines: 
 
 
7.1 Data Cleaning 
 
I. Any responses to duration (time) provided in the hours and minutes response 
option should be converted from hours and minutes into minutes. 
 
II. To ensure that responses in ‘minutes’ were not entered in the ‘hours’ column by 
mistake during self-completion or during data entry process, values of ‘15’, ‘30’, 
‘45’, ‘60’ and ‘90’ in the ‘hours’ column should be converted to ‘15’, ‘30’, ‘45’, ‘60’ 
and ‘90’ minutes, respectively, in the minutes column. 
 
III. In some cases duration (time) will be reported as weekly (not daily) e.g., 
VWHRS, VWMINS. These data should be converted into an average daily time 
by dividing by 7. 
 
IV. If ‘don’t know’ or ‘refused ‘ or data are missing for time or days then that case is 
removed from analysis. 
 
Note: Both the number of days and daily time are required for the creation of categorical and 
continuous summary variables 
 
7.2 Maximum Values for Excluding Outliers 
 
This rule is to exclude data which are unreasonably high; these data are to be 
considered outliers and thus are excluded from analysis. All cases in which the 
sum total of all Walking, Moderate and Vigorous time variables is greater than 960 
minutes (16 hours) should be excluded from the analysis. This assumes that on 
average an individual of 8 hours per day is spent sleeping. 
The ‘days’ variables can take the range 0-7 days, or 8, 9 (don’t know or refused); 
values greater than 9 should not be allowed and those cases excluded from 
analysis. 
 
7.3 Minimum Values for Duration of Activity 
 
Only values of 10 or more minutes of activity should be included in the calculation 
of summary scores. The rationale being that the scientific evidence indicates that 
episodes or bouts of at least 10 minutes are required to achieve health benefits. 
Responses of less than 10 minutes [and their associated days] should be re-coded 
to ‘zero’. 
 
7.4 Truncation of Data Rules 
 
This rule attempts to normalize the distribution of levels of activity which are 
usually skewed in national or large population data sets. 
In IPAQ short - it is recommended that all Walking, Moderate and Vigorous time 
variables exceeding ‘ 3 hours’ or ‘180 minutes’ are truncated (that is re-coded) to 
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be equal to ‘180 minutes’ in a new variable. This rule permits a maximum of 21 
hours of activity in a week to be reported for each category (3 hours * 7 days). 
In IPAQ long – the truncation process is more complicated, but to be consistent 
with the approach for IPAQ short requires that the variables total Walking, total 
Moderateintensity and total Vigorous-intensity activity are calculated and then, for 
each of these summed behaviours, the total value should be truncated to 3 hours 
(180 minutes). 
 
When analysing the data as categorical variable or presenting median and 
interquartile ranges of the MET-minute scores, the application of the truncation 
rule will not affect the results. This rule does have the important effect of 
preventing misclassification in the ‘high’ category. For example, an individual who 
reports walking for 10 minutes on 6 days and 12 hours of moderate activity on one 
day could be coded as ‘high’ because this pattern meets the ‘7 day” and “3000 
MET-min” criteria for ‘high’. However, this uncommon pattern of activity is unlikely 
to yield the health benefits that the ‘high’ category is intended to represent. 
 
Although using median is recommended due to the skewed distribution of scores, 
if 
IPAQ data are analysed and presented as a continuous variable using mean 
values, the application of the truncation rule will produce slightly lower mean 
values than would otherwise be obtained. 
 
7.5 Calculating MET-minute/week Scores 
 
Data processing rules 7.2, 7.3, and 7.4 deals first with excluding outlier data, then 
secondly, with recoding minimum values and then finally dealing with high values. 
These rules will ensure that highly active people remain classified as ‘high’, while 
decreasing the chances that less active individuals are misclassified and coded as 
‘high’. 
Using the resulting variables, convert time and days to MET-minute/week scores 
[see above Sections 5.2 and 6.2; METS x days x daily time]. 
 
7.6 Calculating Total Days for Presenting Categorical Data on Moderate and 
High Levels 
 
Presenting IPAQ data using categorical variables requires the total number of 
‘days’ on which all physical activity was undertaken to be assessed. This is difficult 
because frequency in ‘days’ is asked separately for walking, moderate-intensity 
and vigorous intensity activities, thus allowing the total number of ‘days’ to range 
from a minimum of 0 to a maximum of 21’days’ per week in IPAQ short and higher 
in IPAQ long. The IPAQ instrument does not record if different types of activity are 
undertaken on the same day. 
 
In calculating ‘moderately active’, the primary requirement is to identify those 
individuals who undertake activity on at least ‘5 days’/week [see Sections 4.2 and 
5.3]. Individuals who meet this criterion should be coded in a new variable called 
“at least five days” and this variable should be used to identify those meeting 
criterion b) at least 30 minutes of moderate-intensity activity and/or walking; and 
those meeting criterion c) any combination of walking, moderate-intensity or 
vigorous-intensity activities achieving a minimum of 600 MET-minutes/week. 
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Below are two examples showing this coding in practice: 
 
i) an individual who reports ‘2 days of moderate-intensity’ and ‘3 days of walking’ 
should be coded as a value indicating “at least five days”; 
ii) an individual reporting ‘2 days of vigorous-intensity’, ‘2 days of moderate 
intensity’ and ‘2 days of walking should be coded as a value to indicate “at least 
five days” [even though the actual total is 6]. 
The original frequency of ‘days’ for each type of activity should remain in the data 
file for use in the other calculations. 
The same approach as described above is used to calculate total days for 
computing the ‘high’ category. The primary requirement according to the stated 
criteria is to identify those individuals who undertake a combination of walking, 
moderate intensity and or vigorous-intensity activity on at least 7 days/week [See 
section 4.2]. 
Individuals who meet this criterion should be coded as a value in a new variable to 
reflect “at least 7 days”. 
 
Below are two examples showing this coding in practice: 
i) an individual who reports ‘4 days of moderate-intensity’ and ‘3 days of walking’ 
should be coded as the new variable “at least 7 days”. 
ii) an individual reporting ‘3 days of vigorous-intensity’, ‘3 days moderateintensity’ 
and ‘3 days walking’ should be coded as “at least 7 days” [even though the total 
adds to 9] . 
 
8. Summary algorithms 
 
The algorithms in Appendix 1 and Appendix 2 to this document show how these 
rules work in an analysis plan, to develop the categories 1 [Low], 2 [Moderate], 
and 3 
[High] levels of activity.  
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At A Glance 
IPAQ Scoring Protocol (Short Forms) 
Continuous Score 
 
Expressed as MET-min per week: MET level x minutes of activity/day x days per 
week 
Sample Calculation 
 
MET levels MET-minutes/week for 30 min/day, 5 days 
 
Walking = 3.3 METs 3.3*30*5 = 495 MET-minutes/week 
Moderate Intensity = 4.0 METs 4.0*30*5 = 600 MET-minutes/week 
Vigorous Intensity = 8.0 METs 8.0*30*5 = 1,200 MET-minutes/week 
___________________________ 
TOTAL = 2,295 MET-minutes/week 
Total MET-minutes/week = Walk (METs*min*days) + 
Mod (METs*min*days) + Vig (METs*min*days) 
 
Categorical Score- three levels of physical activity are proposed 
 
1. Low 
 
• No activity is reported OR 
• Some activity is reported but not enough to meet Categories 2 or 3. 
 
2. Moderate 
 
Either of the following 3 criteria 
 
• 3 or more days of vigorous activity of at least 20 minutes per day OR 
• 5 or more days of moderate-intensity activity and/or walking of at least 30 
minutes per day OR 
• 5 or more days of any combination of walking, moderate-intensity or vigorous 
intensity activities achieving a minimum of at least 600 MET-minutes/week. 
 
3. High 
 
Any one of the following 2 criteria 
• Vigorous-intensity activity on at least 3 days and accumulating at least 1500 
MET-minutes/week OR 
• 7 or more days of any combination of walking, moderate- or vigorous-intensity 
activities accumulating at least 3000 MET-minutes/week 
 
Please review the full document “Guidelines for the data processing and analysis of the International 
Physical Activity Questionnaire” for more detailed description of IPAQ analysis and recommendations 
for data cleaning and processing [www.ipaq.ki.se]. 
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Appendix- F; ELISA 
F1-      Endostatin 
Catalogue Number DNST0 
PRINCIPLE OF THE ASSAY 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for human Endostatin has been pre-coated onto a 
microplate. Standards, controls and samples are pipetted into the wells and any 
Endostatin present is bound by the immobilized antibody. After washing away 
any unbound substances, an enzyme-linked monoclonal antibody specific for 
human Endostatin is added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate solution is added to the wells 
and color develops in proportion to the amount of Endostatin bound in the initial 
step. The color development is stopped and the intensity of the color is 
measured. 
 
SAMPLE COLLECTION & STORAGE 
The sample collection and storage conditions listed below are intended as 
general guidelines. Sample stability has not been evaluated. 
 
Cell Culture Supernates - Remove particulates by centrifugation and assay 
immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-
thaw cycles. 
 
Serum - Use a serum separator tube (SST) and allow samples to clot for 30 
minutes at room temperature before centrifugation for 15 minutes at 1000 x g. 
Remove serum and assay immediately or aliquot and store samples at ≤ -20 °C. 
Avoid repeated freeze-thaw cycles. 
 
Plasma - Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge 
for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or 
aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles. 
 
Note: Citrate plasma has not been validated for use in this assay. 
 
Saliva - Collect saliva into a polypropylene tube. Centrifuge for 5 minutes at 
10,000 x g in microcentrifuge tubes. Collect the aqueous layer (no pellet) and 
assay immediately or aliquot and store samples at 2-8 °C. 
Note: Saliva collector must not have any protein binding or filtering 
capabilities. 
SAMPLE PREPARATION 
 
Serum and plasma samples require a 50-fold dilution. A suggested 50-fold 
dilution is 20 μL of sample + 980 μL of Calibrator Diluent RD5P (diluted 1:5). 
 
REAGENT PREPARATION 
Bring all reagents to room temperature before use. 
 
Note: High concentrations of Endostatin are found in saliva. It is recommended 
that a face mask and gloves are used to protect kit reagents from 
contamination. 
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Wash Buffer - If crystals have formed in the concentrate, warm to room 
temperature and mix gently until the crystals have completely dissolved. Add 
20mL of Wash Buffer Concentrate to deionized or distilled water to prepare 
500mL of Wash Buffer. 
 
Substrate Solution - Color Reagents A and B should be mixed together in equal 
volumes within 15 minutes of use. Protect from light. 200 μL of the resultant 
mixture is required per well. 
 
Calibrator Diluent RD5P (diluted 1:5) - Add 20mL of Calibrator Diluent RD5P 
Concentrate to 80mL of deionized or distilled water to prepare 100mL of 
Calibrator Diluent RD5P (diluted 1:5). 
 
Human Endostatin Standard - Refer to the vial label for reconstitution 
volume. 
Reconstitute the Human Endostatin Standard with deionized or distilled water. 
This reconstitution produces a stock solution of 100 ng/mL. Mix the standard to 
ensure complete reconstitution and allow the standard to sit for a minimum of 
15 minutes with gentle agitation prior to making dilutions. Pipette 900 μL of 
Calibrator Diluent RD5P (diluted 1:5) into the 10 ng/mL tube. Pipette 500 μL into 
the remaining tubes. Use the stock solution to produce a dilution series (below). 
Mix each tube thoroughly before the next transfer. The 10 ng/mL standard 
serves as the high standard. Calibrator Diluent RD5P (diluted 1:5) serves as the 
zero standard (0 ng/mL). 
 
ASSAY PROCEDURE 
Bring all reagents and samples to room temperature before use. It is 
recommended that 
 
All standards, samples, and controls be assayed in duplicate. 
Note: High concentrations of Endostatin are found in saliva. It is recommended 
that a face mask and gloves are used to protect kit reagents from 
contamination. 
 
1. Prepare all reagents, working standards, and samples as directed in the 
previous sections. 
 
2. Remove excess microplate strips from the plate frame, return them to the foil 
pouch containing the desiccant pack, and reseal. 
 
3. Add 100 μL of Assay Diluent RD1W to each well. 
 
4. Add 50 μL of Standard, control, or sample* per well. Cover with the adhesive 
strip provided. 
Incubate for 2 hours at room temperature on a horizontal orbital microplate 
shaker 
(0.12" orbit) set at 500 •} 50 rpm. A plate layout is provided to record standards 
and samples assayed. 
 
5. Aspirate each well and wash, repeating the process three times for a total of 
four washes. Wash by filling each well with Wash Buffer (400 μL) using a squirt 
bottle, manifold dispenser, or autowasher. Complete removal of liquid at each 
step is essential to good performance. After the last wash, remove any 
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remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it 
against clean paper towels. 
 
6. Add 200 μL of Human Endostatin Conjugate to each well. Cover with a new 
adhesive strip. 
Incubate for 2 hours at room temperature on the shaker. 
 
7. Repeat the aspiration/wash as in step 5. 
 
8. Add 200 μL of Substrate Solution to each well. Incubate for 30 minutes at 
room temperature on the benchtop. Protect from light. 
 
9. Add 50 μL of Stop Solution to each well. The color in the wells should change 
from blue to yellow. If the color in the wells is green or the color change does 
not appear uniform, gently tap the plate to ensure thorough mixing. 
 
10. Determine the optical density of each well within 30 minutes, using a 
microplate reader set to 450 nm. If wavelength correction is available, set to 
540 nm or 570 nm. If wavelength correction is not available, subtract readings at 
540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for 
optical imperfections in the plate. Readings madedirectly at 450 nm without 
correction may be higher and less accurate. 
 
CALCULATION OF RESULTS 
 
Average the duplicate readings for each standard, control, and sample and 
subtract the average zero standard optical density (O.D.). 
 
Create a standard curve by reducing the data using computer software capable 
of generating a log/log curve-fit. As an alternative, construct a standard curve 
by plotting the mean absorbance for each standard on the y-axis against the 
concentration on the x-axis and draw a best fit curve through the points on a 
log/log graph. The data may be linearized by plotting the log of the human 
Endostatin concentrations versus the log of the O.D. on a linear scale, and the 
best fit line can be determined by regression analysis. 
 
If samples have been diluted, the concentration read from the standard curve 
must be multiplied by the dilution factor. 
 
LIMITATIONS OF THE PROCEDURE 
 
• FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
• The kit should not be used beyond the expiration date on the kit label. 
• Do not mix or substitute reagents with those from other lots or sources. 
• If samples generate values higher than the highest standard, further dilute the 
samples with Calibrator Diluent and repeat the assay. 
• Any variation in standard diluent, operator, pipetting technique, washing 
technique, incubation time or temperature, and kit age can cause variation in 
binding. 
• Variations in sample collection, processing, and storage may cause sample 
value differences. 
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F2-      VEGF ELISA 
 
Catalogue Number DVE00 
 
PRINCIPLE OF THE ASSAY 
 
This assay employs the quantitative sandwich enzyme immunoassay technique. A 
monoclonal antibody specific for VEGF has been pre-coated onto a microplate. 
Standards and samples are pipetted into the wells and any VEGF present is 
bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for VEGF is added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution is added to the wells and color develops in proportion to the 
amount of VEGF bound in the initial step. The color development is stopped and 
the intensity of the color is measured. 
 
SAMPLE COLLECTION & STORAGE 
The sample collection and storage conditions listed below are intended as 
general guidelines. Sample stability has not been evaluated. 
 
Cell Culture Supernates - Cell culture supernates should contain at least 1% 
fetal calf serum for stability of the VEGF. Remove particulates by centrifugation 
and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated 
freeze-thaw cycles. 
 
Serum - Use a serum separator tube (SST) and allow samples to clot for 30 
minutes before centrifugation for 15 minutes at 1000 x g. Remove serum and 
assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated 
freeze-thaw cycles. 
 
Plasma - Collect plasma using EDTA, heparin, or citrate as an anticoagulant. 
Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay 
immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-
thaw cycles. 
 
REAGENT PREPARATION 
 
Bring all reagents to room temperature before use. 
 
Wash Buffer - If crystals have formed in the concentrate, warm to room 
temperature and mix gently until the crystals have completely dissolved. Add 
20mL of Wash Buffer Concentrate to deionized or distilled water to prepare 
500mL of Wash Buffer. 
 
Substrate Solution - Color Reagents A and B should be mixed together in equal 
volumes within 15 minutes of use. Protect from light. 200 μL of the resultant 
mixture is required per well. 
 
VEGF Standard - Refer to the vial label for reconstitution volume. 
Reconstitute the VEGF Standard with Calibrator Diluent RD5K (for cell culture 
supernate samples) or Calibrator Diluent RD6U (for serum/plasma samples). 
Calibrator Diluent RD6U may contain a precipitate. Mix well before and during 
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use. This reconstitution produces a stock solution of 2000 pg/mL. Allow the 
standard to sit for a minimum of 15 minutes with gentle agitation prior to 
making dilutions. 
 
For Cell Culture Supernate Samples: Use polypropylene tubes. Pipette 500 μL 
of Calibrator Diluent RD5K into each tube. Use the stock solution to produce a 
dilution series (below). Mix each tube thoroughly before the next transfer. The 
1000 pg/mL dilution serves as the high standard. Calibrator Diluent RD5K serves 
as the zero standards (0 pg/mL). 
 
For Serum/Plasma Samples: Use polypropylene tubes. Pipette 500μL of 
Calibrator Diluent RD6U into each tube. Use the stock solution to produce a 
dilution series (below). Mix each tube thoroughly before the next transfer. The 
2000 pg/mL standard serves as the high standard. Calibrator Diluent RD6U serves 
as the zero standard (0 pg/mL). 
 
ASSAY PROCEDURE 
 
Bring all reagents and samples to room temperature before use. It is 
recommended that all standards, samples, and controls be assayed in 
duplicate. 
 
1. Prepare all reagents, working standards, and samples as directed in the 
previous sections. 
2. Remove excess microplate strips from the plate frame, return them to the foil 
pouch containing the desiccant pack, and reseal. 
 
3. For Cell Culture Supernate Samples: Add 50 μL of Assay Diluent RD1W to 
each well. 
For Serum/Plasma Samples: Add 100 μL of Assay Diluent RD1W to each well. 
 
4. For Cell Culture Supernate Samples: Add 200 μL of Standard, control, or 
sample per well. 
For Serum/Plasma Samples: Add 100 μL of Standard, control, or sample per 
well. 
Cover with the adhesive strip provided and incubate for 2 hours at room 
temperature. 
A plate layout is provided to record the standards and samples assayed. 
 
5. Aspirate each well and wash, repeating the process twice for a total of three 
washes. Wash by filling each well with Wash Buffer (400 μL) using a squirt 
bottle, manifold dispenser, or autowasher. Complete removal of liquid at each 
step is essential to good performance. 
After the last wash, remove any remaining Wash Buffer by aspirating or 
decanting. Invert the plate and blot it against clean paper towels. 
 
6. Add 200 μL of VEGF Conjugate to each well. Cover with a new adhesive strip. 
Incubate for 2 hours at room temperature. 
 
7. Repeat the aspiration/wash as in step 5. 
 
8. Add 200 μL of Substrate Solution to each well. Protect from light. 
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For Cell Culture Supernate Samples: Incubate for 20 minutes at room 
temperature. 
For Serum/Plasma Samples: Incubate for 25 minutes at room temperature. 
 
9. Add 50 μL of Stop Solution to each well. If color change does not appear 
uniform, gently tap the plate to ensure thorough mixing. If the color in the wells 
is green or the color change does not appear uniform, gently tap the plate to 
ensure thorough mixing. 
 
10. Determine the optical density of each well within 30 minutes, using a 
microplate reader set to 450 nm. If wavelength correction is available, set to 
540 nm or 570 nm. If wavelength correction is not available, subtract readings at 
540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for 
optical imperfections in the plate. Readings made directly at 450 nm without 
correction may be higher and less accurate. 
 
CALCULATION OF RESULTS 
 
Average the duplicate readings for each standard, control, and sample and 
subtract the average zero standard optical density (O.D.). 
 
Create a standard curve by reducing the data using computer software capable 
of generating a four parameter logistic (4-PL) curve fit. As an alternative, 
construct a standard curve by plotting the mean absorbance for each standard 
on the y-axis against the concentration on the x-axis and draw a best fit curve 
through the points on the graph. The data may be linearized by plotting the log 
of the VEGF concentrations versus the log of the O.D. and the best fit line can 
be determined by regression analysis. This procedure will produce an adequate 
but less precise fit of the data. 
 
If samples have been diluted, the concentration read from the standard curve 
must be multiplied by the dilution factor. 
 
LIMITATIONS OF THE PROCEDURE 
 
• FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
• The kit should not be used beyond the expiration date on the kit label. 
• Do not mix or substitute reagents with those from other lots or sources. 
• It is important that the Calibrator Diluent selected for the standard curve be 
consistent with the samples being assayed. 
• If samples generate values higher than the highest standard, dilute the 
samples with the appropriate Calibrator Diluent and repeat the assay. 
• Any variation in standard diluent, operator, pipetting technique, washing 
technique, incubation time or temperature, and kit age can cause variation in 
binding. 
• Variations in sample collection, processing, and storage may cause sample 
value differences. 
• This assay is designed to eliminate interference by other factors present in 
biological samples. Until all factors have been tested in the Quantikine 
Immunoassay, the possibility of interference cannot be excluded.  
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F3-    Insulin ELISA (Mercodia Kit) 
 
Catalogue no 10-1113-01 
 
PRINCIPLE OF THE PROCEDURE 
 
Mercodia Insulin ELISA is a solid phase two-site enzyme immunoassay. It is based 
on the direct sandwich technique in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule. During 
incubation insulin in the sample reacts with peroxidase-conjugated anti-insulin 
antibodies and anti-insulin antibodies bound to microplate welles. A simple 
washing step removes unbound enzyme labelled antibody. The bound conjugate 
is detected by reaction with 3,3’,5,5’-tetramethylbenzidine (TMB). The reaction 
is stopped by adding acid to give a colorimetric endpoint that is read 
spectrophotometrically. 
 
REAGENTS  
Each Mercodia Insulin ELISA kit (10-1113-01) contains reagents for 96 wells, 
sufficient for 42 samples and one calibrator curve in duplicate. For larger series 
of assays, use pooled reagents from packages bearing identical lot numbers. The 
expiry date for the complete kit is stated on the outer label. The recommended 
storage temperature is 2–8°C. 
Coated Plate with Mouse monoclonal anti-insulin 8-well strips 
For unused microplate wells completely reseal the bag using adhesive tape and 
use within two months. 
Calibrators 1, 2, 3, 4, 5  
(recombinant human insulin) Color coded yellow 
Enzyme Conjugate  
Peroxidase conjugated mouse monoclonal anti-insulin. 
Enzyme Conjugate Buffer  
Substrate TMB 1 
Stop Solution  0.5 M H2SO4 
 
SPECIMEN COLLECTION AND HANDLING 
Serum 
Collect blood by venipuncture, allow clotting and separating the serum by 
centrifugation. Samples can be stored at 2–8°C up to 24 hours. For longer p 
eriods, store samples at –20°C. Avoid repeated freezing and thawing. 
 
Plasma 
Collect blood by venipuncture into tubes containing heparin or EDTA as 
anticoagulant, and separate the plasma fraction. Samples can be stored at 2–8°C 
up to 24 hours. For longerperiods store samples at –20°C. Avoid repeated free 
zing and thawing. 
Preparation of samples 
No dilution is normally required, however, samples containing >200 mU/L should 
be diluted 1+9 v/v with Calibrator 0. 
 
TEST PROCEDURE 
All reagents and samples must be brought to room temperature before use. 
Prepare a calibrator curve for each assay run. 
1. Prepare enzyme conjugate 1X solution and wash buffer 1X solution. 
282 
 
282 
 
2. Prepare sufficient microplate wells to accomodate Calibrators and samples in 
duplicate. 
3. Pipette 25 μL each of Calibrators and samples into appropriate wells. 
4. Add 100 μL of enzyme conjugate 1X solution to each well. 
5. Incubate on a plate shaker (700-900 rpm) for 1 hour at room temperature (18–
25°C). 
6. Wash 6 times with 700μL wash buffer 1X solution per well using an automatic 
plate washer with overflow-wash function. Do not include soak step in washing 
procedure. Or manually, discard the reaction volume by inverting the microplate 
over a sink. Add 350μL wash buffer 1X solution to each well. Discard the wash 
solution, tap firmly several times against absorbent paper to remove excess 
liquid. Repeat 5 times. Avoid prolonged soaking during washing. paper to remove 
excess liquid. Repeat 5 times. Avoid prolonged soaking during washing. 
7. Add 200μL Substrate TMB into each well 
8. Incubate for 15 minutes at room temperature (18–25°C). 
9. Add 50μL Stop Solution to each well. Place plate on a shaker for 
approximately 5 seconds to ensure mixing. 
10. Read optical density at 450 nm and calculate results. Read within 30 
minutes. 
Note! To prevent contamination between the conjugate and substrate, separate 
pipettes are recommended. 
 
CALCULATION OF RESULTS 
Computerized calculation 
The concentration of insulin is obtained by computerized data reduction of the 
absorbance for the Calibrators, except for Calibrator 0, versus the 
concentration. 
 
WARNINGS AND PRECAUTIONS 
• For in vitro diagnostic use. 
• The contents of this kit and their residues must not be allowed to come into 
contact with ruminating animals or swine. 
• The Stop solution in this kit contains 0.5 M H2SO4. Follow routine precautions 
for handling hazardous chemicals. 
• All samples should be handled as of capable of transmitting infections. 
• Each well can only be used once. 
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Appendix-G; Legal permission for the Figures 
and graphs used in this thesis 
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Appendix- H; Tables for correlations in chapter 6 
1-Change in VEGF with Physical and metabolic characteristics of volunteers 
Variable 0 Min ∆VEGF10 ∆VEGF 30 ∆VEGF 60 ∆VEGF 120 ∆VEGF 240 ∆VEGF 24hr 
Age (years) -0.239 -0.097 -0.536 -0.146 -0.634 -0.270 -0.058 
 0.569 0.820 0.171 0.730 0.092 0.518 0.891 
Height (cm) -0.167 0.698 0.323 0.101 0.591 -0.335 -0.047 
 0.693 0.054 0.435 0.812 0.123 0.417 0.912 
Weight (kg) -0.306 0.349 -0.041 -0.022 0.128 -0.058 0.036 
 0.461 0.397 0.924 0.959 0.763 0.892 0.932 
Body Fat (Kg) -0.006 -0.037 -0.421 -0.234 -0.408 0.155 -0.165 
 0.988 0.931 0.300 0.577 0.315 0.714 0.696 
Body Fat (%) 0.132 -0.257 -0.609 -0.324 -0.568 0.249 -0.301 
 0.756 0.539 0.109 0.433 0.142 0.552 0.468 
Lean weight (kg) -0.409 0.569 0.372 0.188 0.619 -0.226 0.193 
 0.314 0.141 0.364 0.656 0.102 0.591 0.647 
Body density -0.119 0.125 0.305 0.099 0.493 -0.354 0.040 
 0.779 0.768 0.463 0.815 0.215 0.390 0.925 
body volume -0.383 0.662 -0.061 -0.027 0.171 -0.200 0.022 
 0.397 0.105 0.897 0.954 0.714 0.667 0.962 
BMI (kg/m2) -0.143 -0.269 -0.292 -0.065 -0.368 0.244 0.090 
 0.735 0.519 0.483 0.878 0.370 0.560 0.833 
SBP (mmHg) 0.220 -0.199 -0.545 -0.555 -0.567 -0.131 -0.379 
 0.600 0.637 0.162 0.153 0.143 0.757 0.354 
DBP (mmHg) 0.268 0.198 -0.584 -0.390 -0.270 -0.213 -0.678 
 0.521 0.638 0.129 0.340 0.517 0.613 0.065 
WC (cm) 0.665 0.702 -0.090 -0.432 0.360 0.518 -0.640 
 0.150 0.120 0.866 0.392 0.483 0.293 0.171 
HC (cm) 0.061 0.569 0.147 -0.073 0.748 0.219 -0.281 
 0.908 0.239 0.782 0.891 0.087 0.677 0.590 
W/H ratio 0.512 -0.265 -0.333 -0.315 -0.839 0.098 -0.171 
 0.299 0.612 0.519 0.543 0.037 0.853 0.747 
FBG (mmol) -0.154 0.278 -0.034 0.046 0.252 0.265 -0.037 
 0.716 0.504 0.935 0.914 0.547 0.526 0.931 
TG (mmol) 0.351 -0.582 -0.683 -0.464 -0.894 0.064 -0.343 
 0.394 0.130 0.062 0.247 0.003 0.880 0.405 
Cholesterol (mmol) 0.395 -0.459 -0.750 -0.482 -0.800 0.237 -0.474 
 0.333 0.252 0.032 0.226 0.017 0.572 0.235 
HDL (mmol) 0.123 0.609 0.154 0.003 0.538 0.107 -0.293 
 0.771 0.109 0.716 0.994 0.169 0.800 0.481 
Insulin resistance 0.414 -0.443 -0.673 -0.492 -0.627 0.321 -0.480 
 0.308 0.272 0.067 0.216 0.096 0.438 0.229 
SDLDL (mg/dl) 0.352 -0.278 -0.389 -0.517 -0.392 0.082 -0.356 
 0.393 0.506 0.341 0.190 0.336 0.847 0.387 
NEFA (mg/dl) -0.025 -0.040 0.638 0.403 0.341 0.468 0.561 
 0.953 0.925 0.089 0.322 0.408 0.243 0.148 
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2-Change in VEGF with different exercise parameters of the participants 
Variable ∆VEGF10 ∆VEGF 30 ∆VEGF 60 ∆VEGF 120 ∆VEGF 240 ∆VEGF 24hr 
Basal HR 0.348 0.432 0.422 0.496 -0.016 0.192 
 0.398 0.285 0.297 0.212 0.970 0.649 
Max HR -0.087 -0.148 -0.567 0.095 0.428 -0.632 
 0.839 0.727 0.143 0.824 0.290 0.093 
∆HR -0.294 -0.401 -0.767 -0.225 0.390 -0.680 
 0.480 0.325 0.026 0.592 0.340 0.063 
Change HR % -0.337 -0.498 -0.700 -0.428 0.210 -0.517 
 0.415 0.210 0.053 0.290 0.618 0.190 
Duration 0.123 0.312 -0.087 0.115 -0.321 0.071 
 0.771 0.452 0.838 0.786 0.437 0.866 
distance 0.130 0.327 -0.079 0.120 -0.322 0.094 
 0.759 0.430 0.853 0.776 0.437 0.824 
Max Gradient 0.299 0.339 -0.107 0.339 -0.191 -0.061 
 0.473 0.411 0.802 0.412 0.651 0.887 
Basal VO2 -0.393 0.126 -0.165 -0.153 0.075 0.138 
 0.335 0.767 0.697 0.717 0.861 0.744 
VO2-Max 0.025 0.340 0.071 -0.007 -0.568 0.450 
 0.953 0.409 0.868 0.987 0.142 0.263 
∆vo2 max 0.085 0.350 0.101 0.015 -0.627 0.468 
 0.841 0.395 0.812 0.972 0.096 0.242 
∆VO2 % 0.549 0.220 0.326 0.220 -0.637 0.311 
 0.159 0.601 0.430 0.600 0.089 0.453 
Basal-VCO2 -0.048 0.074 -0.327 -0.046 0.213 -0.064 
 0.910 0.862 0.429 0.915 0.612 0.880 
VCO2-max 0.100 0.022 -0.332 0.063 -0.173 -0.057 
 0.814 0.959 0.422 0.881 0.682 0.892 
∆VCO2 0.109 0.017 -0.320 0.070 -0.199 -0.055 
 0.798 0.968 0.440 0.869 0.636 0.897 
∆VCO2% 0.156 0.004 0.097 0.203 -0.353 0.053 
 0.712 0.993 0.819 0.629 0.392 0.901 
Basal RER 0.263 0.136 -0.328 -0.003 0.349 -0.322 
 0.529 0.748 0.428 0.995 0.397 0.437 
RER-max -0.243 -0.320 -0.732 -0.122 0.256 -0.670 
 0.563 0.440 0.039 0.773 0.540 0.069 
∆RER -0.520 -0.533 -0.761 -0.165 0.098 -0.681 
 0.187 0.174 0.028 0.697 0.817 0.063 
∆RER% -0.616 -0.566 -0.661 -0.151 -0.027 -0.572 
 0.104 0.144 0.074 0.721 0.950 0.139 
Basal RR -0.399 -0.392 -0.327 -0.595 -0.073 0.049 
 0.328 0.337 0.429 0.120 0.863 0.908 
RR-max -0.296 -0.097 0.008 0.255 0.654 -0.207 
 0.476 0.820 0.984 0.542 0.079 0.623 
∆RR -0.113 0.069 0.140 0.477 0.635 -0.211 
 0.790 0.871 0.741 0.232 0.091 0.615 
∆RR % 0.178 0.228 0.261 0.652 0.447 -0.189 
 0.673 0.588 0.532 0.080 0.267 0.655 
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3- Change in Endostatin with Physical and metabolic characteristics of volunteers 
Variable Baseline  ∆ES10 ∆ES 30 ∆ES 60 ∆ES 120 ∆ES 240 ∆ES 24 
Age (years) 0.077 -0.080 -0.340 -0.099 0.347 0.751 0.727 
 0.857 0.851 0.410 0.816 0.400 0.032 0.041 
Height (cm) -0.366 -0.385 -0.253 -0.179 0.042 0.148 -0.230 
 0.372 0.346 0.545 0.672 0.920 0.726 0.585 
Weight (kg) 0.196 -0.454 -0.499 -0.591 0.003 0.683 0.272 
 0.642 0.258 0.208 0.122 0.994 0.062 0.515 
Body Fat (Kg) 0.332 -0.091 -0.329 -0.584 -0.144 0.617 0.488 
 0.422 0.831 0.426 0.128 0.735 0.103 0.220 
Body Fat (%) 0.440 -0.116 -0.424 -0.253 -0.163 0.491 0.525 
 0.275 0.785 0.295 0.545 0.700 0.217 0.182 
Lean weight (kg) -0.045 -0.570 -0.396 -0.284 0.114 0.358 -0.119 
 0.915 0.140 0.332 0.495 0.787 0.384 0.779 
Body density -0.372 -0.148 0.057 0.453 0.195 -0.367 -0.328 
 0.364 0.726 0.894 0.260 0.643 0.371 0.427 
body volume 0.051 -0.468 -0.497 -0.638 0.073 0.697 0.314 
 0.913 0.290 0.256 0.123 0.876 0.082 0.493 
BMI (kg/m2) 0.442 -0.089 -0.231 -0.394 -0.031 0.456 0.409 
 0.273 0.834 0.581 0.334 0.943 0.256 0.315 
SBP (mmHg) 0.633 -0.009 -0.282 0.595 0.072 0.502 0.570 
 0.092 0.983 0.499 0.120 0.865 0.205 0.141 
DBP (mmHg) -0.314 -0.198 -0.493 -0.083 -0.110 0.272 0.308 
 0.449 0.638 0.214 0.845 0.795 0.515 0.458 
WC (cm) 0.530 -0.386 -0.489 -0.044 -0.784 -0.283 -0.412 
 0.280 0.450 0.325 0.934 0.065 0.587 0.417 
HC (cm) 0.174 -0.755 -0.671 -0.038 -0.376 -0.287 -0.468 
 0.741 0.083 0.145 0.943 0.462 0.581 0.349 
W/H ratio 0.215 0.815 0.585 0.047 -0.119 0.215 0.377 
 0.682 0.048 0.223 0.930 0.822 0.682 0.461 
FBG (mmol) 0.450 -0.765 -0.796 -0.136 -0.130 0.428 0.045 
 0.263 0.027 0.018 0.748 0.760 0.291 0.916 
TG (mmol) 0.342 0.446 0.117 0.312 -0.015 0.161 0.554 
 0.407 0.269 0.783 0.452 0.972 0.704 0.154 
Cholesterol (mmol) 0.360 0.226 -0.149 -0.022 -0.218 0.243 0.525 
 0.381 0.591 0.724 0.959 0.603 0.562 0.181 
HDL (mmol) -0.318 -0.364 -0.336 -0.694 -0.417 -0.004 -0.326 
 0.442 0.376 0.416 0.056 0.304 0.993 0.430 
Insulin Resistance 0.629 -0.026 -0.352 0.350 -0.235 0.191 0.414 
 0.095 0.952 0.392 0.396 0.575 0.650 0.307 
SDLDL (mg/dl) 0.750 0.012 -0.181 0.724 -0.093 0.187 0.307 
 0.032 0.978 0.669 0.042 0.827 0.657 0.459 
NEFA (mg/dl) 0.480 0.109 0.389 0.278 -0.095 -0.407 -0.510 
 0.229 0.796 0.341 0.505 0.823 0.317 0.196 
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4-Change in endostatin with different exercise parameters of the participants 
Variable ∆ES10 ∆ES 30 ∆ES 60 ∆ES 120 ∆ES 240 ∆ES 24 
Basal HR -0.376 -0.165 0.703 0.179 -0.384 -0.509 
 0.359 0.696 0.052 0.672 0.348 0.198 
Max HR 0.116 0.014 0.165 -0.717 -0.395 -0.269 
 0.785 0.973 0.696 0.045 0.333 0.519 
∆HR 0.337 0.116 -0.292 -0.747 -0.111 0.078 
 0.415 0.785 0.482 0.033 0.794 0.854 
Change HR % 0.478 0.609 0.330 0.098 -0.222 -0.170 
 0.230 0.109 0.425 0.817 0.598 0.687 
Duration 0.475 0.612 0.320 0.106 -0.201 -0.164 
 0.234 0.107 0.440 0.802 0.634 0.697 
distance 0.189 0.325 0.259 -0.078 -0.223 -0.301 
 0.654 0.433 0.536 0.855 0.596 0.469 
Max Gradient 0.404 0.475 0.750 0.039 -0.263 -0.050 
 0.321 0.234 0.032 0.927 0.528 0.906 
Basal VO2 0.378 0.552 0.407 0.532 0.176 0.141 
 0.356 0.156 0.317 0.174 0.677 0.739 
VO2-Max 0.350 0.529 0.331 0.571 0.229 0.160 
 0.395 0.178 0.424 0.139 0.585 0.705 
∆VO2 max 0.148 0.140 0.358 -0.233 0.093 0.010 
 0.726 0.741 0.385 0.578 0.826 0.981 
∆VO2 % 0.090 0.085 -0.361 -0.097 0.391 0.214 
 0.832 0.841 0.379 0.820 0.338 0.611 
Basal-VCO2 0.082 0.077 -0.409 -0.082 0.402 0.223 
 0.847 0.856 0.315 0.848 0.323 0.595 
VCO2-max 0.460 0.411 -0.005 -0.579 -0.214 -0.284 
 0.251 0.312 0.992 0.133 0.610 0.496 
∆VCO2 0.367 0.196 -0.214 -0.680 -0.218 -0.003 
 0.371 0.642 0.611 0.064 0.605 0.994 
∆VCO2% 0.169 -0.028 -0.288 -0.510 -0.142 0.199 
 0.689 0.947 0.489 0.197 0.737 0.636 
Basal RER 0.275 0.091 -0.347 0.103 0.612 0.669 
 0.510 0.830 0.400 0.808 0.107 0.070 
RER-max -0.326 -0.332 -0.425 -0.551 -0.444 -0.325 
 0.430 0.422 0.294 0.157 0.271 0.432 
∆RER -0.413 -0.344 -0.253 -0.552 -0.658 -0.572 
 0.309 0.404 0.545 0.156 0.076 0.139 
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Appendix- I; Figures for correlations in chapter 4  
For pooled/ gender and walking/running based groups 
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